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Summary 
 
G-protein coupled receptors (GPCRs) are the largest class of cell surface 
receptors. GPCR signalling is mediated through the classical signalling 
pathways, and non-classical signalling via utilisation of β-arrestin molecule and 
the transactivation of protein tyrosine kinase receptors (PTKR) and activation of 
serine/threonine kinase receptors (S/TKR), most notably the transforming 
growth factor (TGF)-β receptor (TGFBR1). Protease-activated receptors (PARs) 
are a family of GPCRs that are activated by the action of thrombin. Thrombin 
via its GPCR, PAR-1, can transactivate both PTKR in particular the epidermal 
growth factor receptor (EGFR) and the S/TKR TGFBR1. Thrombin signalling in 
human vascular smooth muscle cells (VSMCs) has been shown to contribute to 
atherosclerosis. Atherosclerosis commences by the trapping of lipoproteins in 
the vessel wall by modified proteoglycans specifically elongated 
glycosaminoglycan (GAG) chains. Thrombin through the transactivation of the 
EGFR and TGFBR1 leads to an increase of the GAG chain lengths allowing for 
an increase in low density lipoprotein retention. The two transactivation 
dependent pathways have distinct mechanisms. The PTKR mediated response 
involves matrix metalloproteinases and the phosphorylation of Erk. The S/TKR 
mediated response differs markedly and involves the phosphorylation of Smad2 
carboxy terminus.  The aim of this project was to expand on the mechanisms 
involved in transactivation dependent signalling and to find a common 
signalling intermediate which can inhibit both transactivation dependent 
signalling pathways leading to proteoglycan synthesis.  
The in vitro model used human VSMCs. GAG synthesizing gene 
expression was measured and quantified by real time-PCR. Signalling 
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intermediate phospho-proteins were detected and quantified by western blotting. 
Proteoglycan synthesis was assessed by labelling of GAG chains with 
[35S]-Sulphate and assessing incorporation into GAG chains via CPC 
precipitation assay. Proteoglycan GAG chain elongation was assessed by 
SDS-PAGE. Next generation RNA sequencing was conducted using the Ion 
proton sequencer. Reads were aligned to the human genome using TopHat 
software and differentially expressed genes were evaluated using the edgeR 
software. One-way ANOVA, followed by least significance difference post hoc 
analysis was used for statistical significance. 
Thrombin treatment of VSMCs increased the mRNA expression of GAG 
synthesizing genes, CHST11, CHSY1 and CHST3. Thrombin via the 
transactivation of the PTKR, EGFR and S/TKR, TGFBR1 regulated the mRNA 
expression of CHST11, CHSY1, CHST3 and biglycan. The role of Gαq was 
investigated in this transactivation signalling pathway by utilizing Gαq 
antagonist UBO-QIC. Gαq played a role in thrombin transactivation of the 
EGFR and TGFBR1 and was involved in thrombin mediated proteoglycan 
synthesis, GAG elongation and regulation of the mRNA expression of CHST11 
and CHSY1. Mechanistic studies revealed that thrombin transactivation of the 
TGFBR1 is mediated via Gαq which leads to Rho/ROCK signalling which 
activates cell surface integrin αVβ5 leading to the activation of the TGFBR1. 
siRNA knockdown of the Gαq and Gαq/11 revealed that thrombin mediated 
mRNA expression of CHST11 and CHSY1 occurs specifically via Gαq but not 
the Gαq/11 protein. 
Thrombin treatment of VSMCs mediates phosphorylation of four 
serine/threonine residues of the Smad2 linker region. Thrombin mediated 
phosphorylation of the Smad2 linker region is via the transactivation of the 
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TGFBR1 and the EGFR. Phosphorylation of the linker region via transactivation 
of the EGFR occurs within 15 mins and is sustained for 4 hours. The 
phosphorylation of the Smad2 linker region via transactivation of the TGFBR1 
is temporal initiating at 120 mins post thrombin treatment and sustained up to 
4 hours. The individual serine/threonine Smad2 linker region residues were 
phosphorylated by either Erk, p38, PI3K or CDK, however Jnk was only 
involved in thrombin transactivation of the EGFR leading to the 
phosphorylation of the Thr220 residue. Erk, p38 PI3K and CDK are involved in 
regulating thrombin mediated mRNA expression of CHST11 and CHSY1. 
 RNA-Seq sequencing analysis revealed that in human VSMCs thrombin 
was involved in upregulating 293 genes. Thrombin treatment in the presence of 
EGFR antagonist and TGFBR1 antagonist inhibited the expression to 129 and 
151 differentially expressed genes, respectively. Thrombin transactivation of the 
EGFR and TGFBR1 shared 140 genes. Thrombin transactivation of the EGFR 
regulated 512 biological processes and transactivation of the TGFBR1 regulated 
428 biological processes. From the top 50 biological processes enriched by 
transactivation dependent signalling, 28 terms were found to be common 
between the two pathways. Many of the biological processes were associated 
with regulation of cell activity as well as vasculature development. 
 The findings demonstrate that thrombin via the transactivation of the 
EGFR and TGFBR1 regulates the mRNA expression of CHST11, CHSY1, 
CHST13 and biglycan. The transactivation pathways have distinct mechanisms 
and the Gαq protein plays as the central integrating point. The phosphorylation 
of the serine residues of the Smad2 linker region is most likely associated with 
GAG synthesizing genes involved in GAG chain elongation whereas the 
phosphorylation of the threonine residue of Smad2 linker region is not. 
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Transactivation dependent signalling contributes to 50% of PAR-1 mediated 
signalling, with the two transactivation pathways sharing in over 60% of 
common differentially expressed genes. Thus showing that a central integrating 
point in the transactivation dependent signalling pathways may not only be 
essential for proteoglycan synthesis and the initiation of atherosclerosis but may 
help regulate the biological processes associated with the 60% common 
differentially expressed genes.  
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 1.1 Overview 
Atherosclerosis is the main underlying aetiology of cardiovascular disease 
(CVD). The initiating event in atherosclerosis is described in the “response to 
retention hypothesis” (Williams and Tabas, 1995) in which low density 
lipoproteins (LDL) are trapped in the vessel wall by modified proteoglycans 
specifically the elongated and sulphated glycosaminoglycan (GAG) chains of 
biglycan. Proteoglycan synthesis and structure is regulated by vasoactive growth 
factors. G protein coupled receptors (GPCRs) are seven transmembrane 
receptors that are present on vascular smooth muscle cells (VSMCs) where they 
signal important actions such as vascular contraction, cellular migration and 
proliferation. GPCR agonist, thrombin, leads to proteoglycan synthesis with 
elongated GAG chains, which show a higher binding affinity to LDL (Ivey and 
Little, 2008). 
The current paradigm of GPCR signalling covers three major pathways; 
firstly, the classic pathway in which agonist engagement causes G protein 
binding to the receptor with subsequent downstream signalling leading to 
functional responses; secondly the utilization of the β-arrestin signalling 
molecule that form scaffold complexes and lead to intracellular signalling and 
thirdly through a mechanism known as transactivation. Transactivation was first 
described by Ullrich in 1996 (Daub et al., 1996), GPCR agonists through their 
receptors can transactivate protein tyrosine kinase receptor (PTKR), such as 
epidermal growth factor receptor (EGFR), stimulating the immediate 
downstream product phosphorylated Erk1/2. 
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Transactivation has recently been defined as “the agonist occupancy of its 
cognate GPCR complex which leads in a relatively short time and in the absence 
of ‘de novo’ protein synthesis to the activation of and cytosolic generation of the 
immediate downstream product(s) of a second cell surface protein kinase 
receptor” (Kamato et al., 2013b). The activation of PTKR by a GPCR represents 
a major expansion in the cellular outcomes attributable to GPCR signalling.  
The paradigm of GPCR mediated kinase receptor transactivation has been 
expanded to include GPCR mediated transactivation of serine/threonine kinase 
receptors (S/TKR) in particular the transforming growth factor (TGF)-β receptor 
type 1 (TGFBR1) (Burch et al., 2010). GPCR mediated transactivation of the 
TGFBR1 occurs via cytoskeletal rearrangement, which activated Rho associated 
protein kinase (ROCK) signalling, leading to the activation of cell surface 
integrins which bind to the latent TGF-β complex. This results in the TGF-β 
ligand binding to its receptor and activating its downstream signalling cascade. 
In VSMCs the transactivation of the EGFR and TGFBR1 results in the synthesis 
of biglycan molecules with elongated GAG chains. Little is known about the 
role of G proteins in GPCR transactivation of the PTKR and the S/TKRs. The 
role of G proteins is of great interest as it may play as the common point of 
signalling for these transactivation mediated pathways. This project will 
investigate the role of G protein, Gαq in proteinase activated receptor-1 (PAR-1) 
transactivation of the EGFR and TGFBR1 leading to GAG chain elongation. 
1.2 Cardiovascular Disease 
CVD is the largest cause of mortality in developed and developing 
countries (Deaton et al., 2011). CVD is a collective term to describe a group of 
diseases that affect the functioning of the heart, heart valves, blood and 
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vasculature of the body (Federation, 2014). The vasculature is a dynamic organ. 
Its functions include regulation of nutrients from blood to the surrounding 
tissues, maintenance of blood pressure and haemostasis. The major CVD 
condition that imposes a disease burden on the vascular wall and disrupts 
normal functioning is atherosclerosis (Frostegard, 2013, Weber and Noels, 
2011). Atherosclerosis is a chronic inflammatory disorder of the blood vessels 
and is the main aetiology underlying most CVD, representing around 75% of 
associated deaths (Mendis et al., 2011). Atherosclerosis is a pathological 
condition characterised by the accumulation of lipid and inflammatory products 
in the arterial wall leading to the formation of atherosclerotic plaques (Weber 
and Noels, 2011). 
Therapeutics currently available for atherosclerosis are largely restricted 
to targeting the risk factors such as alleviating hyperlipidaemia, hypertension 
and controlling homeostasis to prevent thrombotic complications (Weber and 
Noels, 2011). Lipid lowering drugs are the most effective pharmaceutical 
treatment for CVD and ongoing therapeutic improvements include more 
aggressive lowering of circulating lipoproteins. The most common drugs of this 
class is 3-hydroxy-3-methylglutaryl coenyzyme A (HMG-CoA) reductase 
inhibitors, also known as statins (Taylor et al., 2013). This therapy leads to the 
reduction of blood cholesterol levels, however they offer a less than optimal 
result in atherosclerosis prevention (Pignone, 2001, Pignone et al., 2000). Data 
collected from a cross sectional, retrospective study of 3 data sources: electronic 
medical records (2003-2010), administrative claims data (2003-2010) and 
National Health and Nutrition Examination Survey data (2007-2008) 
demonstrated that among patients undergoing statin therapy, approximately 25% 
of the high risk patients were able to reduce LDL cholesterol levels below 
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70 mg/dL (optimal level for patients high-risk of heart attack)(Jones et al., 
2012). A meta-analysis using data from 8 randomised statin trials analysed the 
proportion of patients not reaching guideline recommended lipid levels on high-
dose statin therapy (Boekholdt et al., 2014). More than 40% of patients treated 
with high-dose statin therapy did not reach a LDL target of less than 70 mg/dL 
(Boekholdt et al., 2014). In over thirty years since the discovery of statins, there 
has been no major new therapeutic agent arising for the existing strategy – 
targeting risk factors. Thus it has been proposed that therapies which target the 
vessel wall are required (Jamkhande et al., 2014, Staels, 2002).  
1.3 Atherosclerosis 
Human arteries have three separate layers, the intima, the media and the 
adventitia (Figure 1.1) (Libby et al., 2002, Holzapfel and Ogden, 2010). The 
intima is a network of extracellular matrix (ECM) containing proteoglycans and 
collagen (Gasser et al., 2006, Rajendran et al., 2013). The intima is lined by a 
mono layer of endothelial cells that form a physical and functional barrier 
between flowing blood and the arterial wall surface, regulating a wide array of 
processes including thrombosis, vascular tone and leukocyte trafficking. 
Endothelial cells adhere on a basement membrane of extracellular matrix 
containing proteoglycans and collagen (Rajendran et al., 2013). In contrast to 
animal species used for atherosclerosis experiments, the human intima contains 
resident vascular smooth muscle cells (VSMC) (Allahverdian et al., 2014).The 
human arterial intimal thickening is made up of predominantly VSMCs 
(Allahverdian et al., 2014). The media is separated from the intima by an 
internal elastic lamina (Figure 1.1). The media is contractile and consists of 
interconnected smooth muscle cell layers that are held together by an ECM 
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consisting largely of elastic fibres and collagen with a lesser content of 
proteoglycan. The layer furthermost from the lumen is the adventitia, which is 
comprised of mostly connective tissue with populations of smooth muscle cells 
and fibroblasts (Figure 1.1) (Libby et al., 2002). 
Atherogenesis refers to the development of atheromatous plaque in the 
inner lining of the arteries. Atherosclerotic plaque formation is slow and 
progressive and can be segmented into three phases, initiation, progression and 
plaque rupture (Figure 1.2). Initiation of an atherosclerotic lesion begins with 
lipid retention and inflammation. Under pro-atherosclerotic conditions, smooth 
muscle cells of the media migrate into the intima causing diffuse intimal 
thickening leading to the formation of a ‘neointima’ and secrete ECM molecules 
termed proteoglycans (Stary et al., 1992, Lusis, 2000). Proteoglycans show an 
increased affinity to bind LDL, subsequently resulting in LDL being retained in 
the neointima. The retained LDL shows an increased susceptibility to oxidation 
and other modifications such as lipolysis and proteolysis (Lusis, 2000). 
Oxidized LDL is taken up by macrophages. Minimally oxidised LDL has 
pro-inflammatory activities (Pentikainen et al., 2000) and can stimulate VSMCs 
and endothelial cells to express a range of inflammatory mediators. 
Additionally, VSMCs are capable of taking up aggregated LDL bound to 
proteoglycans (Llorente-Cortes et al., 2006). Macrophages and VSMCs that take 
up the oxidised LDL form large lipid laden ‘foam cells’ (Kaplan and Aviram, 
2001, Tabas, 1999, Yutani et al., 1999, Mendez-Barbero et al., 2013, Badimon 
et al., 2012, Tarkin et al., 2016).  
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Figure 1.1: A cross sectional diagram of a non-diseased artery. 
The arterial wall is composed of three distinct layers: the intima (I), the media 
(M) and the adventitia (A). Intima is the innermost layer closest to the lumen 
and lined by endothelial cells. Thickness of the subendothelial layer is 
influenced by age and disease state. Media layer is composed of smooth muscle 
cells and elastin and collagen fibrils which align circumferentially to provide 
mechanical integrity and contractility. The adventitia is the outer most layer 
surrounded by loose connective tissue. Image reproduced from (Gasser et al., 
2006).  
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Lesions progress to an advanced complex lesion which is characterised 
by an underlying necrotic core with an overlying protective fibrous cap. The 
pathogenic consequences of an advance complex lesion occurs when the fibrous 
cap becomes vulnerable to rupture. As the fibrous caps structural integrity 
weakens it is susceptible to fissure under haemodynamic pressure. This induces 
thrombus formation which can occlude the vessel at the site, or dislodge forming 
an embolus, leading to blockage, distal to the rupture site. Total obstruction of 
the blood vessel due to thrombus results in ischemia of surrounding tissue, 
leading to pathologies such as myocardial infarction, stroke and peripheral 
vascular disease resulting in death or disability (Sah et al., 2003, Crowther, 
2005). 
 There are several hypotheses that have been formulated to explain 
atherogenesis. The most prominent and well-covered theories are the response to 
injury hypothesis (Ross and Glomset, 1976b, Ross and Glomset, 1976a), the 
oxidative modification hypothesis (Berliner et al., 1995) and the response to 
retention hypothesis (Williams and Tabas, 1995). Retention of lipid and the 
response of the body to this phenomenon forms the basis of the response to 
retention hypothesis and the basis for the work conducted in this project.  
1.4 Response to retention hypothesis  
The response to retention hypothesis was first postulated by Williams 
and Tabas in 1995 (Williams and Tabas, 1995) and describes the retention of 
LDL in the neointima of vessel walls as the key initiating event in lesion 
development. The hypothesis proposes that LDL, which normally diffuses 
through the blood vessel wall is trapped by intimal proteoglycans produced by 
VSMCs; and is consequently retained in the vessel wall (Tabas, 1999, Williams 
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and Tabas, 1995, Williams and Tabas, 1998). The apolipoprotein B (apoB) 
moiety of an LDL molecule contains a proteoglycan binding region (Boren et 
al., 1998, Camejo et al., 1988) that has an overall positive charge. The positively 
charged LDL interacts with the negatively charged constituents of the vessel 
wall ECM (Prydz and Dalen, 2000), of which the majority are sulphated 
proteoglycans. These proteoglycans have a high degree of negative charge 
owing to the sulphate and carboxyl groups on the GAG chains which are 
attached to the core protein. It is this ionic interaction which is hypothesized to 
be responsible for the entrapment of lipids within a vessel wall (Williams and 
Tabas, 1995) and hence a primary step in the formation of an atherosclerotic 
lesion (Figure 1.2). In human coronary artery, proteoglycans secreted by 
VSMCs include biglycan and decorin and to a much lesser extent versican and 
perlecan(Talusan et al., 2005). Histological studies in human arteries show 
strong co-localization between apoB lipoproteins and biglycan (Nakashima et 
al., 2007, O'Brien et al., 1998). The response to retention hypothesis proposes 
that subendothelial lipoprotein retention is the initiating event for 
atherosclerosis. It is estimated that more than 85% of subendothelial lipoprotein 
delivery is the consequence of transcytosis. The ECM of the subendothelium 
particularly proteoglycans are tightly associated with retention of atherogenic 
lipoproteins (Skalen et al., 2002).   
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Figure 1.2: Schematic representation of the initiation and progression of atherosclerotic plaque development. 
The figure depicts the development of atherosclerosis inside the neointima of the arterial wall. (A) The pre-inflammatory phase involves initiation of 
atherosclerosis via the ‘response to retention hypothesis’. Normal LDL diffuse into the vessel wall where it is bound by modified proteoglycans and 
subsequently retained. Retained LDL is oxidised causing expression of adhesion molecules on endothelial cells resulting in invasion of circulating 
monocytes. (B) Inflammatory phase allows for monocytes to differentiate into macrophages and engulf the oxidised LDL to form a foam cell, leading 
to fatty streak formation. (C) Plaque rupture leads to the formation of a thrombus, which can occlude vessels, potentially resulting in complications 
such as myocardial infarction or stroke. 
(A) Pre-inflammatory phase (B)Inflammatory (C) Plaque rupture 
Growth Factors 
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1.5 Proteoglycans 
The ECM is a highly-ordered macromolecular structure with various 
physiological and pathophysiological roles. The cells which produce matrix 
molecules are important in determining matrix function and metabolism. 
(Alberts et al., 2002). Proteoglycans fill the majority of the extracellular 
interstitial space within the tissue in the form of a hydrated gel, synthesized 
primarily by VSMCs (Jarvelainen et al., 2009, Schaefer and Schaefer, 2010, 
Schwartz, 2000a, Schwartz, 2000b). Chondroitin sulphate and dermatan 
sulphate (CS/DS) proteoglycans are made up of a polypeptide backbone (core 
protein), with one or more covalently anchored GAG chains (Figure 1.3) 
(Schwartz, 2000a, Schwartz, 2000b). The proteoglycan core protein has a set 
molecular weight as encoded in its mRNA, this can range from as little as 
10kDa to as large as 400-467kD. Proteoglycans contribute to both the 
maintenance of homeostasis, as well as the progression of many disease states 
including atherosclerosis (Wight and Hascall, 1983). Proteoglycans can be 
divided into different families (Table 1.1), based on the chemical composition of 
the GAG chains. The main proteoglycans concerned with the binding of LDL 
are biglycan (O'Brien et al., 2004) and decorin (Kovanen and Pentikainen, 1999) 
both of which contain a small leucine rich polypeptide core structure with 
adjoining CS and DS GAG chains.  
1.5.1 Biosynthesis of glycosaminoglycan chains 
GAG chains are polymers of non-branching repeating disaccharide units 
consisting of either N-acetyl-D-glucosamine (GlcNAc) or N-acetyl-D-
galactosamine (GalNAc) and an uronic acid either glucuronic (GlcA) or 
iduronic acid (IdoA). Categorisation of proteoglycans is reliant upon the 
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constituents of their GAG chains. In mammals, there are five different 
subgroups of GAG chains hyaluronic acid or hyaluronan (HA), keratin sulphate 
(KS), CS, DS and heparin/heparan sulphate (HS) (Sugahara and Kitagawa, 
2000, Caterson, 2012) (Table 1.1). CS and DS chains are classified as sulphated 
GAG chains made up of repeating disaccharide units. CS chains consists of 
alternating GlcNAc and GalNAc while DS chains are composed of alternating 
IdoA and GalNAc residues (Sugahara and Kitagawa, 2000). For CS synthesis, 
the chain elongates with the addition of GlcA and GalNAc residues by 
N-acetylgalactosaminyltransferase I and glucuronyltransferase (Uyama et al., 
2002). This study will focus on understanding the signalling pathways that 
regulate CS chain modification due to its importance as a therapeutic target in 
atherosclerosis (Little et al., 2008a). 
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Figure 1.3: Diagrammatic representation of a proteoglycan with a hyperelongated GAG chain. 
GAG chains are anchored to the core protein via the tetrasaccharide linkage region at specific serine residues along the core. The linkage region 
consists of a xylose (Xyl), two galactose (Gal) and a glucoronic acid (GlcA) residue. CS/DS GAG synthesizing enzymes work in a concerted manner 
to synthesize the linkage region and GAG chain. CS/DS GAG chains are made up of repeating disaccharide units consisting of GlcA and 
N-acetylgalactosamine (GalNAc). Under pathological conditions the GAG chains become hyperelongated, resulting in increased binding to LDL via 
an ionic interaction between the negative sulphate and the positive residues on the apoB moiety of LDL.  
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Table 1.1: Disaccharide composition of the 5 families of proteoglycans. 
Dotted red boxes indicate the sulphation positions in the GAG chain. Adapted 
from Pyrdz (Prydz and Dalen, 2000). 
Family of 
proteoglycans 
Proteoglycans from 
these families 
Chemical composition 
Chondroitin 
sulphate 
Versican 
 
Dermatan 
sulphate 
Biglycan, Decorin 
 
Keratan sulphate Lumican, 
 
Heparan suphate Perlecan 
 
Hyaluronan No core protein 
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GAG chain formation on proteoglycans is an event that is sequential 
from the endoplasmic reticulum (ER) to the Golgi (Vertel et al., 1993). GAG 
chains are covalently attached to the proteoglycan core protein via a conserved 
linkage region. Disaccharide residues are added to the linkage region to form a 
chain of repeating units that are concomitantly sulphated (Ballinger et al., 2004). 
The initiation of the linkage region involves the action of glycosyltransferases. 
The four glycosyltransferases that are involved in the synthesis of the linkage 
region are xylosyltransferase (XXYLT-1), β1, 4-galactosyltransferase-I 
(B4GALT7), β1, 3-galactosyltransferase II (B3GALT6) and β 1, 3-
glucorynyltransferase I (B3GAT3). GAG chain synthesis begins in the cis 
compartment of the Golgi, where a pentose sugar, xylose, is covalently attached 
to a serine via a hydroxyl linkage catalysed by XXYLT-1 (Schwartz, 2000a). 
This initiating step is followed by the sequential addition of two GalNAc units 
by the two independent enzymes B4GALT7 and B3GALT6 (Figure 1.4).  
Once the tetrasaccharide linker is completed the process of CS/DS chain 
assembly on proteoglycans is mediated by a number of membrane bound 
enzymes located in the ER/Golgi compartment (Silbert and Sugumaran, 2002, 
Mikami and Kitagawa, 2013, Izumikawa et al., 2011, Koike et al., 2014). The 
CS/DS GAG chain elongation occurs with the addition of GlcA and GalNAc 
residues through the actions of glycosyltransferases (Silbert and Sugumaran, 
2002) chondroitin synthase (CHSY)-1, CHSY2, CHSY3, chondroitin 
polymerizing factor (CHPF), chondroitin N-acetylgalactosamine transferase 
(ChGn)-1 and ChGn-2 (Figure 1.4). Sulfotransferases catalyse the transfer of a 
sulpho group from a donor molecule to the acceptor (Kusche-Gullberg and 
Kjellen, 2003). Seven sulfotransferases are responsible for the sulphation of 
CS/DS including chondroitin 4-O-sulfotransferase (CHST11, 12 and 13), 
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dermatan 4-O-sulfotransferase (CHST14), chondroitin 6-O-sulfotransferase 
(CHST3), uronyl 2-O-sulfotransferase and GalNAc 4-sulfate 6-O-
sulfotransferase (Table 1.2).   
 Chapter-1. Introduction Page 17 
Table 1.2: Enzymes involved in CS/DS synthesis  
Adapted from Mikami (Mikami and Kitagawa, 2013). 
Enzymes  
(activity) 
Abbreviation Gene symbols 
 (synonym) 
Glycosyltransferases involved in the synthesis of the tetrasaccharide linkage region 
Xylosyltransferase XylT XXYLT-1 
β1,4-Galactosyltransferase-I GalT-I B4GALT7 
β1,3-Galactosyltransferase-II GalT-II B3GALT6 
β1,3-Glucuronyltransferase-I GlcAT-I B3GAT3 
Glycosyltransferases involved in the synthesis of the CS chains 
Chondroitin synthase ChSy-1 CHSY1 
 ChSy-2 CHSY2 (CSS3) 
 ChSy-3 CHSY3 (CHPF2) 
Chondroitin polymerizing factor ChPF CHPF (CSS2) 
Chondroitin GalNAc transferase ChGn-1 CSGALNACT1 
 ChGn-2 CSGALNACT2 
Sulfotransferases and epimerases 
Chondroitin 4-O-sulfotransferase C4ST-1 C4ST1 (CHST11) 
 C4ST-2 C4ST2 (CHST12) 
 C4ST-3 C4ST3 (CHST13) 
Dermatan 4-O-sulfotransferase D4ST-1 D4ST1 (CHST14) 
Chondroitin 6-O-sulfotransferase C6ST-1 C6ST1 (CHST3) 
Uronyl 2-O-sulfotransferase UST UST 
GalNAc 4-sulfate 6-O-sulfotransferase GalNAc4S-6ST GALNAC4S-6ST  
(CHST15) 
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As the chain is extended, chondroitin polymerization occurs with the 
action of glycosyltransferases CHSY1, CHSY2, CHSY3, CHPF, ChGn-1 and 
ChGn-2 (Izumikawa et al., 2007, Izumikawa et al., 2008, Kitagawa et al., 2003). 
When the growing structure enters the medial/trans Golgi it is subjected to post-
translational modification. Sulphation is generally confined to the trans Golgi 
and may occur with the addition of sulphate at hydroxyl group positions 4’ and 
6’ of the GalNAc residues and position 2 of the GlcA residue to create the CS 
backbone (Kusche-Gullberg and Kjellen, 2003). Sulphation of the 6’ position of 
the chondroitin sulphate GAG occurs in the medial/trans Golgi, whilst 
sulphation of the 4’ position occurs later in the trans Golgi (Silbert and 
Sugumaran, 2002). Sulfotransferase enzymes facilitate the elongation of GAG 
chains, specifically CHST11 in cooperation with ChGN-2 (Figure 1.4) 
(Izumikawa et al., 2011).  
The regulatory mechanisms of glycosyltransferases and sulfotransferases 
involved in CS GAG synthesis are not well understood and require deeper 
investigations (Kitagawa et al., 2003, Koike et al., 2014, Sato et al., 2003, 
Gulberti et al., 2012, Izumikawa et al., 2011, Little et al., 2008b). There is 
considerable interest in understanding the development of atherosclerosis 
associated with CS GAG chain synthesis through the regulation of the GAG 
synthesizing enzymes. The focus of the current study is on CS GAG chain 
synthesis and structure because of its role in binding lipoproteins (Camejo et al., 
1993, Sugahara and Kitagawa, 2000, Sugahara et al., 2003). Thus, changes in 
GAG chain structure are most likely to impact lipid binding and in the artery 
wall in early atherosclerosis. 
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Figure 1.4: Cell biology of CS/DS glycosaminoglycan chain synthesis.  
An initial pentose sugar, xylose is covalently attached to a serine residue of the newly synthesized core protein, catalysed by the XXYLT-1. This 
occurs after the core protein exits the ER in a midway compartment between ER and the Golgi apparatus. This initiating step is followed by the 
sequential completion of the tetrasaccharide linkage region. This process takes place in the cis Golgi network. Synthesis of the repeated disaccharide 
GAG chain occurs and further modification by sulfotransferases proceeds in the trans Golgi region.  
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1.5.2 Role of proteoglycans in cardiovascular disease 
 There is a long history of evidence for the role of proteoglycans in the 
development and progression of atherosclerosis. Proteoglycans are present in the 
ECM of the vessel wall at all stages throughout life and the accumulation of 
proteoglycans is observed in early (Nievelstein et al., 1991) and late 
atherosclerosis (Wight, 1989). Biglycan, decorin and versican are most closely 
associated with lipoprotein binding in the vessel wall (Chang et al., 2000, Skalen 
et al., 2002). Biglycan is well known to be present in the intima of normal 
human saphenous veins and coronary arteries (Merrilees et al., 2001, Gutierrez 
et al., 1997). Biglycan is the major proteoglycan associated with atherosclerosis, 
particularly due to its importance in lipoprotein retention in human blood vessels 
(Williams and Tabas, 1995). This study will focus more on biglycan due to its 
significance in human atherosclerosis. A variety of factors such as hormones or 
growth factors can influence the ‘modification’ or hyperelongation of the GAG 
chains (Little et al., 2008a, Little et al., 2008b). Growth factors such as platelet 
derived growth factor (PDGF) and TGF-β lead to the stimulation of versican 
mRNA expression and GAG elongation in monkey aortic smooth muscle cells 
(Schonherr et al., 1993, Schonherr et al., 1991). However only TGF-β stimulated 
an increase in biglycan mRNA expression (Schonherr et al., 1993). The same 
trend is seen in human VSMCs where both TGF-β and PDGF invoke GAG 
elongation but only TGF-β results in increased expression of biglycan mRNA 
(Little et al., 2002, Dadlani et al., 2008, Burch et al., 2010 , Getachew et al., 
2010b). Several GPCR agonists also lead to GAG hyperelongation such as: 
angiotensin II in human aortic smooth muscle cells (Figueroa and Vijayagopal, 
2002), and thrombin and endothelin-1 (ET-1) in human VSMCs (Ivey and Little, 
2008, Ballinger et al., 2009, Little et al., 2010, Burch et al., 2010).  
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 Immunohistochemistry studies of human arteries show evidence of 
strong co-localization between apo-B100 lipoproteins with biglycan (Nakashima 
et al., 2007, O'Brien et al., 1998, Camejo, 1982). Studies have shown that 
overexpression of biglycan by rat smooth muscle cells leads to the production of 
ECM with higher binding affinity to lipoproteins. The distribution of biglycan 
was shown to co-localize with lipids in the early phase of atherogenesis, which 
proposes that biglycan plays an essential role in initial lipid deposition in the 
arterial intima. The co-localization of biglycan with apo-B and apo-E is also 
found in early as well as advanced human and murine atherosclerotic lesions 
(Nakashima et al., 2007, O'Brien et al., 1998, Kunjathoor et al., 2002).  
 The concept of modified proteoglycans with hyperelongated GAG 
chains showing increased binding to LDL has recently been confirmed in an 
in vivo model of atherosclerosis. Anggraeni et al (Anggraeni et al., 2011) 
demonstrated that mice susceptible to atherosclerosis developed significant 
increase in aortic root plaque after 4 and 8 weeks on a Western diet. They 
detected increased biglycan core protein mRNA levels in the lesions after 8 
weeks of feeding. Gel filtration of CS proteoglycans from the aortas revealed an 
increase in size as early as 2 weeks which continued as lesions progressed. 
Immunostaining revealed co-localization of biglycan and apo-B in the initial 
stages of fatty streak development in these mice. Importantly, it was observed 
that an increase in the mRNA expression and staining of the transferase 
enzymes CHST11 and ChGn-2 at 8 weeks of feeding coincided with biglycan at 
early stages of lesion development. Since these two enzymes may be involved in 
the retention of atherogenic lipoproteins by mediating CS chain elongation, 
information regarding the mechanisms of regulation of these synthesizing 
enzymes may provide a novel therapeutic target to prevent the initiation and 
 Chapter-1. Introduction Page 22 
progression of atherosclerosis (Anggraeni et al., 2011). Another study in human 
cardiac fibroblasts found that XXYLT-1 mRNA expression was up-regulated by 
TGF-β in vitro and this increased level of XXYLT-1 activity corresponded to 
elevated GAG chain synthesis in cardiac tissues (Prante et al., 2007). Knock-
down of the XXYLT-1 mRNA reduced GAG synthesis (Prante et al., 2007). 
This data provides a link not just between biglycan and LDL but also GAG 
hyperelongation and a potential mechanism involving GAG synthesizing 
enzymes in atherogenesis. GPCRs such as thrombin have been shown to be 
involved in proteoglycan synthesis and GAG hyperelongation (Burch et al., 
2010, Burch et al., 2013, Ivey and Little, 2008), however the role of thrombin 
mediated GAG enzyme expression has not yet been investigated. 
1.6 GPCRs 
GPCRs are the most prolific and polyfunctional receptors in biology 
(Marinissen and Gutkind, 2001, Pierce et al., 2002). GPCRs control diverse 
functions including relaxation of blood vessels, acceleration of heart rate, 
transmission of sight impulses, biorhythms and olfaction (Spehr and Munger, 
2009). The early finding that GPCR agonists activate adenylate cyclase, an 
increase in cyclic adenosine-3’, 5’-monophosphate (cAMP) and functional 
outcomes such as vasorelaxation established GPCR signalling as a major area of 
cell biology and the award of a Nobel prize in Physiology and Medicine in 1971 
to Earl W. Sutherland (Robison et al., 1967). The G protein component of this 
signalling pathway elicited the Nobel Prize in Physiology or Medicine in 1994 
to Martin Rodbell and Alfred Gilman (Gilman, 1995, Rodbell, 1995). More 
recently, three decades of outstanding work in GPCR biochemistry and cell 
biology and the seminal discovery of the commonality and generality of the 
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seven transmembrane G-protein-coupled structure (Dixon et al., 1986) was 
recognised by the award of a Nobel Prize in Chemistry in 2012 to Robert J. 
Lefkowitz and his colleague Brian K. Kobilka (Lefkowitz, 2004, Kobilka, 
2007).  
GPCR signalling occurs due to the agonist induction of conformational 
changes in transmembrane receptor proteins (Chung et al., 2011, Neer, 1995, 
Gether et al., 1997, Rosenbaum et al., 2009). GPCR protein conformations can 
be active and inactive. Binding of the agonist favours the active conformation 
and this in turn increases the affinity for binding of the G protein on the 
cytoplasmic surface (Vogel and Siebert, 2001). 
GPCRs are helical transmembrane receptors complemented by functional 
extracellular and intracellular loops (Wess, 1997). Within the GPCR 
superfamily, there have been five major families identified. They are the 
rhodopsin, secretin, glutamate, adhesion and frizzled/taste2 families 
(Fredriksson et al., 2003). Most GPCRs contain seven helices and three 
intracellular loops; however, some members of the rhodopsin family may have 
eight helices and four intracellular loops (Oldham and Hamm, 2008). GPCRs 
bind hormones, neurotransmitters or growth factors (Neer and Clapham, 1988), 
which initiate a plethora of cellular responses. GPCRs are generally ligand 
activated but they can also bind to Gα-subunits in the absence of a ligand, a 
phenomenon known as receptor pre-coupling. GPCRs interact with their 
respective G proteins only upon receptor activation known as the collision 
coupling model or in the absence of agonist known as the pre-coupled receptor 
model (Hein and Bunemann, 2009). 
G proteins are classified into four families according to their α subunit: 
Gi/o, Gs, G12/13 and Gq (Figure 1.5). The Gs and Gi families regulate adenylyl 
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cyclase activity, while Gq activates phospholipase Cβ and G12/13 can activate 
small GTPase families (Neves et al., 2002). The Gq family consists of four 
members: Gq, G11, G14 and G15/16 (Strathmann and Simon, 1990, Wilkie et 
al., 1991) and their respective α subunits are thus Gαq, Gα11, Gα14 and 
Gα15/16. 
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Figure 1.5: Classification of G protein into four families and their 
intracellular targets in vascular smooth muscle cells. 
The Gα subunit is made up of Gαi, Gα12/13, Gαs and Gαq/11. The Gαq subunit 
is made up of four members, which include Gαq, Gαq/11, Gαq/14 and 
Gαq15/16. Different G proteins have different targets in vascular smooth muscle 
cells that allow a GPCR to activate a wide range of intracellular effects.   
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1.6.1 Thrombin receptors 
Thrombin acts on its GPCR PAR-1. Thrombin is a trypsin-like serine 
protease of 39kDa. It was first identified by its role in the coagulation cascade in 
which it cleaves fibrinogen, liberating fibrin (Macfarlane et al., 2001) however, 
subsequent discoveries revealed additional receptor mediated actions of 
thrombin. Pro-thrombin is synthesized in the liver as a prepropeptide and 
undergoes a series of post translational modifications before its secretion 
(Goldsack et al., 1998). Thrombin is short lived in the circulation, with a half-
life of 14 seconds (Goldsack et al., 1998) and it acts near the site of production 
(Coughlin, 2000). In 1991 the cloning of the thrombin receptor was first 
reported by Vu et al (Vu et al., 1991), this provided evidence for thrombin’s 
ability to contribute to cellular events in an agonist/receptor type mechanism. 
PAR-1 is activated when thrombin cleaves the N-terminal Arginine41-Serine42 
bond (Figure 1.6). The N-terminal cleavage of PAR-1 receptor unmasks a 
sequence that takes the function of a ligand and is capable of activating the 
receptor. As a consequence, thrombin cleavage of PAR-1 liberates a “tethered 
ligand” and provides the receptor with its own intrinsic activation method 
(Coughlin, 2000). PAR-1 can also be activated synthetically by a peptide that 
mimics the tethered ligand with the sequence, SFLLRN, albeit at much higher 
concentrations than required by thrombin. Since the discovery of PAR-1 there 
have been 3 additional human PARs cloned these are PAR-2 (Nystedt et al., 
1995), PAR-3 (Ishihara et al., 1997) and PAR-4 (Xu et al., 1998) however 
thrombin is only capable of activating PAR-1, 3 and 4. Table 1.3 outlines the 
expression of these receptors in human tissue and their agonists. 
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Table 1.3: PARs expressed in humans. 
This table demonstrates the different PAR receptors found in humans and the 
cardiovascular tissues they are expressed in, their biological agonists and the 
amino acid sequence of the tethered ligand for each receptor. The table is 
adapted from (Adams et al., 2011)  
.
Protease 
activated 
receptor 
subtype 
Cardiovascular 
tissue expression 
Biological agonists Tethered ligand 
sequence 
PAR-1 Platelets, 
endothelial cells, 
fibroblasts and 
smooth muscle 
cells 
Thrombin, Granzyme A, 
Factor Xa, Plasmin, APC-
EPCR, Trypsin IV, 
KLK1,4,5,6,14, MMP-1, 
Cathepsin G, 
Proatherocytin, Pen C 13 
SFLLRN 
PAR-2 Aortic, endothelial 
and smooth muscle 
cells 
Trypsin, Mast cell tryptase, 
TF-Factor Xa, Factor Viia, 
Acprsom, Matriptase, 
HAT, Trypsin IV, 
Granzyme A, TMPRss2, 
Chitinase, KLK2,4,5,6,14, 
bacterial gingipains, Der 
P1,2&3, Pen C 13 
SLIGKV 
PAR-3 Endothelial cells 
and smooth muscle 
cells 
Thrombin TFRGAP 
PAR-4 Platelets and 
smooth muscle 
cells 
Thrombin, Trypsin, 
Cathepsin G, plasmin and 
bacterial gigipains, 
KLK1,14, Factor Xa, 
MASP-1 and Trypsin IV 
GYPGQV 
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Thrombin has also been implicated in many aspects of CVD. The main 
focus in anti-thrombin therapy has been on anti-platelet strategies for the 
treatment and prevention of atherothrombosis and subsequent ischaemia (Shah, 
2009). Currently this therapy is showing promising results with the FDA 
approval of vorapaxar (formerly SCH530348), an antiplatelet agent that reduces 
the risk of cardiovascular related death and ischemic events in patients with 
atherosclerosis by 13% (Morrow et al., 2012), and atopaxar (formerly E5555) in 
clinical trials (Leonardi et al., 2010).  
Thrombin and its receptor are important in other stages of 
atherosclerosis. Thrombin and prothrombin have both been detected in the 
neointima of pre-atherosclerotic arteries (Patterson et al., 2001, Nelken et al., 
1992) and thrombin receptors are expressed in pre-lesion fatty streaks (Nelken et 
al., 1992). In addition, endogenous thrombin was found to be elevated in adults 
younger than 45 without clinically apparent atherosclerosis and this was 
associated with intima-media thickness as an index of subclinical atherosclerosis 
(Bernhard 2010). PAR-1 knockout mice show a decrease in neointima formation 
and increased medial area compared to wild type mice in an endothelial 
denudation model of vascular injury (Cheung 1999). Blockage of PAR-1 with 
the small molecule inhibitor, JNJ5551794, causes a dose dependent inhibition in 
neointima area and thickness (Andrade-Gordon 2001). As well as the initial and 
final stages of atherogenesis, thrombin plays a role in the early developing 
plaque by promoting inflammatory intermediates and lipid deposition in vessel 
wall due to modification of proteoglycans. Our group has published that 
thrombin leads to the elongation of GAG chains on proteoglycans synthesized 
by human VSMCs such that they show an increase in affinity for LDL and 
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hence may contribute to the deposition and retention of LDL in vessel wall (Ivey 
2008). 
 
 
 
 
Figure 1.6: Thrombin activation of the GPCR, PAR-1. 
Thrombin is a serine protease, a feature it utilises when activating its receptor 
Protease Activated Receptor-1 (PAR-1). Thrombin cleaves an N-terminal 
arginine-serine bond to liberate an intrinsic tethered ligand which activates the 
receptor leading to downstream signalling.  
 Chapter-1. Introduction Page 30 
1.7 Transactivation independent GPCR signalling 
1.7.1 The adenylate cyclase/ cAMP pathway 
The adenylate cyclase pathway is typically activated by the Gα subunit 
in particular  Gαs (Ross and Yallampalli, 2007, Billington and Penn, 2003) and 
is inactivated by Gαi protein (Hsia et al., 1984). Adenylate cyclase converts 
ATP to cAMP. cAMP then activates protein kinase A (PKA), a serine/threonine 
kinase that further propagates signals to the transcriptional level. PKA once 
active, then phosphorylates a variety of intracellular target proteins, by 
transferring a phosphate group from ATP to a serine/threonine residue on the 
target protein. cAMP activates other intracellular signalling molecules, such as 
the cAMP and AMP regulated exchange factor for Rap1 and the cyclic 
nucleotide-gated channel (Neves et al., 2002). This signalling cascade can be 
terminated by the breakdown of cAMP by a family of phosphodiesterases which 
hydrolyse cAMP to AMP. Physiological effects of the activation of this pathway 
in vascular smooth muscle include relaxation, as PKA phosphorylates and 
inactivates myosin light chain kinase. cAMP metabolised to adenosine inhibits 
VSMCs growth, hence the cAMP pathway may contribute to the regulation of 
vascular biology (Dubey et al., 1996).  
1.7.2 The phospholipase Cβ/ inositol phosphate system 
Activation of this signalling pathway begins with the activation of the 
GPCR by ligand binding. This causes dissociation of the Gαq (Rhee, 2001) and 
Gβγ subunits (Blake et al., 2001, Boyer et al., 1992), which are able to activate 
the membrane bound enzyme phospholipase C (PLC)β. Once activated, PLCβ 
cleaves a membrane bound phospholipid, phosphatidylinositol biphosphate 
(PIP2) to form two second messengers, diacylglycerol (DAG) which remains 
associated with the plasma membrane and inositol-(1,4,5)-triphosphate (IP3) 
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which diffuses into the cytoplasm. DAG, with calcium and phosphatidylserine, 
activate protein kinase C (PKC), a family of serine/threonine kinases that 
translocate from the cytosol to the membrane where they become activated and 
phosphorylate intracellular proteins.  
In VSMCs PKC mediates proliferation, an increase in contractile force 
and regulation of cell growth (Lee and Severson, 1994). IP3 stimulates the 
release of calcium by activating receptors on the ER of cells. The ET-1 receptors 
have been shown to couple to Gαq and activate this pathway in VSMCs (Eguchi 
et al., 1993) raising intracellular IP3 and calcium levels (Griendling et al., 1989). 
In a similar manner the thrombin receptor, PAR-1, couples to Gαq and causes an 
increase in intracellular calcium and the activation of PKC in VSMCs.  
1.7.3 The Rho/Rho kinase pathway 
In addition to the heterotrimeric G proteins that are bound to GPCRs, 
other low molecular weight GTPases are present in VSMCs and are able to 
activate their own signalling pathways. Members of the small GTPase family 
include Rac, Ras and Rho of which there are 3 isoforms termed RhoA, RhoB 
and RhoC. Like the G-proteins they are activated by the binding of guanosine 
triphosphate (GTP) which occurs as a result of the exchange of guanosine 
diphosphate (GDP) for GTP and this exchange is regulated by guanine 
nucleotide exchange factors (GEFs) (Seasholtz et al., 1999). The third class of 
Rho regulatory proteins are the guanine nucleotide dissociation inhibitors 
(GDIs). Under basal conditions the majority of cellular Rho is found bound to 
specific GDIs (Seasholtz et al., 1999).GDIs inhibit the GTPase cycling 
(Seasholtz et al., 1999).  
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1.8 Transactivation dependent GPCR signalling 
The classic GPCR signalling pathway (Figure 1.7) is termed direct, from 
the agonist to the GPCR to the coupled G protein interaction with subsequent 
downstream signalling leading to the functional response(s). This well 
researched pathway has been the subject of many reviews (Smith and Luttrell, 
2006) (Premont and Gainetdinov, 2007, Hill, 2006). Two decades ago, this 
linear pathway was complemented by the finding that GPCRs could directly 
activate other cell surface receptors of the tyrosine kinase type (e.g. EGFR) 
leading to the activation of the kinase receptor and its downstream signalling 
pathway (Daub et al., 1996, Prenzel et al., 1999). The activation of PTKRs by a 
GPCR represented a major expansion in the cellular outcomes attributable to 
GPCR signalling. An example in vascular biology is the acute activation of 
GPCR angiotensin II receptor where a classical linear response leads to very 
rapid mobilisation of intracellular calcium ions and vascular contraction (Lee et 
al., 2001, Wynne et al., 2009) whereas transactivation of PTKRs (EGFR) leads 
to a slow vascular remodelling due to cell proliferation and ECM synthesis (Lee 
et al., 2001).  
In very recent times the paradigm of GPCR transactivation signalling has 
expanded to include the transactivation of cell surface receptors of the 
serine/threonine kinase type and notably the important receptor for TGF-β. The 
activation of TGFBR1 either directly by its agonist or via transactivation 
following activation of a thrombin (Burch et al., 2010) or ET-1 (Little et al., 
2010) receptor has been implicated in the modification of the synthesis and 
structure of GAG chains. GAG chain elongation has been implicated in the early 
stages of atherosclerosis in what is termed the “response to retention” hypothesis 
(Williams and Tabas, 1995, Little et al., 2002, Yang et al., 2010).  
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Whereas PTKR and S/TKR have intrinsic catalytic activity, GPCRs do not 
have enzymatic activity but are linked to Gα proteins which are GTPases and 
mediate the signal transduction (Wedegaertner et al., 1995). G proteins of the α, 
β and γ families provide the specificity and functionality of GPCRs. The role of 
G proteins in GPCR signalling has not been as intensively investigated as other 
aspects of GPCR signalling possibly due to the limited availability of 
pharmacological tools. As GPCR signalling in physiology and pathophysiology 
continues to grow, the potential importance of G proteins increases both for the 
fundamental cell biology and as potential therapeutic targets.  
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Figure 1.7: G protein couple receptor signalling mechanisms. 
GPCR signalling can occur via 3 main mechanisms, the first is through the 
intracellular activation of the G proteins which is referred to as transactivation 
independent signalling (1). The second is through the utilization of the β-arrestin 
molecule (2) and thirdly through a mechanism known as transactivation were 
the GPCR can lead to the activation of a PTKR or a S/TKR (3) this is referred to 
as transactivation dependent signalling.  
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1.8.1 Defining GPCR transactivation 
The term transactivation (Figure 1.7) was applied when GPCR lead to the 
activation of either PTKR or S/TKR (Burch et al., 2010, Burch et al., 2013, 
Little et al., 2011). Earlier, several groups identified a similar process but did not 
apply the term transactivation (Sorescu, 2006, Leask, 2010, Xu et al., 2009, 
Jenkins et al., 2006). Berry and colleagues were the first to define 
transactivation as “the process whereby ligand stimulation of one receptor leads 
to activation of another, distinct receptor” (Berry et al., 2001). Wetzker and 
Bohmer (Wetzker and Bohmer, 2003) described transactivation as being when 
one receptor transactivates a heterologous receptor. In order to define GPCR 
transactivation of S/TKR and to conceptually and mechanistically relate the 
phenomena to GPCR transactivation of PTKR, Little and colleagues (Little et 
al., 2011) provided a definition of transactivation as “the agonist occupancy of 
its cognate GPCR complex which leads in a relatively short time and in the 
absence of ‘de novo’ protein synthesis to the activation and cytosolic generation 
of the immediate downstream product(s) of a second cell surface protein kinase 
receptor”. A key parameter is that the receptor to receptor pathways defined as 
transactivation do not involve gene transcription. Thus, there appear to be 
sufficient similarities between GPCR to PTKR and GPCR to S/TKR 
transactivation that is reasonable to apply the term transactivation to both 
responses. The term “transactivation dependent” will be used to describe GPCR 
transactivation signalling and the term “transactivation independent” will refer 
to all other form of signalling downstream of GPCRs (Figure 1.7). 
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1.8.2 GPCR transactivation of protein tyrosine kinase receptors 
The phenomenon of PTKR transactivation by a GPCR was first described 
in 1996 by Axel Ullrich (Daub et al., 1996). In this ground-breaking paper, 
Ullrich and colleagues (Daub et al., 1996) reported that agonists of GPCRs 
could transactivate the PTKR, EGFR, in rat-1 fibroblasts. Rat-1 fibroblasts 
stimulated by agonists ET-1 and thrombin showed a temporal increase in 
phosphorylation of extracellular signal-regulated kinase (phospho-Erk)1/2 
which was blocked by either the highly specific, and well characterised EGFR 
inhibitor, AG1478, or by transfection with a cytoplasmic truncated EGFR 
mutant. This indicated that the increase of phospho-Erk1/2 by these GPCR 
agonists is via the EGFR and is a direct readout of EGFR transactivation (Daub 
et al., 1996). This group expanded their work to show this novel signalling 
mechanism exists in multiple cell lines. They showed that thrombin and 
lysophosphatidic acid (LPA) are capable of transactivating EGFR in human 
HaCat keratinocytes and COS-7 cells (Daub et al., 1997). In COS-7 cells, the 
response is dependent on Gαq and Gαi coupled GPCRs, and provided the first 
mechanistic aspect of the GPCR mediated transactivation signalling (Daub et 
al., 1997). Transactivation of EGFR was shown to have important consequences 
in the vasculature. EGFR transactivation by Gαq- and Gαi-coupled to 
angiotensin II or LPA receptors respectively, stimulate protein synthesis in rat 
aortic smooth muscle cells (Voisin et al., 2002) indicating that the 
transactivation of PTKR may be a mechanism by which GPCR agonists regulate 
cell growth and division. 
Since the original observation by Ullrich and colleagues (Daub et al., 
1996) there have been almost 200 reports of GPCR transactivation of PTKR. 
There has been considerable work on the mechanisms of this transactivation and 
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several pathways are prominent – the “triple membrane bypass” pathway which 
involves the GPCR activating a membrane bound matrix metalloproteinase 
(MMP) or A Disintegrin and A Metalloprotease (ADAM) resulting in the 
cleavage and release of a PTKR ligand which subsequently activates its cognate 
receptor in an autocrine/paracrine manner (Prenzel et al., 1999, Gschwind et al., 
2002). Another candidate for intracellular mediators of transactivation is the 
generation of reactive oxygen species (ROS) (Frank and Eguchi, 2003). 
Stimulation of angiotensin II causes the activation of nicotinamide adenine 
dinucleotide phosphate (NAPDH) oxidase and an increase in intracellular ROS 
production (Frank and Eguchi, 2003). ROS act as second messengers and 
activate a wide variety of serine/threonine and tyrosine kinases and may activate 
the EGFR by targeting the cysteine regions of the active sites of tyrosine 
phosphatases, which in turn activate tyrosine kinases (Shida et al., 2004). ROS 
stimulate the production of a heparin binding EGF-like growth factor (HB-EGF) 
via cleavage by an MMP which is able to activate the EGFR (Figure 1.8) 
(Kalmes et al., 2001). Evidence for the role of HB-EGF in EGFR transactivation 
is supported by the observation that neutralizing antibodies to HB-EGF block 
EGFR activation (Kalmes et al., 2001). 
 In addition, some drugs elicit activation of a GPCR and transactivation of 
the PTKR. Serotonin transactivates the PDGF-β receptor in pulmonary artery 
smooth muscle cells (Liu et al., 2007). Inhibition of PDGF receptor kinase with 
imatinib or AG1478 blocks serotonin mediated PDGF-β receptor 
phosphorylation. The selective serotonin reuptake inhibitor, fluoxetine blocks 
both the serotonin mediated binding and activation of PDGF-β receptor (Liu et 
al., 2007). 
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Figure 1.8: GPCR transactivation of protein tyrosine kinase receptors in 
vascular smooth muscle cells. 
 GPCRs can transactivation PTKRs in a ligand dependent manner, otherwise 
known as triple membrane bypass signalling. This involved the activation of cell 
surface matrix metalloproteinases (MMPs) that cleave and release membrane 
anchored EGFR ligands.  
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Many GPCRs and many PTKR partners participate in GPCR 
transactivation. GPCR transactivation of EGFR is the best characterised 
however transactivation of other PTKRs is well known and includes, Trk, 
fibroblast growth factor, insulin growth like factor 1 and PDGF receptors 
(Puehringer et al., 2013, Nagai et al., 2005, Zhao et al., 2011, Wang et al., 2010, 
Tsai et al., 2014). The Ullrich et al paper (Daub et al., 1996) described above is 
the first to utilize the description of ‘transactivation’ to describe the activation of 
EGFR by GPCRs, however it was not the first example of such mechanism. It 
was the PDGF receptor that first alluded to the potentially novel pathway as a 
link between the PDGF and angiotensin II receptors in VSMCs, although the 
authors did not directly mention transactivation, nor define it (Linseman et al., 
1995). Subsequent research has revealed that angiotensin II can transactivate the 
PDGF receptor leading to phospho-Erk1/2 (Shida et al., 2004) as can LPA 
(Goppelt-Struebe et al., 2000, Herrlich et al., 1998). 
1.8.3 Transactivation of serine/threonine kinase receptors 
GPCR transactivation of PTKR has been extensively researched however 
it has appeared that this phenomenon is not restricted to these kinase receptors 
(Blume-Jensen and Hunter, 2001). Some GPCRs can activate S/TKRs 
specifically from the TGF-β receptor super family (Table 1.4) (Burch et al., 
2013, Burch et al., 2012, Little et al., 2010, Chung et al., 2013).  
It was initially observed that the PAR-1 mediated stimulation of 
proteoglycan synthesis in human VSMCs, was partially blocked by the specific 
TGFBR1 antagonist, SB431542 (Burch et al., 2010). Subsequently, it was 
observed that thrombin stimulated the accumulation of phospho-
Smad2(465/467) in VSMCs and the response was blocked by SB431542 
indicating the involvement of TGFBR1 (Burch et al., 2010). Burch et al. (Burch 
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et al., 2013) described the mechanism in more detail. The transactivation 
involves the GPCR, PAR-1, the cytoskeleton, integrin dependent signalling and 
ultimately the activation of the Large Latent Complex which holds TGF-β near 
the cell surface with the potential for rearrangement and activation of TGFBR1 
(Burch et al., 2013). Recently almost identical data for the PAR-2 mediated 
transactivation of TGFBR1 and EGFR in human proximal tubular epithelial 
cells has been described (Chung et al., 2013). Chung et al (Chung et al., 2013) 
reported that activation of PAR-2 triggered the phosphorylation of Smad2 and 
Smad3, which was partially inhibited by SB431542. PAR-2 activation induced a 
robust phospho-Erk1/2 response which was completely abolished using the 
EGFR specific inhibitor, AGI478. An interesting point in comparison to our 
previous published work on PAR-1 transactivation of TGFBR1 (Burch et al., 
2013) is that Chung et al. (Chung et al., 2013) showed that AG1478 diminished 
PAR-2 mediated phospho-Smad2 but it was not involved in PAR-1 mediated 
phospho-Smad2 in the carboxyl terminus.  
The stimulation of proteoglycan synthesis by thrombin is blocked by 
40-50% by the TGFBR1 receptor antagonist, SB431542, and 40-50% by the 
EGFR antagonist, AG1478 (Burch et al., 2013). This indicates that a partial 
effect of thrombin simulation of proteoglycan synthesis is mediated by 
transactivation of the TGFBR1 and a similar amount is due to the transactivation 
of the EGFR. Dual pharmacological inhibition of the TGFBR1 and the EGFR 
account for the total GAG elongation effect mediated by thrombin (Burch et al., 
2013). Knowing that these effects are additive and yet share no common known 
signalling pathways can further broaden the current understanding of GPCR 
transactivation phenomenon.  
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The involvement of the cytoskeleton and integrin signalling in GPCR 
transactivation of S/TKR in VSMCs is consistent with that observed in other 
cell types (Jenkins et al., 2006, Xu et al., 2009, Belmadani et al., 2008). 
Thrombin mediated transactivation of TGFBR1 in mouse lung epithelial cells 
involves αVβ6 integrin signalling (Jenkins et al., 2006). In a vascular model 
using mouse microvessel VSMCs angiotensin II mediated TGFBR1 
transactivation was abolished by an αVβ3 blocking antibody (Belmadani et al., 
2008), indicating that the integrin isoforms that mediate transactivation of the 
S/TKR may be cell type and context specific. The thrombin transactivation of 
TGFBR1 requires an intact cytoskeleton and RGD binding integrins (Burch et 
al., 2013), however the specific integrins have not yet been determined (Figure 
1.9). 
 
  
 
 Table 1.4: GPCR transactivation of serine/threonine kinase cell surface receptors.
Agonist  GPCR S/TKR Mechanism of action Response Cellular response Cell type  Reference 
Thrombin PAR-1 
 
PAR-1 
PAR-1 
 
PAR-1 
TGFBR1 
 
TGFBR1 
TGFBR1 
 
TGFBR1 
No Data 
 
ROCK/integrin 
No Data 
 
RhoA ROCK/integrin 
αVβ6 
pSmad2 
 
pSmad2 
pSmad2 
 
pSmad2 
Proteoglycan synthesis 
 
Proteoglycan synthesis 
GAG synthesizing genes 
 
Oedema/permeability 
Vascular smooth 
muscle cells 
Vascular smooth 
muscle cells 
Vascular smooth 
muscle cells 
Lung epithelium 
(Burch et al., 2010) 
(Burch et al., 2013)  
(Kamato et al., 2016) 
(Jenkins et al., 2006)6  
2f-LIGRLO-NH2 PAR-2 TGFBR1 MMPs pSmad2 Renal fibrosis Proximal tubular 
epithelial  
(Chung et al., 2013)13 
Factor Xa PAR-1 TGFBR1 Gαq/ROCK/ 
Integrin αVβ5 
pSmad2/3;  
α-SMA 
Fibroblast differentiation Lung fibroblasts (Scotton et al., 2009)  
Endothelin-1 ETR 
 
ETAR 
TGFBR1 
 
TGFBR1 
No Data 
 
No Data 
pSmad2 
 
pSmad3 
Proteoglycan synthesis 
 
Epithelial mesenchymal 
transition 
Vascular smooth 
muscle cells 
Lung alveolar 
epithelium 
(Little et al., 2010)  
(Jain et al., 2007) 
Lysophosphatidic 
acid 
LPA2R 
 
LPA2R 
TGFBR1 
 
TGFBR1 
Gαq/ROCK/ 
Integrin αVβ6 
Integrin αVβ5 
PAI-1 
pSmad2; PAI-1 
Fibrosis 
Airway remodelling 
Lung epithelium 
Airway smooth 
muscle 
(Xu et al., 2009)  
(Tatler et al., 2011)1  
Methacholine Muscarinic R TβRI Integrin αvβ5 pSmad2; PAI-1 Airway remodelling Airway smooth 
muscle 
(Tatler et al., 2011)  
Parathyroid 
Hormone 
PTH1R BMPR2 endocytosis pSmad1 MSC differentiation Mesenchymal stem 
cells 
(Yu et al., 2012) 
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Integrins are a family of ubiquitous cell surface class I transmembrane 
spanning receptors (Ruoslahti and Pierschbacher, 1987). Integrin signalling is an 
interesting biological phenomenon because it involves the transmission of 
signals from the outside to the inside of a cell, so-called ‘outside in signalling’, 
as well as ‘inside out signalling’ and this confers bidirectional signalling 
properties on integrins and places them at an important axis in cellular 
communication (Hynes, 2002). Several examples of integrins and GPCR 
transactivation of S/TKR have been described over the past decade (Jenkins et 
al., 2006, Xu et al., 2009, Tatler et al., 2011, Scotton et al., 2009). Latent TGF-β 
exists in a complex that is anchored to the extracellular plasma membrane. The 
latency associated protein constituent of the complex is known to contain a 
RGD motif, and thus is a candidate for integrin ligation (Worthington et al., 
2011). Inside out integrin signalling has been associated with cytoskeletal 
rearrangement and ROCK signalling. Studies from our laboratory show that 
thrombin can transactivate TGFBR1 via cytoskeletal rearrangement which 
activates ROCK signalling leading to the activation of cell surface integrins 
(Burch et al., 2013). PAR-1 transactivation of PTKRs and the generation of 
phospho-Erk1/2 is not mediated by the same ROCK integrin signalling 
mechanism as for TGFBR1 but rather the well characterised ligand-dependent 
MMP mediated pathways. The first interaction between integrins and MMPs 
was identified in melanoma cells where it was demonstrated that the C-terminal 
domain of MMP-2 binds directly to αVβ3 (Brooks et al., 1996). MMP-8 and 
MMP-13 act in concert with integrin α5β1 to mediate bradykinin-induced 
transactivation of EGFR and phospho-Erk1/2 in kidney cells (Kramarenko et al., 
2010).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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We have shown that in VSMCs, MMPs are involved in thrombin 
generation of phospho-Erk1/2 and the stimulation of proteoglycan synthesis via 
transactivation of the EGFR. These MMP dependent pathways are not involved 
in thrombin transactivation of the TGFBR1 leading to phospho-Smad2(465/467) 
generation (Burch et al., 2013). In contrast Chung et al (Chung et al., 2013) 
examined the effect of broad spectrum MMP inhibitor, marmistat, on the 
phosphorylation of Smad2 linker region in human proximal tubular epithelial 
cells, presenting a partial role for MMPs in PAR-2 mediated transactivation of 
the TGFBR1. However as Smad linker region can be phosphorylated by a 
number of pathways it remains unclear that the response is due to PAR-2 
transactivation of TGFBR1. 
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Figure 1.9: GPCR transactivation of serine/threonine kinase receptors in 
vascular smooth muscle cells.   
S/TKR activation is achieved via cytoskeletal rearrangement which activates 
ROCK signalling, leading the activation of cell surface integrins which bind to 
the latent TGF-β complex. This allows for TGF-β to bind to its receptor leading 
to subsequent Smad signalling.   
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1.8.4 Role of G proteins in GPCR transactivation signalling 
The response to GPCR agonists and the conformational changes in the GPCR 
that are induced by ligand binding are mediated by heterotrimeric G protein 
complexes. Consisting of three subunits; α, β and γ their role is to transduce 
external stimuli into intracellular signalling cascades. Daub et al. (Daub et al., 
1997) investigated the role of G proteins in EGFR transactivation signalling 
using COS-7 cells and found that LPA induced EGFR transactivation was 
partially inhibited by treatment of cells with Gαi inhibitor, pertussis toxin. The 
response however was unaffected in thrombin stimulated cells indicating that 
LPA signals through Gαi and pertussis toxin-sensitive G proteins (Daub et al., 
1997). Pertussis toxin catalyses the ADP-ribosylation of the Gαi proteins 
preventing the coupling with the GPCR. Cells transfected with Gαq-coupled 
GPCRs are unaffected by pertussis toxin while Gαi coupled receptors were 
blocked by pertussis toxin (Koch et al., 1994). Thus, EGFR transactivation may 
occur through both pertussis toxin sensitive and insensitive pathways. Similarly 
in rat-1 fibroblasts, Gαi coupled, but not Gαq/11 coupled receptors mediate 
tyrosine kinase dependent phospho-Erk1/2 (van Corven et al., 1989). The role of 
G proteins in transactivation dependent signalling is of considerable interest; 
however there has been a limited number of studies available in the area. The 
work in this thesis will focus of the role of the Gαq in GPCR mediated 
transactivation dependent signalling. 
1.9 Gα q subunit 
1.9.1 Structure of Gαq 
Gαq and Gαq/11 are products from distinct genes on the same 
chromosome (Wilkie et al., 1991). These two proteins have a 90% similarity in 
the number of amino acids and are functionally almost identical. However, the 
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tissue distribution of the two isoforms is distinct (Wilkie et al., 1991). The 
Gαq/11 is generally expressed ubiquitously with the exception of platelets where 
only Gαq is expressed (Griewank et al., 2011). According to the gene expression 
microarray data from UCSC genome browser, the Gαq/11 gene is highly 
expressed in the heart however Gαq had a much lower expression level. Gαq is a 
359 amino acid protein comprised of two domains: a helical domain and a 
GTPase binding domain (Figure 1.10). The GTPase domain is responsible for 
hydrolysing GTP to GDP (Figure 1.11), as well as binding the Gβγ subunits, 
GPCRs and other effectors. This domain is conserved between all members of 
the G protein superfamily (Oldham and Hamm, 2008). The GTPase domain 
contains three switch regions (Figure 1.10), which are flexible loops that change 
conformation when bound with GTP. The helical domain contains six α-helices 
which encapsulates nucleotides in the protein core by forming a lid over the 
nucleotide-binding pocket. Of all G protein families identified, members of the 
Gαq family share the most amino acid sequence homology. In humans, Gαq/11, 
Gαq/14 and Gαq/16 share 90%, 80% and 57% sequence similarities, 
respectively (Hubbard and Hepler, 2006).  
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Figure 1.10: Schema of Gαq functional domains. 
The helical domain is represented in blue and the GTPase domain is shown in 
purple. The switch regions are as follows: Switch Region 1 (182-192) in orange, 
Switch region 2 (204-224) in red and switch region 3 (236-257) in yellow. 
Adapted from Mizuno and Itoh 2009(Mizuno and Itoh, 2009). 
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1.9.2 Gαq/11 signalling 
In an inactivated state, the α subunit binds GDP, however, upon ligand 
binding, GTPase activity is induced and promotes the exchange of bound GDP 
for GTP (Figure 1.11) to activate the GPCR. The α subunit and βγ complex then 
dissociate from one another and interacts with their associated effectors 
(Berman and Gilman, 1998). In the most common paradigm Gαq activates 
PLCβ which hydrolyses PIP2 releasing DAG and IP3. DAG activates a number 
of isoforms of PKC, whereas IP3 diffuses to the ER and binds to IP3 receptors on 
ligand-gated calcium channels leading to a release of calcium ions into the 
cytosol and subsequently in some cells (Little et al., 1992). The calcium cycle 
continues with the uptake of calcium back into the ER by calcium ATPases.   
Activation of Rho mediated signalling pathways can be indirectly 
mediated by GPCRs, integrins or PTKRs. G proteins, Gαq/12 and Gαq/13, 
activate Rho by activation of a Rho GEF (Singh et al., 2007). It is only when 
RhoA is active that it can interact with and activate downstream effectors such 
as ROCK. Thrombin activation of PAR-1 involves both Gαq/11 and Gαq12/13, 
which cause RhoA activation signalling downstream to stimulate ROCK and 
PKC-related kinase. In human endothelial cells Gαq/11 involves intracellular 
release of calcium through the downstream activation of the two Rho-regulated 
protein kinases, which in turn regulate the contraction of actinomycin and the 
formation of focal adherence.  
Overexpression of active Gαq/11 or stimulation of the m1 muscarinic 
acetylcholine receptor induces apoptosis in HeLa cells. Rho kinase and ROCK 
are stimulated due to the cleavage of activated caspase 3 during apoptosis. There 
have been several studies on the mechanisms involved in Gαq/11 induced 
apoptosis, which show that this phenomenon is cell and context dependent. In 
COS-7 and CHO cells, Gαq/11 induced apoptosis is dependent on PKC, 
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angiotensin II induced myocyte apoptosis is dependent on the release of 
intracellular calcium suggesting the involvement of PLC pathway. The 
molecular mechanism of Gαq/11 induced apoptosis leading to the activation of 
Rho/ROCK is not clearly understood, however some studies have shown that 
Gαq/11 signalling activated RhoA which inhibited insulin-stimulated Akt 
phosphorylation in HeLa cells. In CHO cells Gαq and Gαq/11 regulate actin 
cytoskeleton remodelling through the activation of ADP-ribosylation factor 6 
(Boshans et al., 2000). Platelets stimulated with P2Y1 agonist leads to the 
activation of RhoA, this activation was inhibited by Gαq inhibitor YM-254890, 
indicating that RhoA activation downstream of P2Y1 receptors requires Gαq 
stimulation (Jin et al., 2009). 
  
 Chapter-1. Introduction Page 51 
 
 
 
Figure 1.11: G-protein coupled receptor structure.  
GPCRs are characterised by 7 membrane spanning domains. The N-terminal is 
located at the extracellular surface and generally provides the ligand docking 
site. The C terminus is located at the intracellular interface. Ligand engagement 
causes a conformational change in the GPCR resulting in activation of G protein 
via the exchange of GDP for GTP on the Gα unit and dissociation from the Gβγ 
unit. 
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1.9.3 Functions of Gαq 
Gαq protein plays a role in a number of cellular signalling pathways. In 
the vasculature studies utilising genetically modified mice suggest that receptors 
coupled to the Gαq play a role in the development of heart failure (Fan et al., 
2005). Following treatment to activate Gαq in transgenic mice expressing a 
silent Gαq, the mice rapidly developed a dilated cardiomyopathy and heart 
failure. Transgenic mice expressing an inducible Gαq that cannot activate PLCβ 
do not develop heart failure. Thus, the activation of Gαq resulting in heart 
failure requires the activation of PLCβ (Fan et al., 2005). Gαq deficient mice 
compared to wild type dramatically increased bleeding time and resistance to 
thromboembolism (Offermanns et al., 1997). Angiotensin II dose-dependently 
increases cell proliferation in smooth muscle cells and this is inhibited by the 
Gαq antagonist, GP-2A (Tanski et al., 2004). Gαq is also implicated in insulin-
stimulated glucose transport (Imamura et al., 1999). In 3T3-L1 adipocytes, Gαq 
is required for insulin-induced GLUT4 translocation and the stimulation of 2-
deoxy-D-glucose uptake. Gαq/11 proteins are involved in HIV-1 envelope 
glycoprotein-dependent cell-cell fusion upstream of Rac-1 (Harmon and Ratner, 
2008). 
 
1.9.4 Role of Gαq in the GPCR transactivation of kinase 
receptors  
There is a limited amount of studies on the role of Gαq in transactivation 
dependent signalling. In L6 myoblasts derived from rat skeletal muscle, ET-1 
via the endothelin type A receptor mediated transactivation of PDGF receptor 
was inhibited in the presence of Gαq antagonist, YM-254890 (Harada et al., 
2014). Shear stress induced phospho-Erk1/2 in CHO cells permanently 
transfected with wild type angiotensin II type 1 receptor was completely 
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inhibited in the presence of YM-254890 (Barauna et al., 2013). Shear stress 
activates PTKR (Jin et al., 2003) thus showing that the Gαq plays a role in 
angiotensin II mediated transactivation of PTKR. Purigenic receptor P2Y2R 
transactivation of the insulin-like growth factor receptor in keratinocytes was 
inhibited by Gαq/11 siRNA transfected cells and YM-254890 (Taboubi et al., 
2010). 
Moving onto the role of G proteins in transactivation of S/TKR. Xu and 
colleagues (Xu et al., 2009) showed that in mouse embryonic cells with Gαq and 
Gα12/13 knockout only that the Gαq is involved in LPA induced transactivation 
of the TGFBR1 (Xu et al., 2009). This was confirmed with a pharmacological 
approach using Gαq antagonist GP-2A (Tanski et al., 2004, Mukai et al., 1992). 
In primary epithelial cells LPA induced TGFBR1 activation was inhibited in the 
presence of GP-2A (Xu et al., 2009). PAR-1 induced transactivation of the 
TGFBR1 in idiophathic pulmonary fibrosis lung tissue occurred via the Gαq 
protein (Scotton et al., 2009). Moreover the attenuation of PAR-1 induced 
activation of the TGFBR1 with Rho kinase antagonist (Y-27632) firmly places 
the Rho signalling pathway downstream of this response (Scotton et al., 2009). 
Similarly in murine lung fibroblasts, thrombin mediated CCL2 production 
occurs via PAR-1 coupling to Gαq and the cooperation between Rho signalling 
pathways (Deng et al., 2008). It will be interesting to investigate the role of 
Gαq proteins in PTKR and S/TKR transactivation signalling as it has the 
potential to be a point of commonality in GPCR mediated transactivation 
dependent signalling. 
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Figure 1.12: Pharmacological agents to inhibit downstream signalling 
intermediates of Gαq. 
Once GPCR is activated by its agonist, Gαq signalling activates PLCβ, which 
leads to the hydrolysis of PIP2 and DAG.The former leads to initiate the release 
of IP3 initiating calcium release, activating protein tyrosine kinase 2 
(PYK2),which leads to proto-oncogene tyrosine protein kinase (Src) activating 
Ras guanine nucleotide exchange factor (RasGEF),which leads to the activation 
of MAPK signalling. MAPK signalling pathway can also be downstream of 
DAG that activates protein kinase C (PKC), which leads to the activation of 
MAPK signalling. Gαq signalling can also go indirect of PLCβ by activating 
RhoGEF leading to the activation of the Rho/ROCK signalling pathway. 
Extracted from (Kamato et al., 2015) 
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1.9.5 Molecular and pharmacological approach for the study of 
G proteins  
The reason for the restricted investigations on the role of Gαq in cell 
biology relates to the limited availability of the pharmacological agents. There is 
not a readily available small molecule, which interact with Gαq signalling. In 
the literature there have been some agents of natural products, however the 
availability has varied over the years, in the sections below the pharmacological 
(Figure 1.12) and molecular agents available to study the role of Gαq have been 
reviewed.  
1.9.5.1 Pharmacology of Gαq inhibitor - YM-254890  
The compound known as YM-254890, a cyclic depsipeptide isolated from 
the Chromobacterium sp. QS3666, is a specific Gαq inhibitor. YM-254890 was 
discovered and developed by Yamaguichi Pharmaceuticals Japan; Yamaguichi 
subsequently became the property of Astellas Pharmaceuticals Japan. 
YM-254890 was made available to researchers ten years ago and a small 
number of interesting studies were published. YM-254890 is an inhibitor of Gαq 
and as such blocks the cycling of GDP/GTP specifically blocking the release of 
GDP from the Gα protein (Takasaki et al., 2004, Taniguchi et al., 2003, 
Nishimura et al., 2010). YM-254890 has been shown to inhibit ADP-induced 
platelet aggregation which is mediated via GPCRs, P2Y1 and P2Y12 (Taniguchi 
et al., 2003). These receptors are associated with the Gαq and Gαi signalling 
pathways respectively. YM-254890 has no effect on the P2Y12 signal 
transduction pathway, indicating that the compound has some specificity for 
Gαq. It was also shown to inhibit Gαq coupled GPCR signalling by inhibiting 
calcium mobilisation in P2Y2-expressing C6-15 cells but not cAMP 
accumulation (Takasaki et al., 2004). When bound to GDP, the non-polar side 
chains of YM-254890 form hydrogen bonds with the Switch I region, however, 
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this is a conformation that cannot be maintained when bound with GTP 
(Nishimura et al., 2010). Aside from antiplatelet activity, by electrically 
inducing carotid artery thrombosis in rodents, YM-254890 was also shown to 
have antithrombotic and thrombolytic effects (Kawasaki et al., 2003). 
1.9.5.2 UBO-QIC/FR300359 
FR300359, henceforth referred to as UBO-QIC is also, like YM-254890, a 
cyclic depsipeptide; it is isolated from the Ardisia crenata sims plant (Miyamae, 
1989). UBO-QIC is structurally very similar to YM-254890 except UBO-QIC 
has one methyl group replaced by an ethyl group and another methyl group 
replaced by an isopropyl group (Kukkonen, 2016). UBO-QIC inhibits platelet 
aggregation in rabbits in vitro and causes dose-related hypotension in 
anaesthetised normotensive rodents which is consistent with the effect on blood 
pressure in Gαq knock down mice (Fujioka et al., 1988, Wirth et al., 2008). The 
blood pressure lowering effect was attributed to the ability of UBO-QIC to 
partially mediate nitric oxide release from endothelial cells and inhibit calcium 
migration caused by voltage-dependent and receptor operated channels (Zaima 
et al., 2013). 
There have been limited studies with UBO-QIC since its discovery as a 
Gαq inhibitor. In HEK cells expressing TRPV4, PAR-2 mediated intracellular 
calcium release was abolished by UBO-QIC, however extracellular calcium 
influx through the TRPV4 ion channel was unaffected showing that PAR-2 
coupling to TRPV4 is not mediated by Gαq signalling (Grace et al., 2014). L-
Orn IP1 and calcium responses of transfected CHO cells with GPCR receptor 6 
was mediated through Gαq activation, both these pathways were inhibited by 
UBO-QIC (Jacobsen et al., 2013). Muscarinic M3 receptor induced calcium 
signalling in both non-transfected and CHO cells transfected with Gβ5-RGS7 is 
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dependent on Gαq but not Gαi signalling (Karpinsky-Semper et al., 2014). In 
CHO cells transfected with P2YP and cells expressing M1 muscarinic receptors, 
activation of PLC using ATP and oxotremorine-M was completely blocked in 
the presence of UBO-QIC (Kukkonen, 2016). PGE2 stimulated adenylate 
cyclase production in CHO cells transfected with β2-adrenoreceptors was not 
inhibited in the presence of UBO-QIC, thus showing UBO-QIC does not inhibit 
Gαs signalling (Kukkonen, 2016). PAR mediated platelet aggregation was 
inhibited in a dose dependent manner by UBO-QIC in human platelet cells 
(Inamdar et al., 2015). Furthermore, UBO-QIC had no effect on Akt 
phosphorylation downstream of Gαi pathways or the phosphorylation of 
vasodilator-stimulated phosphoprotein downstream of Gα (Inamdar et al., 2015). 
UBO-QIC was found to be selective over other members of the the Gα subunit 
however it was demonstrated that it is not selective for Gαq as it is invoolved in 
inhibitin Gβγ mediated signalling events following Gαi activation (Gao and 
Jacobson, 2016). There have been no studies directly comparing the activity of 
YM-254890 and UBO-QIC. 
1.9.5.4 Gα gene knockdown using siRNA 
Despite the very large number of GPCRs there are relatively few studies 
that have used the potential of Gαq/11 gene knockdown by siRNA to explore 
their roles in the signalling cascades. One of the first reported gene knockdown 
studies of Gα proteins was the knockdown of Gαq and Gαq/11 gene expression 
using siRNA in HeLa cells (Krumins and Gilman, 2006). This work 
demonstrated an absolute requirement of Gαq/11 to stimulate histamine 
mediated PLC activity. Silencing of Gαq or Gαq/11 caused indistinguishable 
phenotypes, loss of half of histamine-stimulated PLC activity, despite the fact 
that concentrations of Gαq/11 exceed those of Gαq by 10-fold. No 
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compensatory increases of either Gαq or Gαq/11 were observed following loss 
of either protein. Loss of Gαq or Gαq/11 did cause increased accumulation of 
Gαi (Krumins and Gilman, 2006). A study characterising the Gα subunits 
required for PAR-1 mediated endothelial cell permeability showed that both 
Gαq and Gαq/11 were necessary for thrombin to increase permeability while the 
need for Gαq12/13 was less. Both protein subunit families contributed 
significantly to RhoA activation by thrombin (Gavard and Gutkind, 2008). 
Knockdown of Gαq/11 in human pulmonary artery smooth muscle cells alters 
but does not prevent hypoxia-induced mitogenic factor-mediated calcium 
release demonstrating that Gαq/11 contributes to hypoxia-induced PLC 
signalling pathway (Fan et al., 2009). In HEK cells expressing high levels of 
thyrotropin-releasing hormone receptor 2, knockdown of Gαq/11 reduces 
persistent agonist-induced signalling by 82 percent and suggests that Gαq/11 is a 
required component of the activated receptor signalling pathway (Boutin et al., 
2012). Clearly there is considerable scope to use siRNA technology more often 
as a very useful tool in delineating the importance of Gα proteins in GPCR 
signalling. 
1.9.6 Potential of Gαq as a therapeutic target 
Gαq as a protein has several functions which show its value as a 
therapeutic target. The binding of GDP and GTP (Figure 1.11) are potential 
targets in the same manner in which the ATP binding site is target of many 
drugs inhibiting kinases (Liu et al., 2013). The ligand activated GPCR acts as a 
GEF which stimulates the exchange of GDP for GTP on the Gα peptide and this 
could be targeted. Furthermore, the protein contains a switch mechanism and 
this can be targeted as it is the target of the YM class of inhibitors (Nishimura et 
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al., 2010). So it is both theoretically possible and has been demonstrated that 
Gαq can be exploited as a drug target.  
The consequences of targeting signalling molecules have theoretical 
limitations based on the role of such targets in normal physiology but also 
conceptually there may be situations, in which the activity of Gαq is elevated or 
enhanced and presents itself as a target. Such situations are common in 
therapeutics but in most cases can only be established experimentally.  
As discussed above, inhibition of Gαq/11 using YM-254890 has 
demonstrated anti-platelet aggregation, antithrombotic and thrombolytic 
properties in a rat model of carotid artery thrombosis (Kawasaki et al., 
2003). Therefore, compounds that inhibit Gαq/11 could show enormous 
potential in the treatment of thrombotic conditions such as thrombotic stroke and 
myocardial infarction in humans.  Additionally, a number of recent studies have 
also implicated a role for Gαq/11 in a range of metabolic conditions such as 
obesity and type 2 diabetes (Li et al., 2013, Kimple et al., 2014).  Activation of 
Gαq results in pronounced increases in blood glucose levels in a mouse model 
(Li et al., 2013), thus, compounds that inhibit Gαq could also show promise as a 
future treatment option for type 2 diabetes. 
In the important cardiovascular context of hypertension, Gαq knockout 
mice have reduced blood pressure (Wirth et al., 2008) and YM-254890 has 
demonstrated some anti-hypertensive properties (Kawasaki et al., 2003). 
Although there are many effective anti-hypertensive agents currently available, 
there are also many subjects with medication resistant hypertension which does 
require a niche for new therapies although it is unclear if a Gαq/11 inhibitor 
would suitable to consider for such a niche. 
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1.10 Biochemistry and signalling of Smad transcription 
factors 
 Burch et al (Burch et al., 2010 ) showed that there is a correlation 
between TGF-β mediated Smad2 linker region phosphorylation and 
proteoglycan synthesis. As covered in sections above thrombin through the 
transactivation of the EGFR and TGFBR1 leads to proteoglycan synthesis and 
GAG elongation. Hence Smads may play an important role in thrombin 
signalling leading to proteoglycan synthesis and GAG chain hyperelongation. 
Smad proteins are the intracellular mediators of TGF-β superfamily signalling 
which are transcription factors (Shi and Massague, 2003) that regulate gene 
expression (Verrecchia et al., 2006). Following the direct phosphorylation by 
TGFBR1 phosphorylated Smad complexes move to the nucleus where they have 
diverse effects on gene transcription. Smad activity is modulated through the 
recruitment of transcription co-activators and co-expressers (Wrighton et al., 
2009). In the human genome, eight Smad proteins have been identified Smads 
1-8. The Smad family can be divided into three functional groups, receptor 
regulated Smads (R-Smads) which are directly phosphorylated by the activated 
TGFBR1 on a conserved C-terminal motif and include Smad1, Smad2, Smad3, 
Smad5 and Smad8 (Massague et al., 2005), the common mediated Smad4 (co-
Smad) that interacts with the R-Smads in cell signalling (Shi et al., 1997), and 
the inhibitory Smads (I-Smad) Smad6 and Smad7 which are responsible for 
blocking the activation of R-Smad and co-Smad and initiating receptor 
degradation (Itoh et al., 2001).  
 Smad proteins contain 400-500 amino acid residues and contain 3 
distinct regions (Shi and Massague, 2003). A conserved N-terminal domain or 
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“Mad-homology 1” (MH1) domain which is involved in nuclear translocation 
(Massague, 1998, Derynck and Zhang, 2003). This region binds to DNA and 
interacts with DNA-binding cofactors (Massague et al., 2005). Smads contain a 
conserved C-terminal (MH2) domain and thirdly the non-conserved proline rich 
linker region that joins these two domains (Figure 1.13) (Derynck and Zhang, 
2003, Kamato et al., 2013c, Rostam et al., 2015). Mammalian Smad2 and 
Smad3 have a similar amino acid sequence with a 66% and 96% identity in their 
MH1 and MH2 amino acid sequences, respectively (Brown et al., 2007). In 
contrast to the similarity in their amino acid sequences, there are two major 
differences between the overall structures of Smad2 and Smad3. Alignment of 
the MH1 domains of Smad2 and Smad3 reveals that there are two regions of 
amino acid sequences which are present in Smad2 but absent from Smad3. One 
of these is called GAG, a short N-terminal amino acid residue consisting of ten 
residues. The other is a 30-residue sequence referred to as TID (also known as 
exon3). The TID sequence is rich in serine and threonine residues and is shown 
to prevent Smad2 from direct binding to DNA (Yang et al., 2009). The stability 
and intracellular localization of Smad2 and Smad3 are regulated by distinct 
mechanisms resulting in functional and regulatory differences between these 
two proteins (Massague et al., 2005). In mouse astrocytes, TGF-β mediated 
proteoglycan deposition was Smad-dependent (Susarla et al., 2011). TGF-β 
mediated XXYLT-1 mRNA expression required both Smad2 and Smad3, 
however TGF-β mediated mRNA expression of CHSY1 was only dependent on 
Smad2 (Susarla et al., 2011). Thus showing that Smad2 and Smad3 play a 
distinct role in activation and transcription of genes. The structure of Smad2 and 
Smad3 containing residues which are phosphorylated and those that determine 
the properties and functions of the Smads are found in Figure 1.13. 
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Figure 1.13: Structure of human Smad2 and Smad3. 
Amino acid sequence of part of the linker region of human Smad2 transcription 
factor containing the residues which can be phosphorylated in the Smad linker 
region. The sequence shows that three serine (S) residues and one threonine (T) 
residue which are available for phosphorylation. From Kamato et al. (Kamato et 
al., 2013c). 
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1.10.1 The canonical Smad signalling pathway 
 TGF-β signalling of Smads through TGFBR1 provides a rapid and 
specific signal transduction pathway. The R-Smads Smad2 and Smad3 are 
directly phosphorylated by TGFBR1 at the Ser-Ser-X-Ser (SSXS, X being any 
amino acid) motif in the C-terminal sequence. The three serine residues are 
located in positions 464, 465 and 467 of Smad2 and it has been shown that just 
two out of the three serine residues in the motif are phosphorylated (Ser465/467) 
and the other serine (Ser464) residue is not phosphorylated but is required for 
the phosphorylation of the other two sites (Abdollah et al., 1997).  
 Canonical TGF-β signalling refers to the receptor mediated carboxy 
terminal phosphorylation of R-Smads. A TGF-β ligand initiates signalling by 
binding to and bringing together type I and type II TGF-β receptors on the cell 
surface. This allows for TGFBR2 engagement leading to the phosphorylation of 
TGFBR1 kinase domain which then instigates the signalling through 
phosphorylation of the Smad proteins (Wang et al., 2009a). Phosphorylation of 
the C-terminal of Smad2 promotes the binding to Smad4 to form a heteromeric 
complex. The Smad complex enters and accumulates in the nucleus to regulate 
the transcription of numerous target genes (Figure 1.14) (Burch et al., 2011). 
TGF-β signalling is also known to activate a number of intracellular 
serine/threonine kinases in what is termed as non-Smad signalling (Derynck and 
Zhang, 2003, Zhang, 2009). 
1.10.2 Smad linker region phosphorylation 
 In addition to the canonical TGF-β signalling involving C-terminal 
phosphorylation, experiments using linker region specific antibodies have 
shown that the linker region of Smad2/3 can also undergo phosphorylation and 
play an important role in TGF-β mediated biological activities (Hough et al., 
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2012). This has led to the term Smad independent or non Smad-dependent 
cascades (Burch et al., 2011). The linker region of Smad2 has at least four 
important sites that can be phosphorylated. This includes threonine 220 and 
three serine residues in positions 245, 250 and 255 (Figure 1.13) (Wang et al., 
2009a).  
 The linker region can undergo regulatory phosphorylation by multiple 
kinases, including mitogen-activated protein kinases (MAPKs) Erk, c-Jun 
N-terminal kinases (Jnk) and p38, PI3K, cyclin-dependent kinases (CDK), 
ROCK and glycogen synthase kinase (GSK3) (Kamato et al., 2013c). Among 
these kinases, MAPK and CDK are major groups of protein kinases showing 
preference for specific serine/threonine residues in the linker regions (Figure 
1.14) (Malumbres and Barbacid, 2009, Feng et al., 2002). Other vasoactive 
agents can also activate MAPK potentially leadings to linker region 
phosphorylation. Thus, linker region phosphorylation may be a central 
integrating point through which many pro-atherogenic agonists stimulate 
changes in proteoglycan synthesis and as such represent an attractive target for 
the development of a therapeutic target for atherosclerosis (Kamato et al., 
2013c). 
 Previous work from our lab has shown that in VSMCs, regulation of 
proteoglycan synthesis and GAG hyperelongation was mediated by the 
phosphorylation of the Smad2 linker region (Burch et al., 2010 ). We know that 
thrombin treatment of VSMCs leads to proteoglycan synthesis and GAG 
hyperelongation, however the role of the Smad2 linker region has not yet been 
explored in this signalling pathway. This project will emphasize on the specific 
thrombin mediated signalling pathways that involve downstream Smad2 linker 
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region (Thr220, Ser245, 250 and 255) as well as the gene expression of specific 
GAG synthesizing genes for proteoglycan chain elongation in VSMCs. 
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Figure 1.14: TGF-β mediated signalling via the canonical and non-canonical pathway. 
Smad2 carboxy terminus can be directly phosphorylated by activated TGF-β receptor. The Smad2 linker region is phosphorylated indirectly through 
the activation of serine/threonine kinases resulting in regulation of transcriptional activity. 
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1.11 Rationale for the study 
Proteoglycans play a crucial role in atherogenesis through the entrapment of 
LDL as described by the response to retention hypothesis (Williams and Tabas, 1995, 
Skalen et al., 2002). Thrombin through its receptor, PAR-1, has been shown to 
transactivate both the EGFR and TGFBR1 which leads to an increase in GAG chain 
length of biglycan allowing for a binding affinity to LDL (Burch et al., 2010, Burch et 
al., 2013). GAG synthesizing genes are responsible for elongation of GAG chain on 
biglycan and in animal models their elevated expression level contributes to 
atherosclerotic development (Anggraeni et al., 2011). The regulation of GAG 
synthesizing genes in the development of atherosclerosis in humans has not been 
reported to date. The signalling pathway involving PAR-1 transactivation of the 
TGFBR1 and EGFR leading to the expression of these GAG synthesizing enzymes 
contributes to the identification of pathways which may be involved in atherosclerosis 
development. The ultimate aim is to find a universal target for the prevention of 
transactivation signalling which inhibits cellular responses such as proteoglycan 
synthesis which can act as a therapeutic target in the prevention of atherosclerosis 
caused by increased LDL binding to modified GAG chains. 
1.12 Aims of the study 
1. Identify specific GAG synthesizing gene expression that can be stimulated by 
thrombin treatment of VSMCs.  
2. Characterise mechanisms of PAR-1 transactivation of PTKR and S/TKR that 
leads to the expression of GAG synthesizing genes. 
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3. Determine the contribution of G proteins in PAR-1 transactivation dependent 
signalling leading to GAG gene expression. 
4. Investigate whether PAR-1 mediated transactivation of PTKR and S/TKR 
leads to Smad2 linker region phosphorylation. 
5. Investigate which serine/threonine kinases are required for the regulation of 
PAR-1 mediated Smad2 linker region phosphorylation. 
6. Determine the contribution of PAR-1 mediated transactivation of PTKR and 
S/TKR by studying the genes and pathways regulated by transactivation 
dependent signalling. 
 
 Chapter-2. Methods and Materials Page 69 
 
 
 
 
 
 
 
Chapter-2. Methods & 
Materials 
 
 
 
 
 
 
 
 
 
 
 
  
 Chapter-2. Methods and Materials Page 70 
2.1 Materials 
Dulbecco’s Modified Eagle medium (DMEM) (0 and 25mM glucose), 
Trypsin-Versene, antibiotics (10,000 U/ml penicillin, 10,000 μg/ml 
streptomycin) were purchased from GIBCO, (Grand Island, USA). Foetal 
bovine serum (FBS) was from In Vitro Technologies, Pty. Ltd (VIC, Australia). 
RNAse Away Reagent, chemiluminescent molecular weight marker 
(MagicMark XP) and chromogenic molecular weight marker (BenchMark) were 
obtained from Invitrogen Australia Pty Limited. Dulbecco’s phosphate buffered 
saline (PBS)(10X), SB431542, AG1478, GM6001, Hoechst, human epidermal 
growth factor (EGF), sodium dodecyl sulphate (SDS), diethylaminoethyl 
(DEAE)-Sephacel, chondroitin sulphate thrombin, Fura-2AM, Y217632, 2-
mercaptoethanol, 2-propanol and dimethyl sulfoxide (DMSO) were purchased 
from Sigma-Aldrich (MO,USA). Ethanol absolute was purchased from LabServ 
(VIC, Australia). Real-Time Polymerase chain reaction (RT-PCR) primers for 
GAG synthesizing enzymes Chondroitin 4-O-sulfotransferase-1 (CHST11), 
xylosyltransferase-1 (XXYLT-1), chondroitin polymerizing factor (CHPF) and 
Chondroitin sulphate synthase 1 (CHSY1) were based on their respective 
GenBank sequences were purchased from GeneWorks Pty Ltd (SA, Australia). 
Housekeeping gene 18S, biglycan gene primers, RNeasy Mini Kit (containing 
sterile, RW1 buffer, RPE buffer, RPE buffer and RNase-free water), QuantiTect 
Reverse Transcription Kit (containing gDNA Wipeout Buffer, Quantiscript 
Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix and RNase-free 
water), the RNase-Free DNase set (containing 1500kunits RNase-free DNase I, 
RNase free buffer RDD and RNase-free water), miRNeasy kit (containing 
RNeasy mini spin columns, collection tubes, QIAzol lysis reagent, RNase-free 
reagents and buffers) and two-step RT-PCR kit (containing 2×Rotor-Gene 
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SYBR Green PCR Master Mix and RNase-free water) were purchased from 
Qiagen (VIC, Australia). Human transforming growth factor beta-1, antibodies 
to, phospho-EGFR(Y845), phospho-Smad2(Ser465/467), 
phospho-Smad2(Ser245/250/255), phospho-Erk1/2(Thr202/Tyr204), 
phospho-Ezrin(Thr567)/Radixin(Thr564)/Moesin(Thr558) and GAPDH were 
from Cell Signalling Technology (MA, USA). Carrier-free [35S]-sulphate was 
obtained from MP Biomedicals (LA, USA). Cetyl pyridinium chloride (CPC) 
from Unilab Chemicals and Pharmaceuticals (India); Whatman 3MM 
chromatography paper from Biolab (Mulgrave, Australia); Instagel plus 
scintillation fluid from Perkin Elmer (MA, USA). PAR-1 inhibitor SCH79797 
was from Invitro technologies (VIC, Australia). Chemiluminescence ECL 
detection kit was from GE Healthcare UK Ltd. (BKM, UK). Bicinchoninic acid 
(BCA) protein assay kit, SYBR® Gold Nucleic acid gel stain, goat anti-mouse 
IgG secondary antibody, Alexa Fluor® 488 and 594 were from Thermo 
scientific (IL, USA). Polyvinylidene fluoride (PVDF) membrane was from 
Millipore (MA, USA). TEMED, tris base and glycine were from Amresco (OH, 
USA). Tween 20, Poly-Prep columns, 30% acrylamide/Bis solution, 
Ammonium persulphate (APS), Trans-blot® Turbo™ RTA mini PVDF transfer 
kit (containing 40 mini-sized PVDF membranes, 80 transfer stacks, 1L 
5×transfer buffer and 2 gel trays) and Quantity One imaging software were from 
BioRad Laboratories (CA,USA). Human coronary artery smooth muscle cells, 
AD1 4D-Nucleofector™ Y kit (including 24 well plate, electrode 24 well, buffer 
and vector), smooth muscle growth medium-2 bullet kit and Single Quot kit 
supplements and growth factors were from LONZA (VIC, Australia). 
SiGENOME Human GNA11 siRNA SMARTpool (target sequences: 
GCUUUGAGAACGUGACAUC, GAGCAUCAGUACGUCAGUG, 
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GAACUCCUCCGUCAUCCUC and CAAGAUCCUCUACAAGUAC), 
SiGENOME Human GNAQ siRNA SMARTpool (target sequences: 
CAAUAAGGCUCAUGCACAA, CAACAAGAUGUGCUUAGA, 
GCAAGGCUCUCUUUAGAAC and UAGUAGCGCUUAGUGAAUA) and 
siGENOME non targeting siRNA SMARTpool (target sequences: 
UAAGGCUAUGAAGAGAUAC, AUGUAUUGGCCUGUAUUAG, 
AUAACGUGAAUUGCUCAA and UGGUUUACAUGUCGACUAA) were 
purchased from Millennium Science (VIC, Australia). Mouse anti-human 
integrin αVβ3 (Vitronectin Receptor) monoclonal antibody and mouse anti-
human integrin αVβ5 monoclonal antibody were purchased from MERCK 
Millipore (VIC, Australia). Dynabeads® mRNA DIRECT™ Micro kit (contains 
Dynabeads® Oligo, Lysis/binding buffer, Washing Buffer A, Washing buffer B 
and 10mM Tris HCl), Ion PI™ Template OT2 Supplies 200 kit v2 (contains Ion 
OneTouch™ Reagent Tubes, Ion OneTouch™ Recovery Routers, Ion PI™ 
Template OT2 Recovery tubes Ion OneTouch™ Sipper Tubes, Ion OneTouch™ 
2 Amplification plates, Ion OneTouch™ ES supplies and Ion OneTouch™ 2 
Cleaning adapters), Ion PI™ Template OT2 Reagents 200 Kit v2 (containing 
Ion PI™ Enzyme Mix TL, Ion PI™ Ion Sphere™ particles, Ion PI™ PCR 
Reagent X and Ion PI™ Reagent Mix TL), Ion PI™ Template OT2 Solutions 
200 kit v2 (which contains Ion Proton™ OT2 oil, Ion Proton™ OT2 Reaction 
Oil, Ion PI™ PCR Reagent B, Nuclease free water, Ion PI™ OT2 Recovery 
solution, Ion OneTouch™ Wash solution, Ion PI™ MyOne™ Beads Capture 
solution and Ion PI™ ISP resuspension solution), Ion PI™ Sequencing Supplies 
200 (contains Ion Proton™ Reagent tubes with labels, Ion Proton™ reagent tube 
caps, Ion Proton™ reagent tube sippers, Ion Proton™ wash 2 bottles with labels 
and Ion Proton™ wash bottle sippers), Ion PI™ Sequencing reagents 200 
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(contains Ion PI™ dGTP, Ion PI™ dCTP, Ion PI™ dATP, Ion PI™ dTTP, Ion 
PI™ Sequencing polymerase, Ion PI™ sequencing primer and Ion PI™ Control 
Ion Sphere™ particles), Ion PI™ Sequencing solutions 200 v2 (contains Ion 
PI™ W2 solution v2, Ion Proton™ Cleaning tablet, Ion PI™ 1X W3 solution, 
Ion PI™ Annealing buffer and Ion PI™ loading buffer), Ion PI™ Chip 
preparation solution and Ion Proton™ Chip Adapter where purchased from 
LifeTechnologies (VIC, Australia). 
2.2 Methods: 
2.2.1 Culturing human vascular smooth muscle cells 
Primary cultures of human VSMCs were obtained from discarded 
sections of saphenous veins from patients undergoing coronary artery bypass 
grafting at the Alfred Hospital; the acquisition of the vessels was approved by 
the Alfred Hospital Ethics Committee. To isolate the VSMCs, the endothelial 
layer was removed and the vessel placed intima down under a glass cover-slip 
and cultured in 25mM DMEM containing 1% penicillin-streptomycin and 10% 
FBS (Neylon et al., 1990). The primary cultures were expanded in 5mM glucose 
DMEM (10% FBS and 1% penicillin-streptomycin), and stocks frozen and 
stored in liquid nitrogen (see Section 2.2.2). Human coronary artery smooth 
muscle cells (CASMCs) were purchased from Lonza, they were thawed out 
following the manufacturer’s instructions. Once adherent the CASMCs were 
cultured following the same protocols outlined. 
Cells were grown and passaged from liquid nitrogen stocks for 
experiments between passages 5-17. Cells were grown in DMEM (5mM 
glucose, 10% FBS and 1% penicillin-streptomycin at 37⁰C in 5% CO2) in 75cm2 
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Corning cell culture flasks with the medium replaced every 2-4 days until the 
cells reached approximately 90% confluency. To seed tissue culture dishes for 
experiments, cells were trypsinized with Trypsin-Versene and transferred into a 
Corning 50mL Falcon tube with approximately 25mL of DMEM. Cells were 
spun in an Eppendorf 5810R Centrifuge at room temperature for 3 min at 900 
rpm. The supernatant was discarded and the pellet was resuspended in fresh 
DMEM. For experiments, the Z1 D/T Particle Counter (Beckman Coulter, 
NSW, Australia) was used to count cell densities. For each experiment cells 
were grown to confluency then rendered quiescent due to serum deprivation for 
48 hours in DMEM (5mM glucose, 0.1% FBS and 1% penicillin-streptomycin) 
before treatment.  
2.2.2 Freezing cells 
 Each freezing ampoule has a volume of 1.5mL to which 1mL of cell 
suspension was added. The “freezing medium” containing 1:10 ratio of DMSO 
to DMEM (5mM glucose 10%FBS) was prepared. Cells in 75cm2 flasks were 
trypsinized, centrifuged at 900 rpm for 3 min and the total number of cells was 
calculated to determine amount of freeze medium needed (cells should be 
resuspended in freeze medium at 5×106 to 2×107 cells/ml). Cryogenic vials were 
labelled with date, name, and cell line type and passage number. The cells were 
then quickly resuspended in the freezing medium with 1mL of freeze suspension 
per cryogenic vial. Each vial was screwed tightly and placed in holders to store 
into −80° C overnight. Vials were then transferred liquid nitrogen for long term 
storage. 
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2.2.3 Fluorescent imaging of proteins  
VSMCs were plated on 15mm glass coverslips, grown to near 
confluence and fixed in 2% paraformaldehyde in 1×PBS for 10 mins. The slides 
were then washed with 1×PBS for 5 mins with gentle rocking. To block 
non-specific binding of antibodies to cellular protein, the fixed cells were placed 
in a 10% horse serum solution for 45 mins at room temperature. The slides were 
then washed with 1×PBS and cells incubated with the primary antibody 
overnight at 4°C in a humified chamber (Table 1). A goat anti-mouse conjugated 
with flurophore Alexa488 and Alexa594 was used as the secondary antibody. 
Coverslips were incubated with Hoechst stain (1:400) for 30 mins for the 
detection of the nucleus. Cover slips were then mounted on slides and were 
dried for 24 hours at 4°C. Imaging was with a Nixon C1 confocal microscope. 
The excitation wavelengths were 519 nm and 617nm.  
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Table 2.1: Primary antibodies used in fluorescent imaging of vascular 
smooth muscle cells. 
The table details the antibodies, the dilution used and species they are derived 
from. 
Target 
Protein 
1o Antibody Dilution 2o Antibody Dilution Blocking 
Serum 
-actin 
 
Mouse anti-alpha 
smooth muscle 
actin 
1:100 Goat anti-mouse 
conjugated with 
flurophores Alexa594 
1:500 10% horse 
serum 
von 
Willebrand 
Factor 
 
Mouse anti-Von 
Willebrand 
Factor  
1:100 Goat anti-mouse 
conjugated with 
flurophores Alexa488 
1:500 10% horse 
serum 
αVβ3 Rabbit anti- 
αVβ3 
1:500 Goat anti-mouse 
conjugated with 
flurophores Alexa594 
1:500 10% horse 
serum 
αVβ5 Rabbit anti- 
αVβ5 
1:500 Goat anti-mouse 
conjugated with 
flurophores Alexa488 
1:500 10% horse 
serum 
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2.2.4 Quantification of glycosaminoglycan biosynthetic 
enzyme gene expression 
2.2.4.1 RNA Isolation 
The level of the GAG synthesizing gene expression was measured by 
quantitative RT-PCR. Total RNA was isolated from treated cells grown to 
confluency in 6 well plates, and harvested in accordance with the column base 
method provided in the RNeasy mini kit (Qiagen). The addition of 
2-mercaptoethanol (10μl to per 1mL of Buffer RLT) in 1.5mL microfuge tubes 
was performed in the fume hood. The medium was aspirated and cells were 
lysed directly with Buffer RLT (350μL) and 2-mercaptoethanol. Cells were 
gently scraped and collected in 1.5mL microfuge tubes. Cell samples were 
homogenised 10 times through a 20-gauge needle before the addition of 1 
volume of 70% ethanol. Samples (700μL) were transferred to an RNeasy spin 
column, and centrifuged for 15s at 10,000 rpm at room temperature. The flow 
through, which contains cell debris, was discarded and 700μl of Buffer RW1 (to 
wash the spin column membrane) was added to the RNeasy spin column. 
Samples were centrifuged for 15 secs at 10,000 rpm at room temperature. The 
flow through was discarded and Buffer RPE (500μL) (to wash the spin column 
membrane) was added to the RNeasy spin column and samples were centrifuged 
for 15 secs at 10,000 rpm at room temperature. The flow through was discarded 
and 500μL of Buffer RPE (to wash the spin column membrane) was added to 
the RNeasy spin column were samples were centrifuged for 2 mins at 10,000 
rpm at room temperature. The spin column membrane was placed in a new 
1.5mL collection tube were 35μL of RNase-free water was added directly. 
Samples were centrifuged for 1 min at 10,000rpm at room temperature. The 
purity and concentration of total RNA extracted was measured by 
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spectrophotometry using a Nanodrop2000 spectrophotometer (Thermo Fisher 
Scientific). RNA samples were determined to be pure based on the 260/280nm 
wavelength ratios. All samples had pure nucleic acids yield ratio values that 
were between 1.8-2.1.  
2.2.4.2 cDNA synthesis 
First strand cDNA was synthesized from 500ng RNA by following the 
protocol provided by the Quantitect reverse trancriptase kit (Qiagen). This kit 
provides is a two-step procress which comprises the elimination of genomic 
DNA (gDNA) and reverse transcription. The procedure for effective gDNA 
elimination was performed by incubating purified RNA samples with 2 μL of 
gDNA wipeout buffer for 2 mins at 42°C. DNAse treated samples were then 
immediately kept on ice while reverse transcription master mix was prepared 
containing 1µL QuantiTect Reverse Transcriptase, 4µL Quantiscript RT buffer, 
and 1µL RT primer mix. DNase treated template RNA were added to reverse 
transcription master mix and incubated for 15 mins at 42°C. After completed 
cDNA synthesis, the samples were then incubated for 3 min at 95°C to 
inactivate the reverse transcription process by QuantiTect Reverse 
Transcriptase. 
2.2.4.3 Quantitative real-time PCR 
Quantitative real-time PCR was performed using a Rotor-Gene Q 
(Qiagen) and Quanti Fast SYBR Green PCR Master Mix kit (Qiagen). RT-PCR 
used commercial primers (Qiagen) and human specific primers based on 
GenBank database sequences. The data was normalised to 18S house-keeping 
gene (Qiagen). Each treatment sample was processed in duplicate. Each reaction 
tube contained 5µL of SYBR Green, 1µL of 10µM mix of forward and reverse 
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primers, 1µL of 500ng cDNA from Section 2.2.3.2 and 2 µL of RNA free water. 
The reactions were run in a Roto-Gene Q using the protocol outlined in Table 2. 
The Delta-Delta (ΔΔ) Ct method was used to analyse the fold change in gene 
expression from quantitative real-time PCR experiments.  
  
 Chapter-2. Methods and Materials Page 80 
Table 2.2: Cycling Conditions for quantitative real time PCR reactions 
Step Time Temperature 
PCR initial activation step (Hold) 5 min 95oC 
Two-step cycling   
Denaturing 15 sec 95 oC 
Combined/annealing/extension 30 sec 60 oC 
Number of cycles 40  
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2.2.4.4 Quantitation using Comparative cycle threshold 
 Cycle threshold (Ct) values for all GAG enzyme gene expression 
samples were recorded and normalised against the endogenous ribosomal 18S as 
housekeeping gene. The formulas below were used to quantitate the results: 
∆Ct= Ct (gene interest) – Ct (housekeeping gene) 
∆∆Ct= ∆Ct (treatment) – ∆Ct (control) 
Fold regulation = 2-∆∆Ct 
2.2.5 Proteoglycans 
2.2.5.1 Culture of cells for proteoglycan experiments 
VSMC were seeded on 24 well plates at a density of 50,000 cells per 
well. The media (DMEM with 5mM glucose, 10% FBS and 1% antibiotics) was 
replenished the next day and the cells were grown to approximately 90% 
confluency. Cells were allowed to quiesce in DMEM (5mM glucose 0.1%FBS 
and 1% antibiotics) for 48 hours. Quiescent cells were changed to fresh medium 
containing 25µC/mL of [35S]-sulphate in the presence and absence of 
antagonists or growth factors as indicated in text for 24 hours. 
2.2.5.2 Harvesting proteoglycans 
VSMCs secreted proteoglycans were harvested by collecting the culture 
media and adding protease inhibitors (100mM 6-aminocaproic acid, 5mM 
benzamidine hydrochloride) to prevent degradation.  
2.2.5.3 Quantitation of proteoglycans by cetylpyridium chloride 
precipitation 
To assess the quantity of radiolabel incorporation into proteoglycans a 
CPC precipitation assay was used. Duplicate aliquots of (50 μL) of harvest 
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media were spotted onto Whatman 3MM chromatography paper and air dried. 
The papers were then washed (5×30 mins) in CPC (1% CPC, 0.05M NaCl) to 
remove any unbound radiolabel [35S]-sulphate and precipitate proteoglycans. 
This solution forms insoluble proteoglycan aggregates, precipitating them on to 
the paper, so that the unincorporated radiolabel is washed away. After air 
drying, papers were cut, scintillation cocktail was added and the papers were 
analysed for radioactivity [35S]-sulphate using a liquid scintillation counter. 
2.2.5.4 Isolation of proteoglycans for SDS-PAGE 
Ion-exchange chromatography was used for the isolation of 
proteoglycans that were secreted into the culture medium. Harvested media 
containing secreted proteoglycans were applied to Poly-Prep columns 
containing 50%v/v DEAE-Sephacel (500µL) equilibrated in low salt buffer (8M 
urea, 0.25M NaCl, 2mM disodium EDTA, 0.5% Triton X-100). Samples were 
washed with low salt buffer (5×6mL) to remove any unbound radiolabel. Bound 
proteoglycans were eluted (2×0.3mL fractions per column) using high salt 
buffer (8M urea, 3M NaCl, 0.02M EDTA, Triton-X). An aliquot of (10µL) of 
each fraction was counted on a liquid scintillation counter and fractions 
containing the highest number of [35S]-sulphate counts per million (cpm) were 
pooled.  
2.2.5.5 Concentration of isolated proteoglycans 
Equal counts of proteoglycans (20,000 cpm) were precipitated by 
ethanol solution (1.3% potassium acetate in 95% ethanol). Chondroitin sulphate 
(166µg/mL) was added to each sample to facilitate as a “cold carrier”, 
minimising sample loss through adhesion to the tube. Samples were precipitated 
overnight, then centrifuged at 14000 rpm for 10 mins at 4ᵒC to obtain a pellet. 
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The supernatant was removed, the pellet re-suspended in water and 
re-precipitated in ethanol solution and centrifuged again. This procedure was 
repeated 1-2 times. The pellets of proteoglycans were air dried and resuspended 
in buffer (8M urea, 2mM disodium EDTA, pH7.5). 
2.2.5.6 Assessing proteoglycan size by SDS-PAGE 
The Laemmli system was used (Laemmli, 1970) to assess the 
electrophoretic mobility of the proteoglycans and glycosaminoglycan chains. A 
3% stacking gel and a 4-13% gradient separating gel was used. Sample buffer 
(0.5M Tris-HCL pH 6.8, 10% SDS, 50% glycerol, 2-mercaptoethanol, and 0.1% 
bromophenol blue) was added to the samples prior to incubation at 95°C for 
5 mins to denature the proteins. A molecular weight marker Rainbow™ [14C] 
was run simultaneously to indicate the relative molecular size of the 
proteoglycans. Gels were run overnight at 50V, then fixed (5% methanol, 7% 
acetic acid) for 1 hour, soaked in 20g/l polyethylene glycol, 12.5% methanol for 
4 hours before being wrapped in cellophane and air dried at room temperature 
overnight. After air drying the gel was exposed to an imaging plate (Fujifilm 
BAS-MS 2040 imaging plate) for 3-5 days. Images were then developed using a 
phosphoimager (Perkin Elmer Cyclone Plus Storage Phosphor System) and 
viewed using imaging software (OptiQuant). 
2.2.6 Western Blot analysis  
As stated in Section 2.2.1, cells were cultured and treated with various 
inhibitors and agonists. Cells were then gently washed with cold 1×PBS and 
harvested by adding 55μL of lysis buffer (0.01% TritonX100, 150mM NaCl, 
50mM Tris pH 7.5, 1mM EDTA, 1µM EGTA pH 9.0, 0.05% NP-40, 80µM 
PMSF, 100mM 6-amino caproic acid, 5mM benzamidine and 100mM sodium 
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orthovandate), followed by gently scraping and collecting the cells. The lysates 
were homogenised by 20 passes through a 19-gauge needle, centrifuged 
(1000rpm for 10 min at 4C) the supernatant was collected and the protein 
content was determined using the BCA protein assay. Proteins (30-40µg) were 
separated by 10% SDS-PAGE and a 4% stacking gel for size comparison a 
chemiluminescent molecular weight maker as well as a chromogenic molecular 
weight marker were electrophoresed. Proteins were then transferred onto PVDF 
membrane. 
2.2.6.1 Wet Transfer 
 PVDF membranes were activated by soaking in 100% methanol for 
1 min. The membrane was then rinsed with water and soaked in transfer buffer 
(3.7% SDS, 20% methanol, 48mM Tris base, 39mM Glycine) together with 
filter paper and sponges at 4C. The gel was gently removed from the glass 
plates and the cassette was assembled in the following order; clear plastic, 
sponge, filter paper, membrane, gel, filter paper, sponge and the black plastic. 
The transfer was set to 100V for 1 hour at 4C. 
2.2.6.2 Semi dry transfer (Turbo blot) 
PVDF membranes were activated by immersing in 100% ethanol until 
membrane is translucent then immediately transferred into 1×transfer buffer 
(BIO-RAD). Transfer stacks were equilibrated with 1×transfer buffer. One 
wetted stack was then placed on the cassette serving as the bottom ion reservoir 
stack. The wetted membrane was then placed on top of the stack in the cassette. 
The gel was placed on top of the PVDF membrane. Bubbles were carefully 
removed using a roller this followed by the second wetted transfer stack which 
served as the top ion reservoir stack. The assembled sandwich was rolled on 
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with blot roller to expel trapped air bubbles. The cassette lid was closed and 
locked and inserted into the Trans-Blot Turbo Transfer system (BIO-RAD) to 
begin transferring. The protocol was set for mixed molecular weight.  
2.2.7.3 Blocking and probing the membrane 
Membranes were blocked with 5% bovine serum albumin (BSA) to limit 
non-specific binding of antibodies for 60 mins at room temperature with gentle 
rocking. The membrane underwent 3×5min washes with Tris-buffered saline 
with Tween-20 (TBST) (10mM Tris base, 0.15M NaCl, 1% Tween-20, pH7.6). 
The primary antibody was diluted (as detailed in text) in 5% BSA. Membranes 
were incubated overnight in primary antibody at 4C with gentle rocking. 
Membranes were then washed for 3×5 min at room temperature with TBST and 
incubated with species specific secondary antibody diluted (as detailed in text) 
in 5% BSA for 1 hour at room temperature with gentle rocking. Membranes 
were washed again for 3×5 min at room temperature with TBST. The proteins 
were detected by chemiluminescence (ECL™ Western Blotting analysis system, 
Amersham™) using the BIO-RAD gel documentation system and then 
processed using ImageLab XRS® imaging software. 
2.2.6.4 Image densitometry 
Western blot images were opened in ImageLab XRS software and 
images rotated to align the bands for the protein of interest horizontally in the 
window. The rectangle tool was then used to select the band of interest. The 
width and height of the lane rectangle was drawn accurately to cover the band of 
interest without overlap with bands from adjacent lanes. The same rectangle size 
box was then copied and used to measure the background in the respective lane. 
The amount of background for each band was subtracted from the band of 
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interest. The density of the loading control (GAPDH) was measured using the 
same protocol described. The final intensity of the protein of interest was 
obtained after normalizing the measurement of the protein of interest with the 
respective gel loading protein.  
2.2.7 Calcium Assay 
 VSMCs were seeded onto 96-well plates (15,000 cells/well) and cultured 
until 80% confluent and then serum deprived (5mM DMEM 0.1% FBS) for 48 
hours. Cells were loaded with FURA-2AM ester (2µM, 30 min, 37ºC) in the 
presence of 2µM probenecid and 0.01% pluronic F-127. Loading and 
experiments were performed in HANKS buffer (10mM HEPES, 5mM KCL, 
140mM NaCl, 1mM MgCl2, 2mM CaCl2, 11mM Glucose). Cells were pre-
incubated with antagonists for 15-30 min prior to stimulation with agonist. 
Fluorescence was measured (4s intervals) at 340nm and 380nm excitation and 
510nm emission wavelengths using a Flexstation 3 plate reader (Molecular 
Devices, Sunnyvale, CA). The sustained calcium response was calculated as the 
difference between basal fluorescence and the peak fluorescence after thrombin 
treatment.  
2.2.8 Next generation sequencing 
2.2.8.1 RNA extraction of miRNA 
CASMCs were seeded on 60 mm dishes at a density of 200,000 
cells/plate with 3 plates being used per treatment. The media (DMEM with 
5mM glucose, 10%FBS and 1% antibiotics) was replenished the next day and 
cells were grown to approximately 90% confluency. Cells were then made 
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quiescent in DMEM (5mM glucose, 0.1% FBS and 1% antibiotics) for 48 hours. 
VSMCs were pre-incubated with antagonists (SB431542, AG1478 or both for 
30 mins prior to exposure with thrombin for 6 hours. Total RNA was isolated 
from treated VSMCs using the miRNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. The medium was aspirated and cells were lysed 
directly with QIAzol lysis reagent (350 µL/plate). Cells were gently scraped and 
plates from the same treatment were collected into a 1.5 mL microfuge tube. 
Samples were homogenised 10 times through a 19-gauge needle. The tubes 
containing the homogenate were incubated at room temperature for 5 mins. 
140µL of chloroform was added to each tube and shook vigorously for 15 secs 
prior to 3 min incubation at room temperature. The samples were centrifuged for 
15 mins at 10,000 rpm at 4°C. The upper aqueous phase (colourless) was 
transferred into a new microfuge tube and 525 µL of 100% ethanol was added 
and mixed by pipetting up and down. 700 µL of the sample was transferred to an 
RNeasy mini spin column and centrifuged for 15 secs at 10,000 rpm at room 
temperature, the flow-through was discarded and this was repeated with the 
remainder of the sample. Using the RNase-Free DNase Set (Qiagen) a DNase 
digest was conducted according to the manufacturer’s instructions. 350 µL of 
the RWT buffer was added to the RNeasy spin column and centrifuged for 15 
secs at 10,000 rpm; the flow-through was discarded. For each sample 10 µL of 
DNase I stock solution and 70 µL of RDD buffer were gently mixed and added 
directly onto the RNeasy spin column membrane and incubated at room 
temperature for 15 mins. Buffer RWT (350 µL) was added to the RNeasy spin 
column where samples were centrifuged for 15 secs at 10,000 rpm at room 
temperature. The flow through was discarded and 500 µL of Buffer RPE was 
added to the RNeasy spin column and samples were centrifuged for 15 secs at 
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10,000rpm at room temperature. The flow through was discarded and another 
500 µL of Buffer RPE was added to the spin column and samples were 
centrifuged for 2 mins at 10,000 rpm at room temperature. The spin column was 
placed in a new 2mL collection tube and centrifuged for 1 min at full speed. The 
spin column was then transferred into a new 1.5 mL microfuge collection tube 
and 20µL of RNase-free water was added directly onto the spin column 
membrane. Samples were centrifuged for 1 min at 10,000rpm at room 
temperature. RNA extracted was immediately placed on ice prior to the 
measurement of RNA quantity and integrity using a Nanodrop2000 
spectrophotometer (260/280nm). 
2.2.8.2 Purification and isolation of mRNA transcriptome using 
Poly-A enrichment 
2.2.8.2.1 Preparation of Dynabeads® 
200μL of Dynabeads were added to each microfuge tube. Tubes were 
placed on the DynaMag™-2 for 30 secs until the Dynabeads migrated to the 
tube wall. Supernatant was discarded and the tube removed from the magnet. 
100μL of Binding buffer was added to calibrate the beads. Supernatant was 
discarded and 200μL of binding buffer was added to the Dynabeads. 
2.2.8.2.2 Isolation of mRNA 
 RNA was heated to 65°C for 2 mins to disrupt the secondary structure 
then immediately placed on ice. 25μL of prepared Dynabeads/binding buffer 
suspension (from Section 2.2.8.2.1) and 25μL of RNA were gently mixed. The 
suspension was then placed on a mixer for 5 mins at room temperature to allow 
the mRNA to anneal to the oligo on the beads. The suspension was placed on 
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the magnet until the solution cleared; the supernatant was then discarded. Tube 
was removed from the magnet and the mRNA bead complex was washed twice 
with 60μL washing buffer B. The supernatant was removed between each 
washing step. The heat elution buffer was warmed up to 80°C for 2 mins. The 
dried beads were resuspended with 13μL of elution buffer by gentle mixing. The 
bead complex was placed on the magnet, the eluent was collected in a new 
RNase-free tube. 
2.2.8.3 Preparation of whole transcriptome libraries  
2.2.8.3.1 Fragment the RNA using RNase III 
A reaction containing (8-10µL of 100ng PolyA RNA, 1µL of 10V 
RNase III reaction buffer, 1µL RNase III) was prepared on ice. The reaction was 
briefly centrifuged to collect the liquid in the bottom of the tube. The reaction 
was incubated in a thermocycler for 2 mins at 37°C. 20µL of chilled nuclease 
free water was mixed with the fragmented RNA and was then kept on ice. 
2.2.8.3.2 Purify the fragmented RNA 
Nucleic Acid Binding beads were gently vortexed to completely 
resuspend the magnetic beads, 5µL of resuspended beads was added to each 
tube with 90µL of binding solution concentrate. 30µL of fragmented RNA was 
transferred to bead-containing tube. Followed by 150µL of 100% ethanol to 
each tube. The suspension in each tube was thoroughly mixed by pipetting the 
suspension up and down 10 times. The samples were incubated at room 
temperature for 5 mins. Each tube was placed on the magnetic stand for 
5-6 mins to separate the beads from the solution. Once the solution had cleared 
the supernatant was discarded. The tubes were kept on the magnetic stand, and 
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washed with 200µL of wash solution concentrate. The samples were incubated 
at room temperature for 30 secs, the supernatant and any residual liquid was 
discarded. The beads were air dried for 1-2 mins. Tubes were removed from the 
magnetic stand and mixed with 12µL of pre-warmed (37°C) nuclease free water. 
The samples were incubated at room temperature for 1 min then placed on 
magnetic stand for 1 min. The eluent for each of the samples was collected. The 
Qubit RNA Assay kit was used to assess the yield of the fragmented RNA. 
2.2.8.3.3 Hybridization and ligation of the RNA 
To hybridize and ligate the RNA 5µL of the hybridization master mix 
(2µL of Ion Adapto Mix v2, 3µL of Hybridization solution), was used per 
sample to 70ng of fragmented RNA (from Section 2.2.8.3.2). The sample 
containing the fragmented RNA was mixed gently, followed by brief 
centrifuging to collect reaction. The hybridization reaction was placed in 
thermal cycler (65°C for 10 mins, 30°C for 5 mins). On ice, 10µL of 2X ligation 
buffer and 2µL of ligation enzyme mix were added to each of the hybridization 
reactions. The ligation reactions were incubated in a thermal cycler at 30°C for 1 
hour. 
2.2.8.3.4 Reverse transcription 
Reverse transcription master mix was prepared on ice for each sample 
(2µL of nuclease free water, 4µL 10X RT buffer, 2µL 2.5mM dNTP mix and 
8µL of Ion RT Primer v2). 16µL of reverse transcription master mix was 
resuspended with the ligated RNA sample, the reaction was gently vortexed then 
briefly centrifuged. The reaction was incubated in a thermal cycler with a heated 
lid at 70°C for 10 mins, then snapped-cool on ice. 4uL of 10X SuperScript III 
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Enzyme mix was added to each ligated RNA sample, gently vortexed, then 
briefly centrifuged. The ligated RNA sample was incubated in a thermal cycler 
with a heated lid at 42ºC for 30 mins. 
2.2.8.3.5 Purification of the cDNA  
To purify the cDNA Nucleic Acid Binding beads were gently vortexed 
to resuspend the beads. Each sample was designated a tube containing 5µL of 
beads and 120µL of binding solution concentrate. The reverse transcription 
reaction (from Section 2.2.8.3.4) was made up to 100µL by adding nuclease-free 
water then transferred to a bead containing tube. 125µL of 100% ethanol was 
added to each tube then mixed thoroughly by pipetting the suspension up and 
down. The samples were incubated for 5 mins at room temperature. The tubes 
containing the reactions were placed on the magnetic stand for 5-6 mins to 
separate the beads from the solution. Once the solution was clear, the 
supernatant was discarded. The tubes were left on the magnetic stand and 
washed with 200µL of wash solution concentrate. The samples were incubated 
at room temperature for 30 secs the supernatant and any residual liquid was then 
discarded. The beads were air dried for 1-2 mins. The tubes were removed from 
the magnetic stand and mixed with 12µL of pre-warmed (37°C) nuclease free 
water. The samples were incubated at room temperature for 1 min then placed 
on the magnetic stand for 1 min to separate the beads from the solution; the 
eluent was collected for each sample. 
2.2.8.3.6 Amplification of the cDNA 
For each cDNA sample a PCR reaction (45µL Platinum PCR SuperMix 
High Fidelity, 1µL Ion Xpress RNA 3’ Barcode primer) was prepared. 6µL of 
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cDNA sample was transferred to a new PCR tube, and mixed with 46µL of the 
PCR mix. 1µL of the selected Ion Xpress RNA-Seq Barcode primer was added 
to each PCR tube. The reaction was mixed well by gentle up and down 
pipetting, then briefly centrifuged. The PCR reaction was placed in a thermal 
cycler with the following conditions: Hold (94ºC for 2 mins), Cycle 2×(94ºC 
30 secs, 50ºC 30 secs, 68ºC 30 secs), Cycle 16×(94ºC 30 secs, 62ºC 30 secs, 
68ºC 3  secs), Hold (68ºC for 5 mins). 
2.2.8.3.7 Purify the amplified cDNA 
The Nucleic Acid Binding beads were gently vortexed to resuspend the 
magnetic beads. 5µL of beads was added to each tube and mixed with 180µL of 
binding solution concentrate. 53µL of cDNA was transferred to a bead 
containing tube. 130µL of 100% ethanol was added to each tube. The 
suspension was thoroughly mixed by pipetting up and down. The samples were 
incubated for 5 mins at room temperature. The tubes containing the cDNA were 
placed on the magnetic stand for 5-6 mins to separate the beads from the 
solution. Once the solution was clear, the supernatant was discarded. The tubes 
were left on the magnetic stand and washed with 200µL of wash solution 
concentrate. The sample was incubated at room temperature for 30 secs 
supernatant and any residual liquid was then discarded. The beads were air dried 
for 1-2 mins. Tubes containing the beads were removed from the magnetic 
stand, and mixed with 15µL of pre-warmed (37°C) nuclease free water. The 
cDNA was incubated at room temperature for 1 min then placed on the magnetic 
stand for 1 min to separate the beads from the solution. The eluent for each 
sample was collected. 
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2.2.8.4 Template preparation 
2.2.8.4.1 Preparation of template positive particles 
The concentration of the RNA library from Section 2.2.8.3.7 was 
measured using a Bioanalyzer. The libraries were diluted to 1nM. In a 2.5mL 
Eppendorf LoBind tube the following solutions (160µL nuclease free water, 
1200µL Ion PI reagent mix TL, 720µL Ion PI PCR reagent B, 120µL Ion PI 
Enzyme mix TL, 100µL Ion PI Ion Sphere Particles and 100µL diluted libraries) 
were mixed to make the amplification solution. The amplification solution was 
slowly pipetted through the sample port of the Ion PI plus reaction filter 
assembly by adding 800µL at a time. The Ion PI plus reaction filter was inserted 
into the Ion OneTouch 2 Instrument and the instrument ran overnight. The 
screen prompts were followed to centrifuge the sample for a final spin. All but 
100µL of Ion PI OT2 recovery solution was removed from each of the Ion PI 
Template OT2 recovery tubes. The template-positive Ion Pi Ion Sphere particles 
in the remaining recovery solution in each tube were resuspended by pipetting 
the pellet up and down until the pellet was in solution. The suspension from 
each of the recovery tubes was transferred into a new Eppendorf LoBind tube. 
Each recovery tube was washed with 200µL of nuclease-free water two times to 
recover the residual beads, transferring the suspension into the same tube. The 
pellet was vortexed for 30 secs, then centrifuged for 8 mins at 15,500×g. All but 
20µL of supernatant was removed, 80µL of Ion Pi ISP resuspension solution 
was then added and vortexed for 30 secs. 
2.2.8.4.2 Enrichment of the template-positive particles 
The Dynabeads MyOne Streptavidin C1 Beads were vortexed for 30 secs 
to resuspend the beads. 100 µL of the beads was placed in a new 1.5 mL 
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Eppendorf LoBind Tube and placed on the DynaMag magnet for 2 mins. The 
supernatant was removed and discarded without disturbing the pellet of beads. 
The beads were washed with 1 mL of Ion OneTouch wash solution and vortexed 
for 30 secs before placing on the magnet. The supernatant, was discarded and 
130µL of Ion PI MyOne beads capture solution was added. The 8-well strip was 
filled according to Table 2.3. A new tip and an opened PCR tube were placed 
onto the Ion One Touch ES instrument. The 8-well strip was inserted and the 
program was left to run. 
 
Table 2.3: Volume and description of reagents to be placed in the 
appropriate well of the 8-well strip.  
Well 1  Add 100μL of the ISP sample from previous step  
Well 2 130μL of Dyna beads from Section 2.2.8.4.2 
Well 3  300μL of OneTouch Wash solution 
Well 4 300μL of OneTouch Wash solution 
Well 5 300μL of OneTouch Wash solution 
Well 6 Empty 
Well 7  
300uL of freshly prepared Melt off solution  
(280μL of Tween solution and 40μL of 1M NaOH) 
Well 8 Empty 
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2.2.8.5 Sequencing 
2.2.8.5.1 Chip preparation 
Ion Proton chip adaptor was attached to the chip exit well. 200µL of 
100% isopropanol was injected into the chip loading port; the expelled liquid 
was removed from the exit well. The isopropanol was aspirated from the chip 
for 5-10 secs to ensure that the chip is dry. 100µL of Ion PI chip preparation 
solution was injected into the chip loading port; the expelled liquid was removed 
from the exit well. The chip was place on a 50°C heat block for 2 mins. 200µL 
of 100% isopropanol was injected into the chip loading port; the expelled liquid 
was removed from the exit well. This was repeated a total of two times. 200µL 
of nuclease free water was injected into the chip loading port; and the expelled 
liquid removed. 200µL of 0.1M NaOH was then injected into the chip loading 
port, and the expelled liquid was removed from the exit well. The chip was 
incubated at room temperature for 1 min then 200µL of nuclease free water was 
injected into the chip loading port. These steps were repeated a total of three 
times. 200µL of 100% isopropanol was injected into the chip loading port; the 
expelled liquid was removed from the exit well. 100µL of 100% isopropanol 
was pipetted onto the chip loading well, the liquid was then removed from the 
same well. The Ion Proton chip adapter was removed from the chip. 
2.2.8.5.2 Loading of sample on the chip 
To load the sample onto the chip, 55µL of the enriched template (from 
Section 2.2.8.4.2) was loaded onto the chip loading well. The chip was 
centrifuged for 10 mins using the Ion Chip Minifuge. 100µL of foam solution 
(50% Annealing buffer mixed with Triton X) was injected onto the loading well. 
The expelled liquid was removed from the opposite port. The chip was 
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centrifuged for 30 secs in the Ion Chip Minifuge followed by injection of 100µL 
of foaming solution and then centrifuged again for 30 secs. The chip was 
injected with 100µL of the flushing solution 2 times; the expelled solution was 
discarded after each injection. 100µL of 50% annealing buffer was injected into 
the chip loading port three times; the expelled liquid was removed between each 
injection. 65µL of polymerase solution (6µL Ion PI Sequencing polymerase 
with 60µL 50% annealing buffer) was injected; the expelled liquid was 
removed. The chip was left to incubate for 5 mins then secured in the Ion Proton 
sequencer.  
2.2.9 Nucleofection using siRNA 
 CASMCs were seeded at 100,000 cells/well (5mM DMEM, 10% FBS, 
no antibiotics) in a 24 well plate (Nunc). The cells were incubated at 37oC in 5% 
CO2 until they reached 70-80% confluency then serum deprived (5mM DMEM, 
0.1% FBS, no antibiotics) for 24 hours prior to Nucleofection. Using the Lonza 
AD1 4D-Nucleofector Y kit, 1mL of the supplement was mixed with 4.5mL of 
AD1 4D-Nucleofector solution. 105pmol of siRNA was made up with 350µL 
Nucleofector solution. The media was carefully removed and 350µL of the 
siRNA substrate solution was carefully transferred into each well. The 24 well 
dripping electrode array was inserted into the 24 well plate. The Nucleofection 
process began when the plate was placed in 4D-Nucleofecor core Y-unit using 
ER137 pulse. The 24 well dipping electrode array was carefully removed from 
24 well plate. The siRNA substrate solution was removed from each well and 
immediately replaced with 1mL of pre-warmed medium (5mM DMEM, 
0.1%FBS, no antibiotics). The pulsed cells were incubated for 36 hours (unless 
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stated otherwise) before they were treated with agonists to assess mRNA 
expression.  
2.2.10 Statistical Analysis 
Data was normalised and is shown as the mean ± standard error of the 
mean of three independent experiments, unless stated otherwise. A one-way 
ANOVA was used to calculate statistical significance of normalised data as 
stated followed by least significant difference post-hoc analysis. Results were 
considered significant when the probability was less than 0.05 and 0.01.
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3.1 Introduction 
Seven transmembrane GPCRs are the largest group of cell surface 
receptors in biology. GPCR signalling involves the traditional cascade which 
will be referred to as transactivation-independent signalling (Kamato et al., 
2014b) or GPCR mediated transactivation of cell surface PTKR. Two decades 
ago the initial finding of transactivation described GPCR activation of the 
PTKR, EGFR, stimulating the immediate downstream products phospho-Erk1/2 
(Daub et al., 1996). This discovery greatly expanded the known functions of 
GPCRs.  
The paradigm of GPCR mediated kinase receptor transactivation has 
been expanded to include GPCR mediated activation of S/TKR, in particular the 
TGFBR1 (Burch et al., 2010, Burch et al., 2013, Little et al., 2010, Ivey and 
Little, 2008). PAR-1 transactivation of the TGFBR1 is studied by the 
phosphorylation of the immediate downstream intermediate of TGFBR1, Smad2 
in the carboxy terminal (phospho-Smad2C) (Burch et al., 2010, Little et al., 
2010). Thrombin stimulation of human VSMCs leads to the synthesis of the 
ECM molecules proteoglycans. Recently our lab reported that thrombin 
treatment of VSMCs leads to an increase in radio sulphate incorporation into 
secreted proteoglycans a response which is approximately equally blocked by 
antagonists of the EGFR (AG1478) and the TGFBR1 (SB431542). The two 
inhibitors together completely block the response, this shows that all PAR-1 
mediated proteoglycan synthesis signalling is via the transactivation of these 
two receptors (Burch et al., 2013). The involvement of the two kinase receptor 
signalling pathways are supported by the finding that thrombin mediated an 
increase in phospho-Erk1/2 and phospho-Smad2C both these responses are 
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blocked by the PAR-1 antagonist SCH79797 (Burch et al., 2010, Burch et al., 
2013). 
Previous work has shed light on the specific enzymes which mediate the 
synthesis of CS/DS GAG chains on proteoglycans (Sugahara and Kitagawa, 
2000, Silbert and Sugumaran, 2002). The synthesis of CS/DS GAG chains on 
proteoglycans involves the concerted action of a number of GAG synthesizing 
genes (Mikami and Kitagawa, 2013). The growth factor and hormone signalling 
pathways that control the expression of these enzymes are important because 
GAG hyperelongation is a critical step in the early development of 
atherosclerosis (Ivey et al., 2008, Getachew et al., 2010a, Ivey and Little, 2008). 
During the progression of atherosclerosis, the elongation of CS chains in the 
arterial wall involves at least four GAG synthesizing genes specifically 
CHST11, CHSY1, CHPF, and chondroitin N-acetylgalactosaminoglycan-2 
(Anggraeni et al., 2011) (Refer to Chapter 1 Section 1.3 for more details). 
Increased LDL binding in the 8 weeks of the development of atherosclerosis 
was associated with an elevated mRNA expression of the four genes. CHST11 
and CHST3 are sulfotransferases whereas CHPF and CHSY1 are 
glycosyltransferases which are directly involved in the synthesis of the GAG 
chains thus the regulation of proteoglycan size (Izumikawa et al., 2011). As 
such, the signalling pathways leading to the expression of these GAG 
synthesizing enzymes represent potential therapeutic targets for the treatment of 
atherosclerosis.  
Proteoglycans secreted by VSMCs in vivo are present in early 
atherosclerotic lesions (Nakashima et al., 2007). Thrombin treatment of VSMCs 
leads to the hyperelongation of GAG chains of proteoglycans such as biglycan 
(Ivey and Little, 2008). The involvement of transactivation pathways has been 
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described to be involved in this signalling cascade, however the downstream 
gene targets presumably the specific GAG synthesizing enzymes that are 
involved remain unknown. This chapter seeks explores the role of 
transactivation dependent signalling pathways that mediated GAG gene 
expression.  
3.2 Materials and Methods 
3.2.1 Materials 
RT-PCR primers for GAG synthesizing enzymes CHST11, CHSY1, 
XXYLT-1, CHPF, CHST3 and biglycan primers were synthesized based on 
their respective GenBank sequences (see Table 3.1 for sequences) and were 
purchased from GeneWorks Pty Ltd (SA, Australia). Antibodies to 
phospho-Smad2(Ser245/250/255), phospho-Smad2(Ser465/467), GAPDH, 
phospho-EGFR(Tyr2068) and phospho-Erk1/2(Thr202/Tyr204) were from Cell 
Signalling Technology (MA, USA). 
3.2.2 Cell Culture 
Cells were grown in DMEM (5mM glucose, 10% FBS and 1% 
antibiotics at 37⁰C in 5% CO2) VSMCs were seeded in 60 mm dishes and 6-well 
plates (described in more detail Chapter 2 Section 2.1). Cells were grown to 
confluence then rendered quiescent by serum deprivation for 48 hours. 
Inhibitors were pre-incubated for 30 mins prior treatment with agonists. The 
incubation and concentrations used are given in detail in the figure legends. 
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Table 3.1: Target gene and primer sequence 
Target Gene Real-time PCR primer Sequence (5’- 3’) 
XXYLT-1 
Forward 
Reverse 
 
GTGGATCCCGTCAATGTCATC  
GTGTGTGAATTCGGCAGTGG 
CHSY1 
Forward 
Reverse 
 
CCCGCCCCAGAAGAAGTC  
TCTCATAAACCATTCATACTTGTCCAA 
CHPF 
Forward 
Reverse 
 
AGATCCAGGAGTTACAGTGGGAGAT  
CCGGGCGGGATGGT 
CHST11 
Forward 
Reverse 
 
GGCCCTGCGCAAAG  
GGGTGTGTGGGTCGATGAG 
CHST3 
Forward 
Reverse 
 
GGATTCCACCTTTTCCCATCTG 
TGCCCTGCTGGTTGAAGAAC  
 Biglycan 
Forward 
Reverse 
 
CTCAACTACCTGCGCATCTCAG 
GATGGCCTGGATTTTGTTGTG 
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3.2.3 Quantitative RT-PCR 
 Quantitative RT-PCR was conducted as described in Chapter 2 
Section 2.2.3. Data was normalised to the ribosomal 18S housekeeping gene to 
adjust for control variations between individual experiments. Experiments were 
performed at least three times and analysed in duplicate unless otherwise stated. 
Data are presented as mean ± standard error of the mean. 
3.2.4 Western Blotting 
The method of western blot analysis is described in detail in Chapter 2 
Section 2.2.6. Whole cell lysates were resolved by SDS-PAGE and transferred 
onto PVDF. Membranes were blocked with 5% BSA and incubated with 
primary antibody targeting protein of interest followed by HRP-anti-rabbit IgG 
and ECL detection. The protein of interest was normalised with GAPDH to 
determine equal loading.  
3.2.5 Statistical Analysis 
Normalised data expressed as the mean ± standard error of the mean of 
three independent experiments, unless stated otherwise. A one-way ANOVA 
was used to calculate statistical significance of normalised data as stated 
followed by Least Significant Difference post-hoc analysis. Results were 
considered significant when the probability was less than 0.05 (*p < 0.05) and 
0.01 (**p < 0.01). 
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3.3 Results 
 3.3.1 Characterisation of vascular smooth muscle cells 
 
  VSMCs were phenotyped as smooth muscle cells. They exhibited a 
distinct “hill and valley” morphology in Figure 3.1 under phase contrast 
microscopy which is phenotypical of smooth muscle cells (Chamley-Campbell 
et al., 1979). Smooth muscle cells are a contractile cell type, a property that they 
utilise to mediate vascular tone, and as such contain the abundant amounts of the 
contractile protein, smooth muscle α-actin (Skalli et al., 1989). The cells were 
characterised using an antibody to smooth muscle α-actin and were visualised 
by confocal microscopy (Figure 3.1). Smooth muscle α-actin staining appears 
striations in the cells. There is a small possibility of endothelial cell 
contamination in VSMCs and can be detected by staining for endothelial cell 
specific von Willebrand factor cultures (Lin et al., 2000). Endothelial cells 
exhibit “cobblestone path” morphology in culture, which was not observed in 
our cells under microscopic examination. VSMCs were stained using primary 
antibody for von Willebrand factor (Figure 3.1). The VSMCs showed no 
staining for von Willebrand factor. Taken together these results demonstrate that 
the cells used in our in vitro model are VSMCs. 
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Figure 3.1: Characterisation of human VSMCs by immunofluorescence 
using confocal microscopy. 
VSMCs were grown and fixed on coverslips. Cells were incubated with smooth 
muscle α-actin antibody (1:100) or von Willebrand (1:100) factor overnight 
followed by goat anti-mouse conjugated with flurophores Alexa594 or Alexa 
488 for 1 hour. 
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3.3.2 Thrombin stimulates the mRNA expression of GAG 
biosynthesizing genes CHST11 and CHSY1 
 
 We have previously demonstrated that the GPCR agonist thrombin can 
transactivate both EGFR and TGFBR1 to stimulate biglycan GAG chain 
elongation in human VSMCs (Burch et al., 2013). However there have been no 
studies detailing the role of GAG gene expression in the PAR-1 mediated GAG 
chain elongation. To elucidate PAR-1 transactivation leading to GAG chain 
elongation we investigated the mRNA expression of GAG biosynthesizing 
genes, specifically CHST11, CHSY1, XXYLT-1, CHPF, CHST3 and biglycan 
in thrombin treated human VSMCs. 
 VSMCs were treated with thrombin (10 Units/ml) and mRNA expression 
of GAG synthesizing genes CHST11, CHSY1, XXYLT-1 and CHPF was 
measured over a 24 time period at time points 0, 1, 2, 4, 6, 8, 16, 20, 22 and 24 
hours as well as the expression of CHST3 and biglycan measured at 0, 2, 4, 6, 
16, 20 and 24 hours (Figure 3.2). During the biosynthesis of GAG chains, 
GalNAc residues of the repeating disaccharide units are sulphated at C4 and C6 
by CHST11 and CHST3 respectively. Thrombin generated a parabolic time 
dependent increase in the mRNA expression of CHST11 (Figure 3.2A). At 2 
hours post thrombin treatment a 1.4-fold increase (P<0.05) in the mRNA 
expression of CHST11 was detected and reached a peak of 3-fold at 6-8 hours 
post stimulation (P<0.01) (Figure 3.2A). Thrombin treatment of human VSMCs 
also caused a rapid stimulation in the mRNA expression of CHST3 reaching a 
2.5-fold (P<0.01) stimulation at 2 hours which was sustained up to 4 hours 
(P<0.05) post thrombin stimulation (Figure 3.2E). The addition of a 
monosaccharide to an acceptor oligosaccharide is referred to as chondroitin 
polymerization which occurs with the action of six glycosyltransferases: 
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CHSY1, CHSY2, CHSY3, CHPF, ChGn-1 and ChGn-2 (Mikami and Kitagawa, 
2013). In this study, we investigated the thrombin mediated expression of 
CHSY1 and CHPF. Thrombin mediated mRNA expression of CHSY1 followed 
a similar response to the expression of CHST11 where it caused a parabolic time 
dependent increase in the mRNA expression (Figure 3.2B). Thrombin treated 
VSMCs caused a 2-fold increase (P<0.05) in the mRNA expression of CHSY1 
at 4 hours and this was sustained reaching a peak of 3-fold (P<0.01) at 8 hours 
(Figure 3.2B). Thrombin had no effect on the mRNA expression of CHPF 
(Figure 3.2D).  
 To determine the role of VSMCs treatment by thrombin on the synthesis 
of glycosyltransferase XXYLT-1 mRNA expression a 24 hour time course was 
conducted. XXYLT-1 is an enzyme that attaches xylose, the first residue of the 
linkage region that links the CS GAG chain backbone to proteoglycan core 
protein. When looking at the mRNA expression of XXYLT-1 we see a slight 
increase of 1.8-fold (P<0.01) at 4 hours post treatment (Figure 3.2C). However 
we see that from 4 hours onwards thrombin has no effect on the mRNA 
expression of XXYLT-1. The role of thrombin on the mRNA expression of 
biglycan was also studied (Figure 3.2F). The 24 hour time course revealed that 
thrombin only slightly increased the mRNA expression of biglycan to 1.6-fold at 
4 hours (P<0.01) (Figure 3.2F) however from 4 hours onwards thrombin has 
little to no effect on the mRNA expression of biglycan. 
These results demonstrate that thrombin treated VSMCs lead to an 
increase in the mRNA expression of GAG synthesizing genes CHST11 and 
CHSY1 and to a much lesser effect mRNA expression of CHST3 and biglycan. 
The magnitude of thrombin stimulation of CHSY1 mRNA expression was 
higher compared to CHPF mRNA expression. These results suggest that 
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modification of GAG chain through sulphation by sulfotransferase CHST11 is 
directly involved in thrombin mediated pathway associated with increased lipid 
binding in VSMCs (Little et al., 2002). Hence the remainder of the study was 
focused on the signalling pathways leading to the expression of these two genes 
at 6 hours post thrombin stimulation.  
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Figure 3.2: Effects of thrombin treatment on the mRNA expression of five 
GAG synthesizing genes and biglycan.  
VSMCs were treated with thrombin (10 Units/ml) to investigate the effect on 
mRNA expression of A. CHST11, B. CHSY1, C. XXYLT-1, D. CHPF, 
E.CHST3 and F. Biglycan. Total RNA was harvested, cDNA was synthesized 
and the mRNA expression of these genes was analysed using quantitative 
RT-PCR. 18S was used as the house keeping gene. Results are expressed as the 
mean ± standard error of the mean from three independent experiments. 
Statistical significance was determined by one-way ANOVA, followed by the 
least significant difference post-hoc analysis, ** P<0.01 and * P<0.05 basal 
versus agonist. 
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3.3.3 Thrombin via PAR-1 activation leads to the mRNA 
expression of GAG biosynthesizing genes CHST11 and 
CHSY1 
 
Our lab has published that thrombin mediated GAG chain elongation and 
the expression of biglycan core protein in VSMCs is elicited through PAR-1 
(Ivey and Little, 2008, Burch et al., 2010). In this study we explore whether 
PAR-1 is involved in thrombin mediated mRNA expression of CHST11 and 
CHSY1 using the PAR-1 antagonist, SCH79797. Thrombin (10 Units/ml) at 
6 hours increased the mRNA expression of CHST11 by 3-fold (P<0.01) (Figure 
3.3A). Thrombin, in the presence of the PAR-1 antagonist SCH79797, showed a 
dose-dependent inhibition of CHST11 mRNA expression. At 10µM, the mRNA 
level was inhibited by 90% (P<0.01) (Figure 3.3A). We observed similar results 
for the effects of thrombin on the mRNA expression level of CHSY1 (Figure 
3.2B). CHSY1 mRNA expression was increased to 1.8-fold (P<0.05) post 
thrombin stimulation (Figure 3.3B) and in the presence of SCH79797 was 
inhibited in a dose-dependent manner. The data indicates that PAR-1 mediates 
thrombin elicited CHST11 and CHSY1 mRNA expression in these cells. 
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Figure 3.3: The effect of a PAR-1 antagonist on thrombin stimulated GAG 
synthesizing gene mRNA expression. 
VSMCs were pre-incubated with PAR-1 antagonist SCH79797 (1–30μM) for 30 
mins and then treated with thrombin (10 Units/ml) for 6 hours to assess the 
effect on mRNA expression of CHST11 and CHSY1. SCH79797 (10 and 
30μM) alone were used to assess any effects on basal expression. Total RNA 
was harvested and the mRNA expression of A. CHST11 and B. CHSY1 were 
analysed using quantitative RT-PCR. 18S was used as the housekeeping gene. 
Results are the mean ± standard error of the mean from three independent 
experiments. Statistical significance was determined by one-way ANOVA, 
followed by least significant difference post-hoc analysis ##, p < 0.01 and #, p < 
0.05 basal versus thrombin and **, p < 0.01 thrombin versus SCH79797.  
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3.3.4 Growth factors activating their respective receptors 
mediate mRNA expression of CHST11 and CHSY1  
 
Our lab has previously shown that thrombin treated cells produce 
proteoglycans with increased GAG chain length (Ivey and Little, 2008). We 
have further shown that thrombin mediated GAG elongation is blocked by 
inhibition of both PTKR (EGFR) and S/TKR (TGFBR1) (Burch et al., 2010) 
using AG1478 and SB431542, respectively. To investigate the presence of the 
relevant pathways and responses, VSMCs were treated with growth factors 
thrombin, TGF-β and EGF in the presence and absence of their respective 
receptor antagonists SCH79797, SB431542 and AG1478 (Figure 3.4).  
Thrombin treatment of VSMCs increased the mRNA expression of 
CHST11 by nearly 3-fold (P<0.01) (Figure 3.4A). In the presence of SCH79797 
(30µM) this was completely abolished (P<0.01) (Figure 3.4A). A similar fold 
change in the mRNA expression of GAG genes was observed when VSMCs 
were exposed to TGF-β. CHST11 mRNA expression increased to 2.5-fold 
(P<0.05) when treated with TGF-β and to 2.7-fold (P<0.01) when treated with 
EGF (Figure 3.4A) and in the presence of their respective antagonists the 
response was completely blocked (P<0.01)(Figure 3.4A). The responses for the 
mRNA expression of CHSY1 were similar to the mRNA expression of CHST11 
(Figure 3.4B). Thrombin treatment increased the mRNA expression of CHSY1 
by almost 4-fold (P<0.01) (Figure 3.4B) and this response was inhibited by 
SCH79797 (P<0.01) (Figure 3.4B). The mRNA expression of CHSY1 in 
VSMCs treated with TGF-β increased by almost 7-fold (P<0.01) (Figure 3.4B) 
and EGF by 2.5-fold (Figure 3.4B). The mRNA expression of CHSY1 was 
inhibited by SB431542 (P<0.01) and AG1478 (Figure 3.4B). These results 
 Chapter-3. PAR-1 mediated GAG synthesizing gene expression                                      Page 113 
show that thrombin, TGF-β and EGF activate their respective receptors to 
generate the mRNA expression of CHST11 and CHSY1. 
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Figure 3.4: Growth factors activating their respective receptors mediate 
mRNA expression of CHST11 and CHSY1. 
VSMCs were pre-incubated with A-B. SCH79797 (30μM), SB431542 (3μM), 
AG1478 (5μM) or vehicle (-) for 30 min and then exposed to thrombin (Thr) (10 
Units/ml), TGF-β (2ng/ml) or EGF (100nM) for 6 hours. Total RNA was 
harvested and the mRNA expression of A. CHST11 and B. CHSY1 were 
analysed using quantitative RT-PCR. 18S was used as the housekeeping gene. 
Results are the mean ± standard error from three separate experiments. 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis ##, p < 0.01 and #, p < 0.05 basal versus 
agonist **, P<0.01 agonist versus antagonist. 
A 
C 
 
 Chapter-3. PAR-1 mediated GAG synthesizing gene expression                                      Page 115 
3.3.5 Thrombin mediated mRNA expression of GAG 
biosynthesizing genes occurs through the transactivation 
of EGFR and TGFBR1 
 
To investigate if thrombin employs transactivation of the S/TKR, 
TGFBR1, in mediating expression of CHST11 and CHSY1 mRNA levels, we 
used the TGFBR1 inhibitor, SB431542. Thrombin increased the mRNA 
expression of CHST11 by 2.5-fold (P<0.01) (Figure 3.5A) similar the results in 
Figure 3.4A. In the presence of SB431542, the thrombin mediated mRNA 
expression was inhibited dose-dependently (P<0.01) (Figure 3.5A). A similar 
result was seen for the mRNA expression of CHSY1, where thrombin elicited a 
3-fold (P<0.01) (Figure 3.5B) increase and the response in the presence of 
SB431542, was dose-dependently inhibited. For CHSY1 the half maximal 
inhibitory effect was between 0.3-1μM and a maximal inhibitory effect of about 
70-80% occurring at a SB431542 concentration of 3μM (P<0.05) (Figure 3.5B). 
These results suggest that in VSMCs, thrombin mediated mRNA expression of 
CHST11 and CHSY1 involves the PAR-1 mediated transactivation of the 
TGFBR1. 
To evaluate the role of the PTKR, EGFR, in thrombin mediated CHST11 
and CHSY1 mRNA expression, we employed the EGFR antagonist, AG1478 
(Figure 3.5C and D). AG1478 had a dose dependent inhibitory effect on 
thrombin mediated mRNA expression of both CHST11 and CHSY1 (Figure 3.5 
C and D). Thrombin stimulated a 2.5-fold (P<0.01) increase in the mRNA 
expression of CHST11 (Figure 3.5C). In the presence of AG1478 the inhibition 
was concentration dependent with half a maximal inhibitory effect at 
approximately 1μM and a maximal inhibitory effect of 100% occurred at 10μM 
(P<0.01) (Figure 3.5D). Similarly thrombin mediated mRNA expression of 
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CHSY1 showed a 2-fold increase (Figure 3.5D). In the presence of AG1478 
there was a dose-dependent inhibition of the thrombin mediated mRNA 
expression. The half maximal inhibitory effect was approximately 0.5μM and a 
maximal inhibitory effect if 100% occurred at 10μM (P<0.01) (Figure 3.5D). 
These results indicate that thrombin can transactivate the EGFR to generate the 
mRNA expression of CHST11 and CHSY1. 
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Figure 3.5: Effect of EGFR and TGFBR1 antagonists on thrombin 
stimulated GAG gene mRNA expression. 
VSMCs were pre-incubated with A-B. SB431542 (0.1–10μM) or C-D. AG1478 
(0.5-10µM)  or vehicle (-) for 30 mins and then exposed to thrombin (10 
Units/ml) for 6 hours. SCH79797 (30μM) was used as a control. Total RNA was 
harvested and the mRNA expression of CHST11 and CHSY1 were analysed 
using quantitative RT-PCR. 18s was used as the housekeeping gene. Results are 
the mean ± standard error of the mean from three separate experiments. 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis ##, p < 0.01 basal versus thrombin and 
**, p < 0.01 and *, p < 0.05 thrombin versus antagonists (SB431542, AG1478 
and SCH79797). 
 Chapter-3. PAR-1 mediated GAG synthesizing gene expression                                      Page 118 
3.3.6 The TGFBR1 and EGFR pathways combine in PAR-1 
mediated expression of GAG biosynthesizing genes. 
 
Burch et al. (Burch et al., 2013) showed that treatment of VSMCs with 
thrombin caused an increase in [35S]-sulphate incorporation into secreted 
proteoglycans. This was inhibited by 84% in the presence of AG1478 and 68% 
in the presence of SB431542. In the presence of both AG1478 and SB431542, 
thrombin stimulation of [35S]-sulphate incorporation was completely blocked. 
Here we investigated whether thrombin can transactivate EGFR and TGFBR1 to 
cooperate in generating increased mRNA expression of CHST11 and CHSY1. 
To address this aim, the EGFR and TGFBR1 inhibitors AG1478 and SB431542 
respectively were used in VSMCS treated with thrombin. Thrombin treated 
VSMCs showed an increased mRNA expression of CHST11 to almost 3-fold 
(P<0.01) (Figure 3.6A). In the presence of AG1478 the mRNA expression was 
completely inhibited (P<0.01) (Figure 3.6A). SB431542 showed a 50% 
inhibition of thrombin mediated mRNA expression of CHST11 (P<0.01) 
(Figure 3.6A). In the presence of both of the receptor antagonists, AG1478 and 
SB431542, the mRNA expression was completely inhibited (P<0.01) 
(Figure 3.6A). Thrombin increased the mRNA expression of CHSY1 to 2-fold 
(Figure 3.6D). In the presence of AG1478 (P<0.05) and SB431542 (P<0.01) 
(Figure 3.6D) the mRNA expression for CHSY1 was completely inhibited. The 
combination of both receptor antagonists, AG1478 and SB431542 showed a 
total inhibitory effect (P<0.01) (Figure 3.6D).  
To confirm our results we used thrombin receptor activator (TRAP), the 
synthetic peptide that specifically activates PAR-1 (Blackhart et al., 2000). 
TRAP treated VSMCs showed an increased mRNA expression of CHST11 to 
almost 2-fold (P<0.01) (Figure 3.6C). The mRNA expression of CHST11 was 
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inhibited by 80% in the presence of SB431542 (P<0.01) (Figure 3.6C). AG1478 
had a 50% inhibition of TRAP mediated mRNA expression of CHST11 
(P<0.01). In the presence of both receptor antagonists it showed a combined 
inhibitory effect (P<0.01). TRAP increased the mRNA expression of CHSY1 to 
2.3-fold (P<0.01) (Figure 3.6F). In the presence of AG1478 (P<0.01) and 
SB431542 (P<0.01) the mRNA expression of CHSY1 was inhibited by 80%. In 
the presence of both of the receptor antagonists, the mRNA expression showed a 
combined inhibitory effect representing total inhibition of the response (P<0.01) 
(Figure 3.6F). This data demonstrates that PAR-1 signalling leading to GAG 
gene expression utilizes both the PTKR and the S/TKR transactivation 
pathways. 
 To investigate whether or not the PTKR and S/TKR signalling pathways 
independently combine in activating mRNA expression of CHST11 and CHSY1 
we investigated the responses to the direct agonists EGF (100nM) and TGF-β 
(2ng/ml) both individually and in combination. EGF and TGF-β treatment 
individually increased the mRNA expression of CHST11 synthesizing enzyme 
to 2.3-(P<0.05) and 2.1-fold (P<0.05), respectively (Figure 3.6B). When the 
two agonists were combined there was an additive effect in the mRNA 
expression of CHST11 to almost 5-fold (P<0.01) (Figure 3.6B). We observed a 
very similar pattern when looking at the mRNA expression of CHSY1. EGF and 
TGF-β increase the mRNA expression of CHSY1 to 1.5- and 3.1-fold (P<0.01) 
respectively (Figure 3.6E). The two agonists show an additive effect in the 
mRNA expression of CHSY1 to almost 5-fold (P<0.01) (Figure 3.6E). This data 
shows that both EGF and TGF-β pathways are involved in the increase 
expression of CHST11 and CHSY1. The combined effect of stimulating both 
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pathways produces an additive effect indicating that the pathways are at least to 
some extent independent.  
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Figure 3.6: Analysis of agonists and antagonists, on the role on EGFR and 
TGFBR1 in mediating the expression of GAG synthesizing genes.  
VSMCs were pre-incubated with AG1478 (5μM), SB431542 (3μM), both or 
vehicle (-) for 30 min and then exposed to A,D. thrombin (10 Units/ml) or 
C,F.TRAP (500µM) for 6 hours to determine the effects on the mRNA 
expression of A,C. CHST11 and D,F. CHSY1. VSMCs were treated with 
thrombin, EGF (100nM), TGF-β (2ng/ml) or both EGF and TGF-β for 6 hours 
to determine the combined activation for the mRNA expression of B.CHST11 
and E.CHSY1. Total RNA was harvested and the mRNA expression of CHST11 
and CHSY1 were analysed using quantitative RT-PCR. 18S was used as the 
housekeeping gene. Data are expressed as the mean ± standard error of the mean 
from three experiments. Statistical significance was determined by one-way 
ANOVA, followed by least significant difference post-hoc analysis A,C,D,F. 
##, p < 0.01 basal versus thrombin and *, p < 0.05 and **, p < 0.01 thrombin 
versus antagonist (AG1478 and SB431542) B,E. **,P<0.01 basal versus agonist 
was used for statistical analysis. 
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3.3.7 The EGFR and TGFBR1 combine in thrombin mediated 
mRNA expression of CHST3 and biglycan 
 
From our time course studies (Figure 3.2) we found that the mRNA 
expression of CHST3 and biglycan was increased by thrombin at 4 hours post 
treatment. Therefore the role of transactivation dependent signalling was studied 
on these two genes at this time point. Biglycan is the major proteoglycan 
synthesized and secreted by VSMCs (Shimizu-Hirota et al., 2004), and also the 
major proteoglycan that elongated in cells treated by thrombin (Burch et al., 
2010). To study the transactivation pathways on thrombin stimulated mRNA 
expression of CHST3 and biglycan VSMCs were treated with thrombin for 4 
hours in the presence and absences of TGFBR1 inhibitor, SB431542, or EGFR 
antagonist, AG1478.  
Thrombin treated VMSCs showed an increased mRNA expression of 
CHST3 to 2-fold (P<0.01) (Figure 3.7A). In the presence of AG1478 and 
SB431542 the mRNA expression was completely inhibited (P<0.01) 
(Figure 3.7A). In the presence of both receptor antagonists, AG1478 and 
SB431542, the mRNA expression was completely inhibited (P<0.01) 
(Figure 3.7A). Thrombin treatment resulted in an approximately 1.2-fold 
increase (P<0.05) in the level of expression of biglycan mRNA (Figure 3.7B); 
this is a low level of expression but it is similar with earlier reports of TGF-β 
stimulation in VSMCs (Kamato et al., 2013a). In the presence of SB431542 
(P<0.01) and AG1478 (P<0.05) the mRNA expression of biglycan was 
completely inhibited. When the two antagonists where used together this 
accounted for all the thrombin signalling leading to biglycan mRNA expression.  
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Figure 3.7: Thrombin mediated mRNA expression of CHST3 and biglycan 
is mediated by the cooperation of both EGFR and TGFBR1 signalling 
pathways. 
VSMCs were pre-incubated with AG1478 (5µM), SB431542 (3µM), both or 
vehicle (-) for 30 min and then exposed to thrombin (10 Units/ml) for 4 hours to 
determine the inhibitory effect for the mRNA expression of A. CHST3 and B. 
biglycan. Total RNA was harvested and the mRNA expression was analysed 
using quantitative RT-PCR. 18S was used as the housekeeping gene. Data are 
expressed as the mean ± standard error of the mean from three experiments. 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis ##, P<0.01 basal versus thrombin and 
*P<0.01 thrombin versus antagonist.     
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3.3.8 The combined roles of the TGFBR1 and EGFR pathways 
on the phosphorylation of Erk and the Smad2 linker 
region 
 
The canonical TGF-β signalling pathway involves direct 
carboxy-terminal phosphorylation of the Smad2 by the TGFBR1. In addition to 
carboxy-terminal phosphorylation Smads can also be phosphorylated in the 
linker region (Burch et al., 2010 , Burch et al., 2011, Kamato et al., 2013c, 
Kamato et al., 2014a, Rezaei et al., 2012, Matsuzaki, 2011, Matsuzaki et al., 
2009). Smad linker region phosphorylation occurs indirectly via the 
phosphorylation of serine/threonine kinases including MAPKs (Erk, p38 and 
Jnk). In VSMCs, Smad2 linker region phosphorylation correlates with 
proteoglycan synthesis and GAG elongation. The data presented earlier in this 
chapter highlights that mRNA expression of GAG synthesizing genes CHST11 
and CHSY1 correlates with previous published work on proteoglycan synthesis 
and GAG elongation (Burch et al., 2010, Burch et al., 2013). Hence, the 
signalling to Smad2 linker region could correlate with the results obtained on 
the regulation of mRNA of CHST11 an CHSY1. 
Having established a role for thrombin in activation of GAG gene 
expression in VSMCs we wished to study each of the relevant signalling 
pathways. Thus, to investigate the roles of EGFR and TGFBR1 pathways on 
Erk1/2 (Figure 3.8A) and Smad2 linker region phosphorylation(Figure 3.8B)  
we used respective agonists EGF and TGF-β and compared the results to that of 
thrombin treated cells. Thrombin had a 2-fold increase of phopsho-Erk1/2 
(Figure 3.8A). EGF and TGF-β increased the phospho-Erk1/2 to 6- (P<0.01) 
and 2-fold respectively (Figure 3.8A). When the two agonists were combined 
phospho-Erk1/2 increased 6-fold (P<0.01) (Figure 3.8A). We observed a very 
 Chapter-3. PAR-1 mediated GAG synthesizing gene expression                                      Page 126 
similar pattern with the Smad2 linker region, thrombin caused a 2-fold (P<0.05) 
increase in phospho-Smad2(245/250/255) (Figure 3.8B). EGF and TGF-β 
resulted in a 3.7- (P<0.01) and 2-fold (P<0.05) increase in the 
phospho-Smad2(245/250/255), respectively (Figure 3.8B). The signalling EGFR 
and TGFBR1 pathways appear to be additive as the action of the combined 
agonists shows a 3.7-fold (P<0.01) increase in phospho-Smad2(245/250/255). 
Thus, there is a correlation between the signalling response pattern of Smad2 
linker region phosphorylation and the gene expression results.  
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Figure 3.8: Direct stimulation of EGFR and TGFBR1 leads to an increase 
in the phosphorylation of Erk1/2 and Smad2 linker region. 
VSMCs were treated with thrombin (10 Units/ml) A. 15 min B. 4 hours, EGF 
(100nM) A. 15 mins B. 60 mins, TGF-β (2ng/ml) A. 4 hours B. 30 min or both 
EGF and TGF-β A. 15 mins and 4 hours B. 60 mins and 30 mins respectively. 
Cell lysates were collected and proteins (40µg) were resolved on 10% SDS-
PAGE then transferred to a PVDF membrane. The membrane was incubated 
with A. anti-phospho-Erk1/2(Thr202/Tyr204) (1:1000) or B. 
anti-phospho-Smad2(Ser245/250/255) (1:1000) followed by peroxidase-labelled 
rabbit IgG secondary antibody. The membranes were reprobed with GAPDH 
HRP-conjugated antibody (1:4000) to determine equal loading. Histograms 
represent band density expressed as fold per basal from three independent 
experiments (*P<0.05 vs. basal) (**P<0.01 vs. basal) using a one-way ANOVA 
followed by least significant difference post-hoc analysis 
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3.3.9 Thrombin mediated Smad2 linker region phosphorylation 
is partially dependent on MMP shedding however 
phosphorylation of Smad2 in the carboxy terminal is not. 
 
We have previously shown that the PAR-1 mediated EGFR 
transactivation in VSMCs follows the well characterised MMP mediated 
triple-membrane bypass system of activation (Prenzel et al., 1999) however the 
TGFBR1 transactivation is not dependent on MMPs (Burch et al., 2013). The 
MMP mediated involvement in the transactivation of TGFBR1 by PAR-2 was 
demonstrated by Chung et al (Chung et al., 2013). Chung et al (Chung et al., 
2013) used an antibody directed to the Smad2 linker region to study PAR-2 
transactivation of the TGFBR1 which produces an unclear outcome (see details 
in Chapter 5). Here we examined the role of MMPs in PAR-1 to TGFBR1 
transactivation using antibodies which target both phosphorylated linker and 
carboxy terminal sites on Smad2. To determine if thrombin mediated 
phosphorylation of the Smad linker region requires the activation of MMPs, we 
used the broad-spectrum MMP inhibitor, GM6001 (Santiskulvong and 
Rozengurt, 2003). Thrombin treated cells had a 3-and 3.5-fold stimulation of 
phospho-Smad2(245/250/255) at 2 and 4 hours respectively (P<0.05, P<0.01) 
(Figure 3.9A). GM6001 markedly inhibited the thrombin mediated stimulation 
of phospho-Smad2(245/250/255) at both 2 and 4 hour stimulation to 1.7-and 
2- fold (P<0.01)(Figure 3.9A) which is consistent with the results of Chung et al 
(Chung et al., 2013). We then showed that GM6001 has no effect on the ability 
of TGF-β mediated stimulation of phospho-Smad2(245/250/255) (Figure 3.9A). 
VSMCs treated with thrombin showed an increase in the carboxy terminal 
phosphorylation of Smad2(Ser465/467) and GM6001 had no effect the same 
results as previous published data (Burch et al., 2013). To confirm that PAR-1 
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mediated EGFR transactivation occurs through MMP activation in this cell 
model phospho-EGFR antibody was utilised. Thrombin stimulated a 5-fold 
increase in phospho-EGFR at 30 min (P<0.01) (Figure 3.9B). This was 
completely abolished in the presence of GM6001 (P<0.01) (Figure 3.9B). As a 
control we also show that GM6001 has no effect on the direct EGFR pathway as 
it fails to inhibit EGF stimulation of phospho-EGFR at 5 min (Figure 3.9B). 
These results show that MMPs are involved in PAR-1 to EGFR transactivation 
but as we have previously reported MMPs are not involved in PAR-1 mediated 
transactivation of TGFBR1.  
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Figure 3.9: Smad2 linker region phosphorylation is partially dependent on 
MMP shedding however phosphorylation of Smad2C is not. 
A. VSMCs were pre-incubated with GM6001 (10µM), SCH79797 (10µM) or 
vehicle for 30 min and then exposed to thrombin (10 Units/ml) for 120 and 240 
mins. VSMCs stimulated with TGF-β (2 ng/ml) for 60 min in the presence and 
absence of GM6001 or SB431542 (3µM). B. VSMCs were pre-incubated with 
GM6001 or vehicle for 30 min and then exposed to thrombin or EGF (100nM) 
for 5 min. Cell lysates were collected and proteins (40µg) were resolved over 
10% SDS-PAGE and transferred to a PVDF membrane. The membranes were 
incubated with A. anti-phospho-Smad2(245/250/255) (1:1000) or 
B. anti-phospho-EGFR(Tyr1068) (1:1000) .The membranes were reprobed with 
anti-phospho-Smad2(465/467) (1:1000) and with GAPDH HRP-conjugated 
antibody. Histograms represent band density expressed as fold per basal from 
three independent experiments (*P<0.05 versus basal) (##P<0.01 agonist 
versus antagonist) using a one-way ANOVA followed by least significant 
difference post-hoc analysis. 
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3.4 Summary of results of Chapter 3 
The key findings from this chapter are: 
 Thrombin treatment of VSMCs leads to the mRNA expression of GAG 
biosynthesizing genes CHST11, CHSY1, XXYLT-1, CHST3 and the 
mRNA expression of biglycan. 
 Thrombin acts through its receptor PAR-1 to mediate the mRNA 
expression of GAG biosynthesizing genes CHST11 and CHSY1 
 Thrombin mediated mRNA expression CHST11, CHSY1, CHST3 and 
biglycan are inhibited by TGFBR1 antagonist, SB431542 and EGFR 
antagonist, AG1478. 
 Agonists to the TGFBR1 and EGFR pathways lead to the mRNA 
expression of GAG synthesizing genes. 
 Thrombin leads to the phosphorylation of the Smad2 linker region. 
 Agonists to TGFBR1 and EGFR  pathways are involved in the 
phosphorylation of the Smad2 linker region 
 Thrombin mediated Smad2 linker region phosphorylation is partially 
inhibited by MMP inhibitor GM6001. The phosphorylation of Smad2 
carboxy terminal is unaffected. 
3.5 Discussion 
The signalling pathways that control the processes that regulate the length 
and sulphation pattern of GAG chains on the proteoglycan, biglycan, represent a 
potential therapeutic target for the prevention of atherosclerosis (Little et al., 
2002). Thrombin is expressed in atherosclerotic plaques and is therefore a 
potential contributor to CVD (Stoop et al., 2000). Our lab has shown that all of 
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the signalling for GAG hyperelongation response occurred through PAR-1 
mediated transactivation of the EGFR and TGFBR1 (Burch et al., 2010, Burch 
et al., 2013). In this chapter the main aim was to investigate whether thrombin 
regulates the mRNA expression of GAG synthesizing genes potentially 
associated with the expression of the enzymes which mediate GAG elongation.. 
These genes which are responsible for CS GAG chain synthesis where chosen as 
they had previously been shown to play a critical role in the development of 
early atherosclerosis (Anggraeni et al., 2011).  
The lipid binding properties of CS proteoglycans specifically biglycan are 
dependent on the polyanionic GAG chains. In human VSMCs, selected GAG 
synthesizing gene mRNA expression was regulated through PAR-1 signalling 
pathway namely, CHST11, CHSY1 and CHST3 as well as biglycan mRNA 
expression. The increased expression of these genes correlates with the GAG 
elongation effect of thrombin (Burch et al., 2013). 
The expression of CHST11 and CHSY1 was increased up to at least 8 hours 
with a peak increase of 3-4 fold. In a high fat diet mouse study CHSY1 was 
reported to be the most highly expressed gene in atherosclerotic plaque 
development (Anggraeni et al., 2011) suggesting that these genes mediate GAG 
elongation and hyperelongation in vivo. In addition, in vivo studies show that in 
a CHSY1 knockout mouse model, the CS GAG synthesis was reduced (Wilson 
et al., 2012). CHSY1 plays an important role by its capability of producing dual 
transferase activities as both B3GALT6 and B4GALT7 activity which enables 
the synthesis of repeating disaccharide units of CS and GAG chain (Izumikawa 
et al., 2008, Izumikawa et al., 2007, Kitagawa et al., 2001). Therefore we 
speculate that in the VSMC model thrombin mediated GAG chain 
hyperelongation requires CHSY1 regulation. The CHST11 enzyme is crucially 
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as important in CS GAG chain synthesis as it catalyses the transfer of sulphate 
to position 4 of the GalNAc residue of chondroitin. A CHST11 deficient mouse 
model showed a 90% decrease in GalNAc structure and CS amount (Izumikawa 
et al., 2011). Through its sulphation actions, CHST11 induces GAG chain 
hyperelongation while producing sulphated disaccharides. Therefore CHST11 is 
directly involved in thrombin mediated GAG chain hyperelongation associated 
with an increase in LDL binding in VSMCs (Ivey and Little, 2008).  
We then investigated the cellular signalling pathways underlying the action 
of thrombin on CHST11 and CHSY1 gene expression. The thrombin stimulated 
expression of CHST11 and CHSY1 was blocked in a concentration dependent 
manner and to a total inhibition of 100 per cent by the PAR-1 antagonist, 
SCH79797, strongly suggesting that the response is mediated via PAR-1. We 
then investigated the contribution of GPCR to kinase receptor transactivation 
pathways in this response. Thrombin mediated expression of CHST11 and 
CHSY1 was blocked in a concentration dependent manner by the TGFBR1 and 
EGFR antagonists. This data shows that thrombin mediated GAG gene 
regulation is via transactivation of the TGFBR1 and EGFR consistent with our 
previous work showing that thrombin mediated proteoglycan synthesis occurs 
via the activation of these two receptors (Burch et al., 2010). The expression of 
CHST11 and CHSY1 are both increased when treated with EGF and TGF-β 
confirming the presence of these receptors and active pathways in these cells. 
When the antagonists SB431542 and AG1478 were concomitantly present all of 
the thrombin mediated increase in CHST11, CHSY1, CHST3 and biglycan 
mRNA expression was blocked strongly indicating that all of the signalling is 
through the (dual) kinase receptor transactivation pathways. 
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Chung et al. (Chung et al., 2013) recently demonstrated PAR-2 
transactivation of TGFBR1, and they reported identical mechanisms to that 
occurring in their renal fibrosis model as in the VSMC model with the notable 
exception that they reported the process of transactivation of TGFBR1 to be 
dependent on MMPs whereas it was previously reported that the process does 
not involve MMPs (Burch et al., 2013). Smad linker region phosphorylation can 
occur via the TGF-β mediated activation of a plethora of serine/threonine 
kinases (or alternatively many other agonist-activated serine/threonine kinases) 
(Kamato et al., 2013c) whereas the response of carboxy terminal 
phosphorylation of Smad occurs only as a direct result of the kinase activity of 
TGFBR1 directed to Smad2 or Smad3 (Kamato et al., 2013c, Kamato et al., 
2014a). To address the role of MMPs in PAR-1 mediated transactivation of 
S/TKR the phosphorylation of Smad2 in both the linker region and the carboxy 
terminal was assessed. Thrombin stimulated the phosphorylation of Smad2 in 
both the linker region and the carboxy terminal domains but only linker region 
phosphorylation was blocked by the broad spectrum MMP inhibitor, GM6001, 
therefore indicating the role of MMPs in linker region but not carboxy terminal 
phosphorylation. There are many pathways leading to linker region 
phosphorylation but based on the current literature only one pathway to carboxy 
terminal phosphorylation. These results thus explain the findings of Chung et al. 
(Chung et al., 2013) and confirms that MMPs are not involved in GPCR 
transactivation of TGFBR1. 
The results observed in these studies in VSMCs of thrombin stimulated 
mRNA expression for two of the genes associated with GAG hyperelongation 
are consistent with those observed when studying functional or structural 
readout of the actual size of the biglycan molecules determined by SDS-PAGE 
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(Burch et al., 2013). In the studies based on biglycan bands we observed a 
partial role for each of the EGFR and TGFBR1 transactivation pathways and 
based on studies with pharmacological agents it was concluded that all of the 
signalling was mediated via the two transactivation pathways (Burch et al., 
2013). In the present studies examining the expression of the mRNA of two 
genes associated with GAG hyperelongation we observed that each of the 
individual pathways, when assessed by the use of the relevant pharmacological 
antagonists appeared to mediate almost 100 per cent of response. Consistent 
with earlier data both pathways accounted for all of signalling which reinforces 
the importance of the transactivation pathways in this response. We do not at the 
moment have an understanding of why the individual pathways of EGFR and 
TGFBR1 mediate such a high proportion of the gene expression responses to 
thrombin. Importantly, our lab has previously reported that SB431542 does not 
block EGFR signalling and that AG1478 does not block TGFBR1 signalling 
(Burch et al., 2010) so there is no spillover of inhibitory activity from one 
pathway to another which could explain these results.  
There is considerable evidence from in vitro, animal and human studies that 
hyperelongation of GAG chains on biglycan is associated with the early stages 
of atherosclerosis (Nakashima et al., 2007, Ballinger et al., 2010). Ultimately, to 
establish causation, one would need to analyse the size of biglycan molecules or 
their GAG chains an atherosclerotic model(Anggraeni et al., 2011, Skalen et al., 
2002). It is sometimes more practical to use a surrogate measure of a potential 
therapeutic target, in our case GAG hyperelongation. Thus, we have commenced 
studies of the expression of the genes which might represent the multitude of 
enzymes which mediate the synthesis of CS/DS GAG chains (Silbert and 
Sugumaran, 2002, Kitagawa et al., 2001, Gotoh et al., 2002, Uyama et al., 2002, 
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Uyama et al., 2003, Yada et al., 2003, Sato et al., 2003). The mechanism of 
CS/DS GAG synthesis has not been fully elucidated but as many as 12 enzymes 
are involved being transferases to add monosaccharides moieties to the growing 
chains, as well as sulfotransferases which add sulphate residues to the 
disaccharide units in the growing chain but may also be involved in the control 
of GAG length. We have been able to deduce by correlation that thrombin 
increases GAG hyperelongation and also increases the expression of three of the 
genes of interest, CHST11, CHST3 and CHSY1, but clearly further studies are 
required to establish the specific role of these enzymes in thrombin mediated 
GAG hyperelongation. However, on the assumption that these agents are 
important in GAG synthesis and GAG hyperelongation, and noting that 
Anggraeni and colleagues (Anggraeni et al., 2011) have reported an increase in 
the expression of CHST11 in the vessels of a murine model of atherosclerosis, 
then we can speculate that these genes can be used as targets to assess the role of 
up regulation of these genes in atherosclerosis. Also our specific interest is the 
potential to inhibit the expression of these genes thus preventing GAG 
hyperelongation, lipid deposition and atherosclerosis an outcome we have 
previously reported for studies with imatinib (Ballinger et al., 2010). 
The signalling consequences of these studies are that the role of GPCR 
mediated transactivation of TGFBR1 extends from the general response of GAG 
hyperelongation to the specific responses of the expression of two individual 
genes and that concurrently the transactivation of the EGFR along with 
TGFBR1 explains all of the signalling in this model. Our data showing that 
MMPs are not involved in PAR-1 to TGFBR1 transactivation indicates the 
mechanisms of PAR-1 transactivation of the EGFR and the TGFBR1 are 
mechanistically completely distinct (Kamato et al., 2014b, Burch et al., 2013).  
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4.1 Introduction 
The major proximal effectors of GPCR signalling are the GTP-binding, 
GTPase active, G proteins. G proteins are a point of convergence in GPCR 
signalling. G proteins are classified into four families according to their α 
subunit: Gi, Gs, G12/13 and Gq. The Gs and Gi families regulate adenylyl 
cyclase activity, while Gq activates PLCβ and G12/13 can activate small 
GTPase families (Neves et al., 2002). The Gq family consists of four members: 
Gq, G11, G14 and G15/16 (Strathmann and Simon, 1990, Wilkie et al., 1991) 
and their respective α subunits thus are: Gαq, Gαq/11, Gαq/14 and Gαq/15/16. 
The Gαq, and Gαq/11, isoforms share in 88% homology at the protein level 
(Hubbard and Hepler, 2006), these two isoforms are the most prominent and 
ubiquitously expressed and will be the focus of this chapter.  
In an inactivated state, in the absence of a cognate ligand, the G protein α 
subunit is bound to GDP, however upon ligand engagement with the GPCR, the 
receptor undergoes conformational changes promoting the exchange of bound 
GDP for GTP (described in (Tuteja, 2009)).  The α subunit and βγ complex then 
dissociate from one another and interact with their associated effectors (Berman 
and Gilman, 1998). In the most common signalling pathways, Gαq activates 
PLCβ, which hydrolyzes PIP2 releasing DAG and IP3. DAG activates several 
isoforms of PKC, whereas IP3 diffuses to the ER and binds to IP3 receptors on 
ligand-gated calcium channels on the surface of the ER leading to a massive 
release of calcium ions into the cytosol and subsequently in some cells, the 
opening of cell surface calcium channels leading to the influx of extracellular 
calcium (Little et al., 1992, Rochdi and Parent, 2003, McCudden et al., 2005). 
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One of the major and expanding areas of GPCR signalling is 
transactivation dependent signalling (Kamato et al., 2014b) in which GPCRs 
transactivate PTKRs such as EGFR or S/TKR such as TGFBR1. In Chapter 3 
the paradigm of GPCR signalling in which PAR-1 transactivates both the 
TGFBR1 and the EGFR leading to an increase in the mRNA expression of GAG 
genes CHST11 and CHSY1 was presented. Mimicking the increase in 
intracellular calcium with ionomycin does not stimulate proteoglycan synthesis 
and GAG elongation (Survase et al., 2005). Calcium channel blockers slightly 
inhibit growth factor stimulated GAG hyperelongation (Vijayagopal et al., 1980) 
but the mechanism does not depend on the blocking of calcium channels 
(Survase et al., 2005). Yang et al. (Yang et al., 2006) studied Gαq coupled 
glutamate receptor responses in cultured neurones found that the stimulation of 
the phosphorylation of the MAPK, Jnk, occurred via transactivation of the 
EGFR and did not involve the traditional PLC, PKC and IP3 pathways. These 
results suggested that the PLC pathway and the pathway to transactivation of the 
EGFR are occurring in parallel.  
The role of G proteins in GPCR signalling has not been as intensively 
investigated as other aspects of GPCR signalling due to the limited availability 
of pharmacological tools. Two natural products YM-254890 from the bacteria 
Chromobacterium sp. QS3666 (Taniguchi et al., 2003) and UBO-QIC also 
known as FR300359 from the Ardisia crenata sims plant (Miyamae, 1989) are 
potent inhibitors of Gαq. These two compounds have been investigated in the 
therapeutic context of inhibitors of the thrombin receptor, PAR-1 and the 
inhibition of platelet aggregation (Kawasaki et al., 2003, Taniguchi et al., 2003, 
Grace et al., 2014, Kamato et al., 2015, Schrage et al., 2015). The YM-254890 
has only recently become commercially available and there are no other suitable 
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alternatives hence the difficulty in studying the role of Gαq in cell biology. For 
this Chapter we had a very limited amount of UBO-QIC gifted to us, which was 
used to study the role of Gαq in GPCR mediated transactivation signalling.  
The inhibitory profile of the UBO-QIC compound has recently been 
characterised (Kukkonen, 2016). Endogenously expressed receptor utilizing 
Gαi, Gαs and Gαq protein were assessed in CHO, UBO-QIC was an effective 
inhibitor of the Gαq mediated responses, but was inactive at Gαi and Gαs 
mediated responses. In human erythroleukemia cells, UBO-QIC inhibited 
responses downstream of the Gαq/11 and the Gαq/16 (Kukkonen, 2016). Within 
the same time period, Schrage and colleagues (Schrage et al., 2015) published a 
major study on the characterisation of UBO-QIC. Inhibition of Gαq, Gαq/11 and 
Gαq/14 signalling by UBO-QIC was observed whereas, signalling via Gαq/16 
was completely unaffected. These results in transfected HEK cells describe 
UBO-QIC to be an inhibitor of Gαq, Gαq/11 and Gαq/14. Thus showing a 
difference between the two studies, which may be cell and context dependent. A 
very recent paper confirms that UBO-QIC inhibits Gαq mediated signalling and 
had no effect on Gαi and Gαs mediated signalling (Gao and Jacobson, 2016). 
However UBO-QIC was also observed to interact with Gβγ mediated signalling 
following the activation of the Gαi- coupled receptor (Gao and Jacobson, 2016). 
Thus we acknowledge that UBO-QIC may not be specific for Gαq mediated 
signalling, hence siRNA will be used to validate whether this signalling is Gαq 
dependent. However for the purpose of this thesis we have referred to UBO-QIC 
as a broad Gαq antagonist. 
 Chapter-4. Role of Gαq  Page 143 
4.2 Materials and Methods 
4.2.1 Materials 
RT-PCR primers for GAG synthesizing genes; CHST11 and CHSY1 
were based on their respective GenBank sequences and were purchased from 
GeneWorks Pty Ltd (SA, Australia)(Table 3.1). AD1 4D-Nucleofector Y kit was 
purchased from Lonza. siGENOME Human GNA11, GNAQ and non targeting 
siRNA SMARTpool, were purchased from Millennium Science. Mouse human 
integrin αVβ3 and αVβ5 monoclonal antibodies were purchased from MERCK 
Millipore. GNAQ antibody (ab75825) and GNA11 antibody (ab192507) were 
purchased from Abcam. 
4.2.2 Cell culture 
Cells were grown in DMEM (5mM glucose, 10% FBS and 1% 
antibiotics at 37°C in 5% CO2). VSMCs were seeded in 96-, 24-, 12- and 6-well 
plates or on cover slips (described in more detail in Chapter 2 Section 2.1). Cells 
were grown to confluence then rendered quiescent by serum deprivation for 
either 24 or 48 hours. Inhibitors were pre-incubated for 30 mins prior treatment 
with agonists. The incubation times and concentration are given in detail in the 
figure legends. 
4.2.3 Quantification of intracellular calcium release 
Quiescent VSMCs seeded into 96-well plates were loaded with 
FURA-2AM ester. The cells were pre-incubated with antagonists for 30 mins 
prior to stimulation with thrombin. Fluorescence was measured at 340nm and 
380nm excitation and 510nm emission wavelengths using a Flexstation 3 plate 
reader. The sustained calcium response was calculated as the difference between 
basal fluorescence and the peak fluorescence after thrombin stimulation.  
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4.2.3.1 YM-280193 
YM-254890 has 5 naturally occurring analogues (Taniguchi et al., 2004). 
Professor Margaret Brimble (University of Auckland) provided us with one of 
the analogues, YM-280193, in two forms, cyclic and linear. The chemical 
structures of UBO-QIC and the YM-280193 peptide presented in Figure 4.1D 
show that the main difference between the two chemical structures is the 
additional side chain hydroxyleucine residue outlined by the circle 
 
 
 
 
 
 
 
 
Figure 4.1: Chemical structure of UBO-QIC and YM-280193. 
 
4.2.4 Western blotting 
The method of western blot analysis is described in detail in Chapter 2 
Section 2.2.6. Whole cell lysates were resolved by SDS-PAGE and transferred 
onto PVDF. Membranes were blocked with 5% BSA and incubated with 
primary antibody targeting protein of interest followed by HRP-anti-rabbit IgG 
and ECL detection. The protein of interest was normalised with GAPDH to 
adjust for control variations. 
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4.2.5 Quantitative RT-PCR 
Quantitative RT-PCR was conducted as described in Chapter 2 Section 
2.2.3. Data was normalised to the ribosomal 18S housekeeping gene to adjust 
for control variations between individual experiments. Experiments were 
performed at least three times and analysed in duplicate.  
4.2.6 Quantitation of proteoglycan synthesis and analysis of 
proteoglycan size 
 Quiescent cells were changed to fresh medium containing 
50μCi/ml [35S]-sulphate in the presence or absence of agonists or antagonists for 
24 hours. Media from the cell cultures was harvested and protease inhibitors 
were added to prevent degradation. Incorporation of the radiolabel into 
proteoglycans was measured by CPC precipitation assay (described in more 
detail Chapter 2 Section 2.2.4). Proteoglycans labelled with [35S]-sulphate were 
prepared for SDS-PAGE by isolation through DEAE-Sephacel anionic exchange 
mini columns. Fractions containing the highest number of [35S]-sulphate cpm 
were pooled. Radiolabeled proteoglycans were separated on 4-13% acrylamide 
gels with a 3% stacking gel at 50V overnight. Gels were then fixed and dried 
and exposed to phospho imaging plate (Fujifilm BAS-MS 2040 imaging plate) 
for 3-5 days. Images were then developed using a phosphoimager (Perkin Elmer 
Cyclone Plus Storage Phosphor System) and viewed using imaging software 
(OptiQuant). 
4.2.7 siRNA Knockdown of G proteins 
 Quiescent VSMCs were seeded in 24 well plates, Lonza AD1 
4D-Nucleofector Y kit was utilized according to manufacturers’ instructions 
(see Chapter 2 Section 2.2.11 for more detail). siRNA to GNAQ and GNA11 at 
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105pmol was utilized. Culture was continued for 36 hours post transfection prior 
to RNA extraction or treatment with thrombin. 
4.2.8 Confocal imaging of G protein and integrins 
 Cells were grown and treated on glass coverslips then fixed with 2% 
paraformaldehyde in 1×PBS. The coverslips were then washed with 1×PBS and 
blocked by 10% horse serum for 30 mins. Cells were incubated with mouse 
anti-human αVβ3, αVβ5, anti-rabbit GNAQ and GNA11 overnight in a 
humidified chamber followed by a goat anti-mouse or anti-rabbit conjugated 
with flurophores Alexa594 and Alexa488 for 1 hour. Coverslips were incubated 
with Hoechst stain for 30 mins and then mounted on slides and dried overnight 
at 4°C. Cells were imaged using a Nixon C1 confocal microscope. 
4.2.9 Statistical analysis 
 Data was normalised and is shown as the mean ± standard error of the 
mean of three independent experiments, unless stated otherwise. A one-way 
ANOVA was used to calculate statistical significance of normalised data as 
stated followed by least significant difference post-hoc analysis. Results were 
considered significant when the probability was less than 0.05 and 0.01. 
4.3 Results 
4.3.1 UBO-QIC inhibits thrombin mediated intracellular release 
of calcium 
 
YM-254890 has 5 naturally occurring analogues (Taniguchi et al., 2004). 
Professor Margaret Brimble (University of Auckland) provided us with one of 
the analogues YM-280193 in two forms, cyclic and linear. The hypothesis was 
that in our model UBO-QIC and the 2 forms of the YM-280193 peptide would 
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act as Gαq inhibitors. To address our aim GPCR mediated intracellular calcium 
release was used to study the Gαq signalling pathway (Masuda et al., 1998). 
VSMCs treated with thrombin showed a substantial increase in the intracellular 
release of calcium (P<0.01)(Figure 4.2A). In the presence of UBO-QIC (1-
1000nM) we observed a dose-dependent inhibition with 50% inhibition seen at 
30nM and a complete block of thrombin mediated intracellular calcium release 
at 100-1000nM (P<0.01). This data shows that UBO-QIC in VSMCs works as a 
Gαq antagonist. 
 Closely related analogue to the Gαq/11 antagonist YM-254890, 
YM-280193 (Kaur et al., 2015), was evaluated for its effects as a Gαq inhibitor. 
VSMCs treated with thrombin stimulated (P<0.01) the intracellular release of 
calcium, YM-280193-linear (1-1000nM) (Figure 4.2B) had no effect on the 
thrombin mediated intracellular calcium levels, however UBO-QIC used as a 
positive control almost completely inhibited thrombin mediated intracellular 
calcium release. Thrombin mediated intracellular calcium release was 
unaffected by YM-280193-cyclic (1-1000nM) (Figure 4.2C), however as 
expected UBO-QIC inhibited the thrombin mediated intracellular calcium 
release. These results show that both the linear and cyclic YM-280193 peptide is 
ineffective at inhibiting GPCR mediated intracellular calcium release, thus 
unlike its analogue YM-254890, YM-280193 is not a Gαq antagonist. The 
chemical structures of UBO-QIC and the YM-280193 peptide presented in 
Figure 4.1 show that the main difference between the two chemical structures is 
the additional side chain hydroxyleucine residue outlined by the circle. From 
this we postulate that this hydroxyleucine side chain plays an important role in 
the binding to the Gαq protein to inhibit Gαq signalling. 
A 
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C  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: UBO-QIC dose dependently inhibits thrombin mediated 
intracellular calcium release. 
VSMCs loaded with FURA-2A ester (2µM) for 30 min and pre-incubated by A. 
UBO-QIC (1-1000nM), B. YM-280193 cyclic (1-1000nM) and C. YM-280193-
linear (1-1000nM) for 15 min prior stimulation with thrombin (1 Units/ml). The 
peak fluorescence ratio (340/380nm) minus the baseline was used to express the 
relative data. The results are the mean and standard error from three separate 
experiments repeated in triplicate. Statistical significance was determined by 
one-way ANOVA, followed by least significant difference post hoc analysis 
##,P<0.01 basal versus thrombin and **,P<0.01 thrombin versus antagonist 
was used.  
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4.3.2 The Gαq protein is involved in PAR-1 mediated 
transactivation of the TGFBR1 and EGFR 
 
We have previously demonstrated that GPCR agonist thrombin 
transactivates the TGFBR1 leading to the generation of phosphorylated Smad2 
in the carboxy terminal. Thrombin has also been shown to transactivate the 
EGFR leading to the phospho-Erk1/2. The mechanisms which define and 
characterise the two transactivation pathways have been extensively reviewed 
(Kamato et al., 2014b, Burch et al., 2012, Cattaneo et al., 2014, Wang, 2016). 
The literature as well as our findings (Burch et al., 2013, Kamato et al., 2014b, 
Prenzel et al., 1999, Daub et al., 1997, Gschwind et al., 2002, Frank and Eguchi, 
2003, Jenkins et al., 2006, Xu et al., 2009) indicate that the distal components of 
these two transactivation pathways are mechanistically distinct. From the point 
of view of discovery of a potential therapeutic target, the ultimate aim is to find 
a common mechanism or target which can mediate the transactivation dependent 
signalling. We hypothesize that G proteins such as the Gαq family members 
may play a role in GPCR mediated transactivation of both the EGFR and 
TGFBR1 therefore Gαq could be common hence we sought to test this 
hypothesis experimentally.   
VSMCs treated with thrombin showed a 2.8-fold increase (P<0.01) in 
the phospho-Smad2(465/467) (Figure 4.3A). In the presence of UBO-QIC 
thrombin mediated phospho-Smad2(465/467) was inhibited by 75% to 1.4-fold 
(P<0.01) when compared to thrombin stimulated cells (Figure 4.3A). In the 
presence of TGFBR1 antagonist SB431542 the thrombin mediated 
phospho-Smad2(465/467) was abolished (P<0.01) (Figure 4.3A). To evaluate 
any possible direct effects on TGFBR1 signalling, VSMCs were treated with 
TGF-β in the presence and absence of UBO-QIC and SB431542. The results 
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show that TGF-β treated cells had a 30-fold increase in the phospho-
Smad2(465/467) which as expected was unaffected by UBO-QIC (Figure 4.2A). 
As expected TGFBR1 antagonist, SB431542, inhibited TGF-β mediated 
signalling by approximately 70% (Figure 4.2A). 
Similarly, the role of Gαq was investigated on thrombin mediated 
transactivation of the EGFR. Thrombin treatment showed a 2-fold increase 
(P<0.01) of phospho-Erk1/2 (Figure 4.3B). Thrombin mediated phospho-Erk1/2 
was inhibited in the presence of UBO-QIC by 95% (P<0.01)(Figure 4.3B). 
EGFR antagonist, AG1478, completely inhibited (<0.01) thrombin mediated 
phospho-Erk1/2. To study whether UBO-QIC had any effect on direct EGFR 
signalling, VSMCs were treated with EGF in the presence and absence of UBO-
QIC and AG1478. As expected EGF showed a substantial 5-fold increase in 
phospho-Erk1/2 (Figure 4.3B) and this was unaffected by UBO-QIC but 
completely abolished by AG1478 (Figure 4.3B). These results demonstrate that 
thrombin mediated transactivation of the EGFR and TGFBR1 involved 
UBO-QIC sensitive Gαq signalling. Gαq may act as the common integrating 
point for all transactivation dependent signalling.  
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Figure 4.3: Gαq is involved in PAR-1 mediated transactivation of the TGF-
β and EGF receptors. 
VSMCs were pre-incubated with A. UBO-QIC (100nM), SB431542 (3µM) or 
vehicle for 30 mins then exposed to thrombin (10 Units/ml) for 240 mins or 
TGF-β (2ng/ml) for 10 mins B. UBO-QIC (100nM), AG1478 (5µM) or vehicle 
for 30 mins then exposed to thrombin (10 Units/ml) for 15 mins or EGF 
(100nM) for 5 mins. Cell lysates were collected and proteins (40µg) were 
resolved over 10% SDS-PAGE and transferred to a PVDF membrane. The 
membrane was then incubated with A. anti-phospho-Smad2(Ser465/467) 
(1:1000) or B. anti-phospho-Erk1/2(Thr202/Tyr204) (1:1000) followed by 
peroxidase-labelled rabbit IgG secondary antibody. Membranes were reprobed 
with GAPDH HRP-conjugated antibody. Histograms represent band density 
expressed as fold per basal from three independent experiments. Statistical 
significance was determined by one-way ANOVA, followed by least significant 
difference post hoc analysis ##,P<0.01 basal versus agonist and **,P<0.01 
agonist versus antagonist.  
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4.3.3 Thrombin signalling via Gαq requires the activation of 
ROCK signalling. 
 
 Thrombin mediated transactivation of the TGFBR1 is achieved through 
cytoskeletal rearrangement, which involves ROCK signalling activating cell 
surface integrins which bind to the latent TGF-β complex (Burch et al., 2013). 
To investigate whether thrombin mediated transactivation of the TGFBR1 via 
the Gαq follows this signalling cascade, we investigated the effects of thrombin 
mediated Gαq signalling against the immediate downstream product of ROCK, 
the group of homologous proteins ERM. Thrombin caused a small increase up to 
1.4-fold in the phosphorylation of ERM, in the presence of UBO-QIC, thrombin 
mediated phosphorylation of ERM was completely inhibited (Figure 4.4). Y-
27632 a small molecule inhibitor of ROCK completely abolished thrombin 
mediated phosphorylation of ERM. These results show that thrombin mediated 
transactivation of the TGFBR1 involves the Gαq protein signalling to activate 
ROCK signalling pathways which will lead to integrin activation allowing for 
the TGF-β ligand to bind to its receptor.  
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Figure 4.4: Thrombin signalling via Gαq requires the activation of ROCK 
signalling. 
VSMCs were pre-incubated with UBO-QIC (100nM), Y-27632 (10µM) or 
vehicle for 30 min in the presence and absence of thrombin (10 Units/ml) for 5 
mins. Cell lysates were collected and proteins (40µg) were resolved over 10% 
SDS-PAGE and then transferred to a PVDF membrane. The membrane was then 
incubated with anti-phospho-Ezrin(Thr567)/Radixin(Thr564)/Moesin(Thr558) 
antibody (1:4000) followed by peroxidase-labelled rabbit IgG secondary 
antibody. Membranes were reprobed with GAPDH HRP-conjugated antibody. 
Histograms represent band density expressed as fold per basal from two 
independent experiments. 
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4.3.4 Gαq and Rho/ROCK are involved in PAR-1 mediated 
mRNA expression of GAG enzymes CHST11 and CHSY1. 
 
 Previously our lab has published that thrombin mediated proteoglycan 
synthesis and GAG chain elongation occurs via the transactivation of the EGFR 
and TGFBR1 (Burch et al., 2010, Burch et al., 2013). Chapter 3 shows that 
thrombin leads to an increase in the mRNA expression of GAG synthesizing 
genes CHST11 and CHSY1. Thrombin mediated mRNA expression of these 
two GAG synthesizing genes occurred via the transactivation of both the EGFR 
and TGFBR1. The CHSY1 enzyme is directly involved in addition of repeated 
disaccharide units on GAG chains, the CHST11 is involved in the sulphation of 
the GAG chain. Based on the results of the signalling data presented in Chapter 
4 Section 4.3.1 and 4.3.2 we hypothesize that the Gαq protein will be involved 
in thrombin mediated proteoglycan synthesis and the mRNA expression of GAG 
synthesizing genes CHST11 and CHSY1.  
 We assessed the role of thrombin mediated Gαq signalling in 
proteoglycan synthesis using UBO-QIC. VSMCs treated with thrombin showed 
a 3-fold (P<0.01) increase [35S]-sulphate incorporation into secreted 
proteoglycans compared to untreated controls (Figure 4.5A). Thrombin treated 
VSMCs in the presence of UBO-QIC had a 30% inhibition to 2-fold of 
[35S]-sulphate incorporation into proteoglycans. VSMCs were treated with 
TGF-β or EGF alone which increased the incorporation of [35S]-sulphate into 
secreted proteoglycans to approximately 2-fold (P<0.01). The [35S]-sulphate 
incorporation was unaffected in the presence of UBO-QIC (Figure 4.5A).  
 Separation of proteoglycans by SDS-PAGE showed a decrease in 
electrophoretic mobility of biglycan in the presence of thrombin compared to 
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untreated controls (Figure 4.5B). In the presence of 30nM and 100nM 
UBO-QIC, relative to thrombin treatment alone, there was an increase in 
biglycan electrophoretic mobility (Figure 4.5B). TGF-β and EGF showed a 
decrease in electrophoretic mobility of biglycan which was unaffected in the 
presence of UBO-QIC. These results demonstrate that the increase in the size of 
biglycan molecules in thrombin stimulated VSMCs is inhibited by UBO-QIC. 
To investigate whether Gαq or Rho/ROCK pathways are involved in 
PAR-1 mediated mRNA expression of GAG synthesizing genes, VSMCs were 
treated with thrombin in the presence and absence of UBO-QIC, Rho/ROCK 
antagonist Y-27632 and PAR-1 antagonist SCH79797 and the expression of 
both CHST11 and CHSY1 was studied. Thrombin showed a 2.2-fold increase 
(P<0.01) in the mRNA expression of CHST11 (Figure 4.5C). In the presence of 
UBO-QIC and Y-27632 the thrombin mediated mRNA expression of C4ST-1 
was abolished (P<0.01) (Figure 4.5C). In the presence of SCH79797 thrombin 
mediated mRNA expression of CHST11 was inhibited by 50% to 1.2-fold 
(P<0.01) (Figure 4.5C). A similar trend was seen when looking at the mRNA 
expression of CHSY1. Thrombin showed a 2.5-fold increase in the mRNA 
expression of CHSY1 (P<0.01) (Figure 4.5D). Thrombin mediated mRNA 
expression of CHSY1 was completely inhibited (P<0.01) in the presence of 
UBO-QIC. Rho/ROCK inhibitor Y-27362 and PAR-1 antagonist SCH79797 
partially inhibited the thrombin mediated mRNA expression of CHSY1 to 2- 
and 1.2-fold respectively (P<0.01) (Figure 4.5D). The results presented show 
that thrombin mediated GAG synthesizing gene mRNA expression involves 
Gαq protein. 
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Figure 4.5: Gαq is involved in PAR-1 mediated proteoglycan synthesis, 
GAG chain elongation and the regulation of mRNA expression CHST11 
and CHSY1. 
A,B. VSMCs were pre-incubated with UBO-QIC (100nM) in the presence and 
absence of thrombin (10 Units/mL), TGF-β (2ng/mL) or EGF (100nM) for 24 
hours with [35S]-sulphate (50μCi/mL). A. Medium containing secreted 
proteoglycans harvested and spotted onto 3MM paper and were quantitated by 
CPC precipitation to measure radiolabel incorporation. The histogram shows the 
fold-change compared to basal. B. Secreted proteoglycans were isolated using 
ion exchange chromatography and electrophoresed on a 4-13% SDS-PAGE. 
C,D. VSMCs were pre-incubated with UBO-QIC, Y-27632 (10µM) or 
SCH79797 (10µM) for 30 min and then exposed to thrombin for 6 hours. Total 
RNA was harvested and the mRNA expression of C. CHST11 and D. CHSY1 
were analysed using quantitative RT-PCR. Results are the mean and standard 
error from three separate experiments. Statistical significance was determined 
by one-way ANOVA, followed by least significant difference post-hoc analysis 
##, P<0.01 basal versus thrombin and **,P<0.01 thrombin versus antagonists.  
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4.3.5 siRNA knockdown validation of GNAQ and GNA11 in 
human coronary artery smooth muscle cells  
 
In the experiments presented earlier UBO-QIC was used as a Gαq 
antagonist. UBO-QIC has been shown to inhibit both Gαq signalling as well as 
Gαq/11 signalling (Schrage et al., 2015). Since these two Gαq isoforms share 
similarities and have approximately 90% homology at the protein level (Wilkie 
et al., 1991) we wanted to find whether the Gαq mediated transactivation 
leading to gene expression is isoform dependent. To address this we used siRNA 
specific to the GNAQ and GNA11. 
The GNAQ and GNA11 mRNA expression was measured 48 hours post 
electroporation. VSMCs were pulsed in the presence of siRNA specific to either 
GNAQ or GNA11. The GNAQ siRNA caused a 90% knockdown in the mRNA 
expression of GNAQ (Figure 4.6A). The siRNA specific to GNA11 had no 
effect on the mRNA expression of GNAQ (Figure 4.6A). To study the 
specificity of the siRNA, CASMCs were transfected with siRNA to GNAQ and 
GNA11. GNA11 siRNA caused an 80% knockdown in the mRNA expression of 
GNA11, the GNAQ siRNA had no effect (Figure 4.6C). These results show that 
although the Gαq and Gαq/11 share approximately 90% homology at the protein 
level there is no crossover in the knockdown targets of the siRNA regarding the 
two Gαq isoforms.  
To ensure that the knockdown of the mRNA expression results in 
knockdown at the protein level, the protein expression was measured as detailed 
in Section 4.2.8. siRNA which targets the GNAQ had a 50% knockdown of the 
protein expression of Gαq at 24 hours post transfection and an 80% knockdown 
at 48 hours (Figure 4.6B). siRNA specific to the GNA11 isoform lead to a 50% 
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knock down of Gαq/11 protein expression 24 hours post transfection and only a 
65% knockdown at 48 hours (Figure 4.6D). These results show that the 
knockdown of the mRNA expression results in a knockdown at the protein level.  
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Figure 4.6: Validation of siRNA knock own of GNAQ and GNA11 on 
mRNA and protein expression in human VSMCs. 
VSMCs were loaded with 4D-Nucleofector Y-kit solution and siRNA to GNAQ, 
GNAQ11 or non-targeting at 105pmol. A.C. total RNA was harvested 48 hours 
post electroporation and the mRNA expression A.GNAQ and C. GNA11 were 
analysed using RT-PCR. 18S was used as the house keeping gene. Data are 
expressed as the mean and standard error of the mean from two independent 
experiments. B.D. Cells were fixed with 2% paraformaldehyde 24 or 36 hours 
post electroporation. Cells were incubated with B. anti-Gαq or D. anti Gαq/11 
overnight followed by goat anti-rabbit conjugated with Alexa488 or Alexa594. 
Images are representative of two independent experiments. Histograms represent 
mean intensity of cells presented in 5 field views. Data expressed as mean ± 
standard error of the mean. 
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4.3.6 Thrombin mediated mRNA expression of the CHST11 and 
CHSY1 is specifically via Gαq and not Gαq/11 
 
To distinguish which of the Gαq proteins is involved isoform specific 
siRNA was used to knockdown the levels of GNAQ and GNA11 (described in 
detail in Chapter 4 Section 4.3.5). VSMCs were treated with thrombin in the 
presence and absence of the siRNA and the mRNA expression of CHST11 and 
CHSY1 was measured. Thrombin treatment resulted in a 2.7-fold 
(P<0.01)(Figure 4.7A) increase in the mRNA expression of CHST11. The 
knockdown of GNAQ had a 50% inhibition in thrombin mediated mRNA 
expression of CHST11 to 1.6-fold (P<0.01)(Figure 4.7A). The knockdown of 
GNA11 had no effect on thrombin mediated mRNA expression of CHST11. To 
determine the effects on basal cell activity a non-targeting siRNA was used and 
this had no effect on thrombin mediated mRNA expression of CHST11. A 
similar pattern was observed when investigating thrombin mediated mRNA 
expression of CHSY1. Thrombin treatment of VSMCs mediated a 1.8-fold 
(P<0.01) (Figure 4.7B) increase in the mRNA expression of CHST11. 
Knockdown of GNAQ completely inhibited (P<0.01)(Figure 4.7B) thrombin 
mediated mRNA expression of CHSY1. In contrast thrombin mediated mRNA 
expression of CHSY1 was unaffected by GNA11 knockdown. As expected the 
non-targeting siRNA had no effect (Figure 4.7B). These results demonstrate that 
thrombin mediated mRNA expression of CHST11 and CHSY1 occurs via of the 
Gαq but not the Gαq/11 protein. 
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Figure 4.7: Specific knockdown of each of the two Gαq isoforms –Gαq and 
Gαq/11 on thrombin mediated mRNA expression of the GAG synthesizing 
genes CHST11 and CHSY1. 
VSMCs were loaded with 4D-Nucleofector Y kit solution and siRNA to GNAQ, 
GNAQ11 or non targeting (NT) at 105pmol followed by thrombin stimulation 
for 6 hours. Total RNA was harvested and the mRNA expression of A. CHST11 
and B. CHSY1 were analysed using RT-PCR. 18S was used as a house keeping 
gene. Results are the mean and standard error from three separate experiments. 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis ##, P<0.01 basal versus thrombin and 
**,P<0.01 thrombin versus antagonists.     
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4.3.7 Thrombin mediated transactivation of the TGFBR1 occurs via 
the activation of the αVβ5 but not the αVβ3 integrin 
 
PAR-1 transactivation of EGFR and TGFBR1 have distinct mechanisms, the 
Gαq plays as the central integrating point for transactivation dependent signalling. In 
VSMCs thrombin mediated transactivation of the TGFBR1 occurs via cytoskeletal 
rearrangement which activates ROCK signalling (Burch et al., 2013). Earlier in this 
Chapter (Section 4.3.4) the role of ROCK signalling being downstream of the Gαq 
was outlined. Inside out integrin signalling has been associated with cytoskeletal 
rearrangement and ROCK signalling (Jenkins et al., 2006). Various members of the 
integrin family including all αV integrins (αVβ3 and αVβ5), αIIβ3, α5β1 and α8β1 of 
cell surface molecules activate the latent TGF-β complex (Munger et al., 1999, Asano 
et al., 2005a, Asano et al., 2005b). Taking into account the relationship of integrin and 
the cytoskeleton/ROCK signalling, integrins make a likely candidate for a key player 
in the transactivation of the TGFBR1. Integrins contain an RGD binding motif, using 
an RGD peptide which prevents them from binding to further RGD sites, the role of 
integrins was studied in thrombin mediated transactivation of the TGFBR1 in VSMCs 
(Burch et al., 2013). Integrins play an important role in the transactivation of the 
TGFBR1, however it remains unknown which specific integrin is involved in the 
transactivation signalling cascade in VSMCs. In these experiments we endeavoured to 
uncover the specific integrins involved in this signalling cascade. 
To evaluate whether the αVβ3 and αVβ5 integrins are present in the cell 
surface of the VSMCs, immunofluorescence experiments were conducted (as per 
Section 4.2.5). The immuno-fluorescent images shows that the αVβ3 integrin shown 
by the red fluorescence is present on the cell surface of the VSMCs (Figure 4.8A). 
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The αVβ5 integrin represented by the green fluorescence (Figure 4.8B) also shows to 
be present on the cell surface of the VSMCs. These results demonstrate that both the 
αVβ3 and αVβ5 integrins are present on the cell surface of VSMCs. 
To evaluate the role of αVβ3 in this study, VSMCs were pre-treated with an 
αVβ3 specific blocking antibody, in the presence and absence of thrombin. Thrombin 
lead to a 2.5-fold increase in phospho-Smad2(465/467) at four hours (Figure 4.9A) in 
the presence of αVβ3 neutralizing antibody there was no effect on thrombin mediated 
phospho-Smad2(465/467). Utilisation of antibody which blocks the αVβ5 integrin, 
thrombin mediated phospho-Smad2(465/467) at one and four hours (P<0.01)(Figure 
4.9B) was completely inhibited (P<0.01). These results demonstrate that thrombin 
mediated transactivation of the TGFBR1 occurs specifically via αVβ5 but not the 
αVβ3 integrin. 
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Figure 4.8: Human VSMCs express cell surface αVβ3 and αVβ5. 
VSMCs were grown on coverslips for 24 hours. Cells were fixed with 2% 
paraformaldehyde and incubated with A. anti-αVβ3 or B. anti-αVβ5 overnight 
followed by goat anti-mouse conjugated with flurophores Alexa594 or Alexa488. 
Confocal images are representative of three independent experiments. 
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Figure 4.9: Thrombin mediated stimulation of phospho-Smad2(Ser465/467) is 
dependent on the αVβ5 but not αVβ3 integrin in human VSMCs. 
VSMCs were pre-incubated with A. anti-αVβ5 or B. anti-αVβ3 for 30 minutes and 
then treated with thrombin (10 units/mL) for 1 and 4 hours. Cell lysates were 
collected and proteins (40μg) were resolved over 10% SDS-PAGE and transferred to 
a PVDF membrane. The membrane was then incubated with anti-phospho-
Smad2(Ser465/467) (1:1000) followed by peroxidase labelled rabbit IgG secondary 
antibody. Membranes were reprobed with GAPDH HRP-conjugated antibody. 
Histograms represent band density as fold over basal from three separate experiments. 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post hoc analysis ##,P<0.01 basal versus thrombin and 
**,P<0.01 thrombin versus integrin.  
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4.4 Summary of results 
The results presented in this chapter demonstrate that thrombin mediated 
transactivation of the EGFR and TGFBR1 is via the Gαq protein which leads to GAG 
chain elongation evaluated by an increase in the mRNA expression of CHST11 and 
CHSY1 in VSMCs in vitro. The specific findings from these experiments are: 
 Thrombin mediated intracellular release of calcium is dose dependently 
inhibited in the presence of Gαq antagonist UBO-QIC. 
 Thrombin mediated phospho-Smad2(465/467) and phospho-Erk1/2 were both 
inhibited in the presence of, UBO-QIC. 
 Thrombin mediated phosphorylation of ERM, the immediate downstream 
products of ROCK were inhibited in the presence of UBO-QIC. 
 UBO-QIC, partially inhibits thrombin mediated proteoglycan synthesis and 
GAG elongation. 
 Thrombin mediated mRNA expression of CHST11 and CHSY1 was 
completely inhibited by UBO-QIC. 
 Gαq and Gαq/11 were both present in CASMCs (mRNA and protein). siRNA 
targeting each isoform successfully knockdown both mRNA and protein 
expression but to different extents. 
 Thrombin mediated mRNA expression of CHST11 and CHSY1 was inhibited 
in Gαq knockout cells and unaffected in Gαq/11 knockout cells. 
 Thrombin mediated phospho-Smad2(465/467) was inhibited in the presence of 
αVβ5 blocking antibody but remains unaffected in the presence of αVβ3 
blocking antibody although both integrins were present on the cells surface of 
VSMCs. 
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4.5 Discussion 
  The studies in this chapter show that PAR-1 signals through the Gαq protein 
which leads to the transactivation of the EGFR and the TGFBR1 leading to 
proteoglycan synthesis and GAG chain elongation. PAR-1 mediated transactivation of 
the TGFBR1 via the Gαq leads to ROCK activation which triggers cell surface 
integrin αVβ5. Thrombin mediated mRNA expression of the two GAG synthesizing 
genes CHST11 and CHSY1 occurs via Gαq activation but not the Gαq/11 isoform. 
Limited availability of antagonists to the Gαq proteins has made it very difficult to 
study their role in GPCR signalling. YM-254890 and the UBO-QIC are potent 
inhibitors of Gαq protein (Inamdar et al., 2015, Kukkonen, 2016, Gao and Jacobson, 
2016, Uemura et al., 2006a, Uemura et al., 2006b, Kawasaki et al., 2005, Taniguchi et 
al., 2003). YM-254890 was discovered and developed by Yamaguichi 
Pharmaceuticals, Japan, and was made available for researchers for a limited time 
before being taken off the market (Kawasaki et al., 2006)(In the time that this thesis 
was being prepared (2016) YM-254890 has been made available again). UBO-QIC 
has a chemical structure very similar to YM-254890, a cyclic depsipeptide. UBO-QIC 
was available for purchase from University of Bonn in Germany for a brief time 
before it was withdrawn. Hence there is a need for agents which can inhibit 
downstream signalling pathways of Gαq. Taniguchi et al (Taniguchi et al., 2004) 
isolated three analogues of the YM-254890; YM-254891, YM-254892 and YM-
280193. The YM-280193 had the same cyclic core of the YM-254890 minus the 
hydroxyleucine residue. The first report of the synthesis of the YM-280193 was by 
our collaborator Brimble and colleagues (Kaur et al., 2015). The biological studies of 
the YM-280193 presented in this chapter (conducted in our lab) showed that unlike its 
analogue YM-254890, this cyclic depsipeptide was not a Gαq antagonist as it did not 
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inhibit thrombin mediated intracellular calcium release. The YM-254890 was co-
crystalized with a Gαq-Gβγ complex and it shows that YM-254890 inhibits Gαq by 
binding to a pocket in the Gαq that prevents the activation of the Gαq by a cognate 
GPCR (Nishimura et al., 2010). A major study by Schrage and colleagues (Schrage et 
al., 2015) compared the binding energies and mode of action of UBO-QIC and 
YM-254890. The binding capacity was very similar and the results showed that UBO-
QIC and YM-254890 share the same mode of action (Schrage et al., 2015). The YM-
254890 and the UBO-QIC share a similar chemical structure however the YM-
280193 lacks the hydroxyleuicine residue, hence we postulate that this residue plays 
an important role in the cyclic depsipeptide inhibiting Gαq activation. 
PAR-1 mediated transactivation of the EGFR and TGFBR1 leads to proteoglycan 
synthesis and GAG elongation (Burch et al., 2010). The signalling through each of the 
transactivation pathways has a distinct mechanism (Burch et al., 2013). Finding a 
common target could account for all the thrombin mediated GAG elongation thus this 
target could be potentially therapeutically beneficial as it can inhibit the pre-
inflammatory phase of atherosclerosis (Little, 2013). Thrombin mediated 
transactivation of the EGFR and TGFBR1 is regulated by the Gαq protein (Figure 
4.3). Thrombin mediated mRNA expression of the GAG synthesizing genes leading 
to proteoglycan synthesis and GAG chain elongation is regulated by Gαq (Figure 4.4). 
This shows that Gαq plays a central integrating point in GPCR mediated GAG 
elongation. UBO-QIC has no selectivity for the Gαq isoforms (Schrage et al., 2015) 
hence, using siRNA knockdown, the results obtained show that only the Gαq is 
involved in thrombin mediated GAG elongation evaluated by the mRNA expression 
of CHST11 and CHSY1. Although the role of the Gαq and Gαq/11 was not studied on 
the downstream intermediate of EGFR (phospho-Erk1/2) and TGFBR1 (phospho-
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Smad2(465/467)), we postulate that only the Gαq is involved in GPCR mediated 
transactivation in VSMCs. Future studies require the use of siRNA to knockdown the 
Gαq and Gαq/11 to study their role on thrombin mediated phospho-Smad2(465/467) 
and the phospho-Erk1/2. Apart from the results in this Chapter there have been no 
studies which compare these two isoforms in any human model. 
The results in this chapter show that Gαq plays a central integrating point in 
GPCR mediated proteoglycan synthesis (Burch et al., 2010, Burch et al., 2013, Little 
et al., 2010). There have been a number of studies showing the importance of Gαq 
signalling in the vasculature (Adams et al., 1998, D'Angelo et al., 1997). The Gαq 
signalling was pharmacologically studied using the YM-254890. The Gαq played an 
important role in platelet function and in vitro thrombus formation under high shear 
stress in cynomolgus monkeys (Uemura et al., 2006a). YM-254890 inhibited 
phenylephrine, serotonin and ET-1 induced contractions in the rat aorta improving 
blood flow (Uemura et al., 2006b). Thus YM-254890 was useful in treating peripheral 
arterial disease in a rat model. YM-254890 compound also had antithrombotic effects 
in an electrically induced arterial thrombosis in a rat model (Kawasaki et al., 2003). 
Shortly after the same group showed that oral administration of YM-254890 inhibited 
neointima formation 3 weeks after vascular injury (Kawasaki et al., 2005). However 
YM-254890 caused hypotensive effects at doses three times higher than those that 
produced inhibitory effects on neointima formation (Kawasaki et al., 2005). Hence 
the systemic use of a Gαq antagonist may be limited, owing to the narrow therapeutic 
window of YM-254890. There is a need for a small chemical entity that targets GPCR 
mediated Gαq signalling which can be used to inhibit the pre-inflammatory stage of 
atherosclerosis by inhibiting GAG chain elongation.  
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There are a limited amount of studies on the role of Gαq in GPCR transactivation 
of PTKR. In L6 myoblasts derived from rat skeletal muscle, ET-1 via the endothelin 
type A receptor mediated transactivation of PDGF receptor was inhibited in the 
presence of YM-254890 (Harada et al., 2014). Shear stress induced phospho-Erk1/2 
in CHO cells permanently transfected with wild type angiotensin II type 1 receptor 
was completely inhibited in the presence of YM-254890 (Barauna et al., 2013). Shear 
stress activates PTKRs (Jin et al., 2003) thus showing that the Gαq plays a role in 
angiotensin II mediated transactivation of PTKR. Purigenic receptor P2Y2R 
transactivation of the insulin-like growth factor receptor in keratinocytes was 
inhibited by Gαq/11 siRNA transfected cells and YM-254890 (Taboubi et al., 2010). 
Consistent with the literature the data presented in this Chapter shows that the Gαq 
plays a role in transactivation of the PTKR in this case the EGFR. In keratinocytes 
transactivation dependent signalling was observed to occur via the Gαq/11, however 
in VSMCs transactivation dependent signalling leading to GAG enzyme expression 
occurs via the Gαq. 
VSMC data presented in Figure 4.3A shows the Gαq plays a role in thrombin 
mediated transactivation of the TGFBR1. The GPCR mediated transactivation of the 
TGFBR1 mechanisms downstream of Gαq, shows that PAR-1 activation of ROCK 
activates cell surface integrin αVβ5. The exact mechanism of how integrin signalling 
activated TGFBR1 is unknown. It has been proposed that the pathway is restricted to 
the extracellular surface where a GPCR activates ROCK signalling via cytoskeletal 
rearrangement, leading to integrin activation. Activated integrins can bind to the large 
latent complex leading to conformational changes, exposing the TGF-β ligand 
(Lawrence et al., 1984). The ligand is then free to engage the TGFBR1 and initiate 
downstream signalling (Munger et al., 1999, Wipff and Hinz, 2008). There are 24 
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known integrins however the RGD motif of fibronectin can recognise and be 
activated by eight of the αV integrins (Margadant and Sonnenberg, 2010, Jenkins et 
al., 2006). Three different ligands including thrombin were used to show PAR-1 
transactivation of the TGFBR1 via αVβ6 dependent mechanisms in mouse lung 
epithelial cells (Jenkins et al., 2006). The same group has also shown that LPA can 
induce αVβ6 mediated TGFBR1 activation in human epithelial cells via Gαq 
mediated activation pathways (Xu et al., 2009). In mouse VSMCs isolated from 
mouse arteries angiotensin II induced transactivation of the TGFBR1 was inhibited in 
the presence of αVβ3-integrin antagonist, SB22345 (Belmadani et al., 2008). LPA 
and methacholine induced TGFBR1 transactivation in human airway smooth muscle 
cells was inhibited in the presence of αVβ5 neutralizing antibody (Tatler et al., 2011). 
TGFBR1 signalling in dermal fibroblasts is also dependent on the αVβ5 integrin 
(Asano et al., 2006a, Asano et al., 2006b, Boo and Dagnino, 2013, Vi et al., 2011). 
Taking into account the results presented in this Chapter and the literature, integrin 
activation of the TGFBR1 is context dependent. In the mouse VSMCs the αVβ3 
integrin is involved in angiotensin II transactivation of the TGFBR1 (Belmadani et 
al., 2008) however in human VSMCs and idiopathic pulmonary fibrosis lung tissue 
(Scotton et al., 2009) the αVβ5 integrin is involved in PAR-1 transactivation of the 
TGFBR1. Thus showing that the integrins involved in transactivation may be 
dependent to the GPCR agonist or the difference in isoform expressed in different cell 
types. 
Studies on role of Gαq in GPCR mediated transactivation of the S/TKR are 
limited. Xu and colleagues (Xu et al., 2009) studied the role of G proteins in LPA 
mediated transactivation of the TGFBR1. Mouse embryonic cells with Gαq and 
Gα12/13 knockout showed only that the Gαq is involved in LPA induced 
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transactivation of the TGFBR1 (Xu et al., 2009). This was confirmed with a 
pharmacological approach using Gαq antagonist GP-2A (Tanski et al., 2004, Mukai et 
al., 1992). In primary epithelial cells LPA induced TGFBR1 activation was inhibited 
in the presence of GP-2A (Xu et al., 2009). In idiophathic pulmonary fibrosis lung 
tissue, PAR-1 induced transactivation of the TGFBR1 occurred via the Gαq protein 
(Scotton et al., 2009). Moreover the attenuation of PAR-1 induced activation of the 
TGFBR1 with Rho kinase antagonist (Y-27632) firmly places the Rho signalling 
pathway downstream of this response (Scotton et al., 2009). Similarly in murine lung 
fibroblasts, thrombin mediated CCL2 production occurs via PAR-1 coupling to Gαq 
and the cooperation between Rho signalling pathways (Deng et al., 2008). The results 
from the literature outline that GPCR transactivation of the TGFBR1 occurs via Gαq 
mediated signalling which activates the Rho kinase. The results observed in this 
Chapter are consistent with what is currently known of this cascade. With the novel 
finding that of the two highly expressed Gαq isoforms, the transactivation dependent 
signalling may be specific to only the Gαq. 
In summary, this Chapter has identified that PAR-1 transactivation of the 
TGFBR1 and the EGFR is via the Gαq protein. Thrombin mediated mRNA 
expression of CHST11 and CHSY1 leading to proteoglycan synthesis and GAG 
elongation is regulated by Gαq. Thus Gαq is a central target for transactivation 
dependent GAG elongation. Gαq isoforms Gαq and Gαq/11 are the most highly and 
ubiquitously expressed isoforms. In VSMCs thrombin mediated mRNA expression of 
CHST11 and CHSY1 occurs via the activation of Gαq but not Gαq/11 isoform. 
Thrombin transactivation of the TGFBR1 is via Gαq which activates ROCK 
signalling, leading to the activation of the αVβ5 integrin but not the αVβ3 integrin. 
These findings show specific mechanisms in thrombin transactivation of the 
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TGFBR1. The results of this Chapter show that Gαq mediates all transactivation 
signalling and is a potential target to prevent pathophysiology arising from PAR-1 
signalling. 
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5.1 Introduction  
From the data presented in Chapter 3 it was concluded that thrombin 
stimulated mRNA expression of CHST11 and CHSY1 is through the 
transactivation of both the TGFBR1 and EGFR. TGFBR1 signals downstream 
via Smad transcription factors (Derynck and Zhang, 2003). The canonical TGF-
β signalling pathway involves direct carboxy-terminal phosphorylation of 
Smad2 by TGFBR1. Two serine residues 465 and 467 are phosphorylated then 
the product complexes with co-Smad4 for translocation to the nucleus and the 
regulation of gene expression. In addition to the carboxy-terminal 
phosphorylation, Smads can be phosphorylated in the linker region (Massague et 
al., 2005, Hough et al., 2012, Burch et al., 2010 , Burch et al., 2011, Kamato et 
al., 2013c, Kamato et al., 2014a, Rezaei et al., 2012, Matsuzaki, 2011, 
Matsuzaki et al., 2009). Smad linker region has been shown to be 
phosphorylated by multiple kinases including MAPK (Erk, Jnk and p38), 
phosphatidylinositide 3-kinase (PI3K) and CDK (Kamato et al., 2013c). The 
role of serine/threonine kinases in the Smad linker region phosphorylation has 
been reviewed in the literature (Kamato et al., 2013c, Rostam et al., 2015, 
Rezaei et al., 2012). The linker region has been shown to play an important role 
in TGF-β mediated biological activity. Initial observations indicated that linker 
region phosphorylation prevented nuclear translocation and thus inhibited 
TGF-β signalling (Kretzschmar et al., 1999, Matsuzaki, 2011) however, 
subsequent studies have shown that the phosphorylation of this region can result 
in a range of complex responses (Kamato et al., 2014a, Hough et al., 2012, 
Burch et al., 2010 ).  
There are multiple sites in the linker region of Smads that are potential 
phosphorylation sites and these include Thr220, Ser245, Ser250 and Ser255 (in 
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Smad2) (Burch et al., 2010 , Kamato et al., 2013c, Kamato et al., 2014a, 
Matsuzaki, 2011, Matsuzaki et al., 2009, Liu and Feng, 2010, Wrighton et al., 
2009). Previous work from our lab used phosphorylation site-specific antibodies 
to these four residues in vascular endothelial cells to explore the signalling 
pathways with the ultimate aim of understanding the role of TGF-β in 
endothelial dysfunction (Kamato et al., 2014a). The pathways of 
phosphorylation by different serine/threonine kinases were highly specific for 
the four target residues. The TGF-β mediated regulation of PAI-1 mRNA 
expression is via the activation of different serine/threonine kinases, thus 
demonstrating the complex nature of non-Smad signalling. 
In the context of ECM synthesis and proteoglycan modification, the 
stimulation of biglycan expression as well as the hyperelongation of biglycan 
GAG chains are dependent on Smad2 linker region phosphorylation (Burch et 
al., 2010 ). Using a Smad2 linker region antibody which targets the three 
phosphorylated serine residues, it was found that Erk and p38 mediated Smad2 
linker region phosphorylation and these kinases also stimulated proteoglycan 
synthesis. Smad2 linker region phosphorylation is an important avenue for the 
integration of multiple signalling networks to influence the outcome of 
proteoglycan synthesis in this model. As previously described, thrombin is a 
well characterised agonist which drives the pathways that result in proteoglycan 
modifications (Burch et al., 2010, Ivey and Little, 2008). In human VSMCs, 
thrombin mediated proteoglycan synthesis occurs via the transactivation of 
PTKR and S/TKR, EGFR and TGFBR1, respectively (Burch et al., 2013). The 
data in Chapter 3 shows that PAR-1 mediated GAG synthesizing gene mRNA 
expression also requires the activation of these two signalling pathways. Hence 
in this Chapter we will investigate the hypothesis that thrombin will signal via 
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the transactivation of both the TGFBR1 and the EGFR leading to the activation 
of serine/threonine kinases which will phosphorylate the individual Smad2 
linker region residues. Furthermore, these results will provide mechanistic 
insight into thrombin mediated mRNA expression of CHST11 and CHSY1 in 
response to the same serine/threonine kinases.  
5.2 Materials and Methods 
5.2.1 Materials 
 Flavopiridol, SP600125, SB202190 and LY294002 were purchased from 
Sigma-Aldrich (St Louis, USA). UO126 was from Promega (WI, USA). 
Anti-phospho-Smad2(Thr220), anti-phospho-Smad2(Ser245), 
anti-phospho-Smad2(Ser250) and anti-phospho-Smad2(Ser255) rabbit IgG 
polyclonal were a gift from Professor Koichi Matsuzaki (Kansai Medical 
University, Osaka, Japan) 
5.2.2 Cell culture 
 VSMCs were grown in DMEM (5mM glucose, 10% FBS and 1% 
antibiotics at 37°C in 5% CO2). VSMCs were seeded in 60 mm dishes and 
6 well-plates (described in detail Chapter 2 Section 2.1). Cells were grown to 
confluence then rendered quiescent by serum deprivation for 48 hours. 
Inhibitors were pre-incubated for 30 mins prior to treatment with agonists. 
Incubation times and concentrations are given in detail in the figure legends. 
5.2.3 Western blotting 
 The method of western blot analysis is described in detail in Chapter 2 
Section 2.2.6. Whole cell lysates were resolved by SDS-PAGE and transferred 
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onto PVDF. Membranes were blocked with 5% BSA and incubated with 
primary antibody targeting protein of interest followed by HRP-anti-rabbit IgG 
and ECL detection. The protein of interest was normalised with GAPDH to 
determine equal loading. 
5.2.4 Measurement of mRNA gene expression 
 Quantitative RT-PCR was conducted as described in Chapter 2 Section 
2.2.3. Data was normalised to the ribosomal 18S housekeeping gene to adjust 
for control variations between individual experiments.  
5.2.5 Statistical analysis 
 Normalised data is expressed as the mean ± standard error of the mean of 
three independent experiments, unless stated otherwise. A one-way ANOVA 
was used to calculate statistical significance of normalised data as stated 
followed by least significant difference post-hoc analysis. Results were 
considered significant when the probability was less than 0.05 and 0.01. 
5.3 Results 
5.3.1 Thrombin stimulates the phosphorylation of individual 
Smad2 linker region residues in VSMCs 
 
There are at least four important phosphorylation sites on the human 
Smad2 linker region at Thr220, Ser245, Ser250 and Ser255 (Kamato et al., 
2013c). To determine whether site-specific linker region phosphorylation is 
mediated by thrombin signalling in VSMCs a time course study was preformed 
utilising separate antibodies specific for the individual phosphorylated linker 
region residues (Thr220, Ser245, Ser250 and Ser255)(Sekimoto et al., 2007). 
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Thrombin treated VSMCs showed a rapid increase in phospho-Smad2(Thr220) 
residue of the Smad2 linker region. Thrombin mediated phosphorylation peaked 
at 15 mins with a 2.5-fold change (P<0.01) when compared to basal (Figure 
5.1A). Thrombin mediated phospho-Smad2(Thr220) was sustained although 
there was a gradual decline over the 240 min treatment. There was a rapid 
increase in phospho-Smad2(Ser245) residue reaching a peak of 1.9-fold at 15 
mins (P<0.01) when compared to basal (Figure 5.1B). The thrombin mediated 
phosphorylation was sustained for the 240 min treatment. Similarly there was a 
rapid increase of phospho-Smad2(Ser250) in the presence of thrombin with a 
peak phosphorylation of 2.5-fold (P<0.01) at 15 mins (Figure 5.1C). The 
phosphorylation of this residue was sustained for 60 mins. Thrombin causes a 
rapid increase in phospho-Smad2(Ser255) with a peak at 15 mins of 2.5-fold 
(P<0.01) when compared to basal and this gradually declined over the 120 
mins.  
These results demonstrate that the phosphorylation of Thr220, Ser245, 
Ser250 and Ser255 residues on the Smad2 linker region are mediated by 
thrombin signalling pathway. Thrombin mediated phosphorylation of each of 
the individual residues showed a rapid response with the maximum 
phosphorylation for all residues at 15 mins, the earliest time point evaluated. 
Thr220, Ser250 and Ser255 showed maximal phosphorylation with 2.5-fold 
increase at 15 mins (Figure 5.1). Ser245 showed the least amount of 
phosphorylation when VSMCs were treated with thrombin. The four residues 
show similar temporal characteristics but the question is the signalling pathways 
and kinases that are involved in mediating their phosphorylation. 
 
 Chapter-5. Smad2 linker region phosphorylation Page 186 
 
 Chapter-5. Smad2 linker region phosphorylation Page 187 
 
  
 Chapter-5. Smad2 linker region phosphorylation Page 188 
Figure 5.1: Time course of thrombin mediated phosphorylation of Smad2 
linker region residues. 
VSMCs treated with thrombin (10 Units/ml) for up to 240 min. Cells lysates 
were collected and proteins were resolved over 10% SDS-PAGE and transferred 
to a PVDF membrane. The membrane was incubated overnight with A anti-
phospho-Smad2/3(Thr220/179) B anti-phospho-Smad2(Ser245) C anti-
phospho-Smad2(Ser250) and D anti-phospho-Smad2(Ser255) (1:1000). 
Followed by peroxidase-labelled rabbit IgG secondary antibody. Membranes 
were reprobed with Smad2 monoclonal antibody and GAPDH HRP-conjugated 
antibody. Histograms represent band density expressed as fold over basal from 
three independent experiments (*P<0.05 vs basal) (**P<0.01 vs basal) using 
one-way ANOVA followed by least significant difference post-hoc analysis.  
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5.3.2 Thrombin mediated Smad2 linker region phosphorylation 
occurs via transactivation signalling 
 
 Burch et al (Burch et al., 2010 ) showed a correlation between TGF-β 
mediated Smad2 linker region phosphorylation and proteoglycan synthesis. 
Thrombin mediated proteoglycan synthesis occurs due to the transactivation of 
both EGFR and TGFBR1 (Burch et al., 2013). Therefore to study whether 
thrombin mediated Smad2 linker region phosphorylation occurs via the 
transactivation pathways we utilized the EGFR antagonist, AG1478 (Zhu et al., 
2001) and the TGFBR1 antagonist, SB431542 (Inman et al., 2002).  
 To have an initial look at whether thrombin mediated phosphorylation of 
the Smad2 linker region was dependent on transactivation of the EGFR and 
TGFBR1, the pan Smad2 linker antibody targeting the three serine residues was 
used. VSMCs stimulated with thrombin for 30 mins showed a 4.5-fold (P<0.01) 
(Figure 5.2) increase in the phospho-Smad2(Ser245/250/255). SB431542 had a 
slight inhibitory effect on thrombin mediated linker region phosphorylation 
however was not statistically significant. AG1478 inhibited thrombin mediated 
phospho-Smad2(Ser245/250/255) by approximately 60% to 2.5-fold 
(P<0.01)(Figure 5.2). To show that these distinct pathway are activated and the 
antagonists are inhibiting their respective pathways, VSMCs were treated with 
TGF-β and EGF in the presence and absence of their antagonists. TGF-β had a 
3-fold (P<0.01) (Figure 5.2) increase in phospho-Smad2(Ser245/250/255), in 
the presence of SB431542 the TGF-β mediated phospho-
Smad2(Ser245/250/255) was inhibited to 1.5-fold (P<0.01). EGF stimulated 
VSMCs caused a 2.5-fold (P<0.01) increase in the phospho-
Smad2(Ser245/250/255), this was abolished in the presence of AG1478 (Figure 
5.2). These results demonstrate that at 30 mins thrombin mediated Smad2 linker 
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region phosphorylation occurs via the transactivation of the EGFR but not the 
TGFBR1. The results presented in this experiment show that direct stimulation 
of the TGFBR1 and the EGFR result in Smad2 linker region phosphorylation. 
Hence in the following sections the role concentration and time dependence of 
the TGFBR1 in thrombin mediated Smad2 linker region phosphorylation was 
determined. 
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Figure 5.2: Thrombin mediated phosphorylation of Smad2 linker region is 
mediated through transactivation of the EGFR. 
VSMCs treated with thrombin (10 Units/ml), TGF-β (2 ng/ml) or EGF (100 nM) 
at 30 mins in the presence and absence of SB431542 (3µM) AG1478 (5µM). 
Cells lysates were collected and proteins were resolved over 10% SDS-PAGE 
and transferred to a PVDF membrane. The membrane was incubated overnight 
with anti-phospho-Smad2(Ser245/250/255) (1:1000). Followed by 
peroxidase-labelled rabbit IgG secondary antibody. The membranes were 
reprobed with GAPDH HRP-conjugated antibody. Histograms represent band 
density expressed as fold per basal from three independent experiments 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis **,P<0.01 versus basal and ##, P<0.01 
agonist versus antagonist.  
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5.3.3 Thrombin mediated Smad2 linker region phosphorylation 
occurs through the transactivation of the EGFR 
 
The results presented in Figure 5.2 show that thrombin mediated Smad2 
linker region phosphorylation at 30 mins is only via transactivation of the 
EGFR. The results presented in Figure 5.2 as well as published data (Burch et 
al., 2010 ) show that TGF-β stimulated VSMCs leads to Smad2 linker region 
phosphorylation at the same time point. Our previous published data also shows 
that TGF-β mediated phosphorylation of the Smad2 linker region correlates with 
proteoglycan synthesis and GAG chain elongation (Burch et al., 2010 ). 
Thrombin mediated proteoglycan synthesis and GAG elongation occurs via the 
transactivation of both the EGFR and TGFBR1 (Burch et al., 2010). The 
hypothesis is that thrombin mediated Smad2 linker region phosphorylation 
occurs via transactivation of both EGFR and TGFBR1. TGF-β mediated 
phosphorylation of the Smad2 linker region was studied in bovine aortic 
endothelial cells, a 10μM concentration of SB431542 was used to effectively 
inhibit signalling downstream of TGFBR1 (Kamato et al., 2014a). This 
concentration is consistent with the published study characterising SB431542 as 
a TGFBR1 antagonist in which 10μM of the antagonist was optimal to inhibit 
TGFBR1 signalling (Inman et al., 2002). The concentration of SB431542 used 
in Figure 5.2 was 3μM therefore we propose that the response may be 
concentration dependent. To address this hypothesis a dose-dependent study was 
conducted using EGFR antagonist, AG1478 (0.5-10µM) and TGFBR1 
antagonist, SB431542 (0.3-30µM), in the presence of thrombin for 30 mins. 
VSMCs were also treated with agonists to the EGF and TGF-β pathways in the 
presence and absence of their respective inhibitors to ensure that the activation 
of these pathways leads to the phosphorylation of the Smad2 linker region. 
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Thrombin increased phospho-Smad2(Thr220) to 2.7 fold (P<0.01) when 
compared to basal (Figure 5.3A). In the presence of AG1478, thrombin 
mediated phospho-Smad2(Thr220) was dose dependently inhibited showing 
significant inhibition at concentrations of 0.5-10µM (P<0.01) (Figure 5.3A). 
AG1478 at 1μM completely inhibited thrombin mediated 
phospho-Smad2(Thr220). EGF used as a positive control had a 2.5-fold 
(P<0.01) increase in phospho-Smad2(Thr220) and as expected this response 
was abolished in the presence of AG1478. Thrombin mediated phosphorylation 
of the serine residues of the Smad2 linker region had a similar response to the 
phosphorylation of the Thr220 residue. Thrombin treated VSMCs showed a 
7.7-fold (P<0.01) increase in phospho-Smad2(Ser245/250/255) (Figure 5.3B). 
In the presence of AG1478 a partial inhibition of approximately 4-fold 
(P<0.01)(0.1-5μM) was seen (Figure 5.3B). EGF treated VSMCs showed a 
5-fold (P<0.01) increase in the phospho-Smad2(Ser245/250/255) and as 
expected this was completely abolished in the presence of AG1478. The data 
presented demonstrates that thrombin transactivates the EGFR to phosphorylate 
the serine and Thr220 residues of the Smad2 linker region. Thrombin mediated 
phospho-Smad2(Thr220) at 30 mins is completely due to the transactivation of 
the EGFR. However thrombin mediated phospho-Smad2(Ser245/250/255) at 
30 mins is only partially due to transactivation as AG1478 does not completely 
inhibit this response.  
 Thrombin treated VSMCs showed a 5-fold (P<0.01) increase in 
phospho-Smad2(Thr220) (Figure 5.3C). This response was unaffected in the 
presence of SB431542 from 0.3-30µM. VSMCs stimulated with TGF-β as a 
positive control resulted in a 10-fold (P<0.01) increase in phospho-
Smad2(Thr220) residue and this was abolished in the presence of SB431542 
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(P<0.01) (Figure 5.3C). Thrombin treated VSMCs showed a 12-fold (P<0.01) 
increase in phospho-Smad2(Ser245/250/255). This response was maintained in 
the presence of SB431542 (0.3-30µM) (Figure 5.3D). However, as expected 
TGF-β increased phospho-Smad2(Ser245/250/255) and this was inhibited by 
SB431542 (P<0.01) (Figure 5.3D). These results indicate that at 30 mins 
thrombin mediated Smad2 linker region phosphorylation is occurring only 
through the transactivation of the EGFR and not the TGFBR1. 
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Figure 5.3: Thrombin mediated linker region phosphorylation is through 
the transactivation EGFR 
VSMCs treated with thrombin (10 Units/ml) or TGF-β (2 ng/ml) for 30 mins 
EGF (100 nM) for 15 mins, in the presence and absence of A-B AG1478 
(0.5-10µM) or C-D SB431542 (0.3-30µM). Cell lysates were collected and 
proteins were resolved on 10% SDS-PAGE and transferred to a PVDF 
membrane. The membrane was incubated with 
A,C. anti-phospho-Smad2/3(Thr220/179) (1:1000) or 
B,C. anti-phospho-Smad2(Ser245/250/255) (1:1000). Followed by 
peroxidase-labelled rabbit IgG secondary antibody. The membranes were 
reprobed with GAPDH HRP-conjugated antibody. Histograms represent band 
density expressed as fold per basal from three independent experiments 
Statistical significance was determined by one-way ANOVA, followed by least 
significant difference post-hoc analysis ##,P<0.01 versus basal and **, P<0.01 
agonist versus antagonist.  
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5.3.4 Thrombin mediated transactivation of the TGFBR1 
leading to phosphorylation of the Smad2 linker region is 
time dependent.  
 
The results presented in Figures 5.2 and 5.3C and D show that at 30 mins 
thrombin mediated phosphorylation of the Smad2 linker region does not occur 
via the transactivation of the TGFBR1. In bovine aortic endothelial cells TGF-β 
mediated phosphorylation of the Smad2 linker region residues peaked at 
60 mins (Kamato et al., 2014a). Similarly in VSMCs, TGF-β mediated 
phosphorylation of the Smad2 linker region was not studied until the 60 min 
time point (Burch et al., 2010 ). The hypothesis is thrombin transactivation of 
the TGFBR1 leading to Smad2 linker region phosphorylation has a different 
temporal response when compared to thrombin transactivation of the EGFR. To 
address this hypothesis VSMCs were treated with thrombin (10 Units/ml) at 60, 
120 and 240 mins in the presence and absence of TGFBR1 antagonist 
SB431542. TGF-β for 60 mins in the presence and absence of SB431542 was 
used as a positive control.  
Thrombin treatment of VSMCs at 60 mins caused a 2.2-fold increase in 
phospho-Smad2(Thr220), this was unaffected in the presence of SB431542. At 
120 min post thrombin stimulation there was a 4.2-fold (P<0.01) increase in 
phospho-Smad2(Thr220), this was inhibited to 1.8 fold (P<0.01) in the presence 
of SB431542 (Figure 5.4A). Similarly at 240 mins a 3.8-fold (P<0.01) increase 
in phospho-Smad2(Thr220) was seen and this was inhibited by 50% in the 
presence of SB431542 (P<0.01) (Figure 5.4A). TGF-β caused a large increase 
of 4-fold (P<0.01) in phospho-Smad2(Thr220) and this was abolished by 
SB431542. 
 Chapter-5. Smad2 linker region phosphorylation Page 199 
The thrombin mediated phospho-Smad2(Ser245/250/255) followed a 
similar pattern where at 60 mins post thrombin treatment there was a 2.2-fold 
increase that was unaffected in the presence of SB431542 (Figure 5.4B). 
Thrombin treatment of 120 mins leads to a 3.8-fold (P<0.01) increase in 
phospho-Smad2(Ser245/250/255), this was inhibited to 1.8-fold (P<0.01) in the 
presence of SB431542 (Figure 5.4B). VSMCs stimulated with thrombin for 
240 mins had a 4-fold (P<0.01) increase in phospho-Smad2(Ser245/250/255) 
and this was inhibited by 50% to 1.8-fold (P<0.01) in the presence of 
SB431542. TGF-β treated VSMCs caused a large increase of 6.2-fold (P<0.01) 
in phospho-Smad2(Ser245/250/255) which was abolished in the presence of the 
receptor antagonist, SB431542 (P<0.01). These results indicated that in VSMCs 
thrombin mediated phosphorylation of the Smad2 linker region via the 
transactivation of the TGFBR1 is time dependent. The same pathway occurs for 
phosphorylation of both the serine and Thr220 residues. In summary the 
thrombin transactivation of the EGFR occurs in 30 mins post thrombin 
stimulation however the transactivation of the TGFBR1 is activated at 120 mins 
and is sustained for 240 mins. 
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Figure 5.4: Thrombin mediated Smad2 linker region phosphorylation via 
the TGFBR1 is time dependent. 
VSMCs treated with thrombin (10 Units/ml) over 240 mins time course or TGF-
β (2ng/ml) for 60 mins in the presence and absence of SB431542 (10µM). Cell 
lysates were collected and proteins were resolved on 10% SDS-PAGE and 
transferred to a PVDF membrane. The membrane was incubated with A. 
anti-phospho-Smad2/3(Thr220/179) (1:1000) or B. 
anti-phospho-Smad2(Ser245/250/255) (1:1000). Followed by 
peroxidase-labelled rabbit IgG secondary antibody. The membranes were 
reprobed with Smad2 antibody and GAPDH HRP conjugated antibody. Blots 
are representative of three-independent experiments. Histogram represents band 
density expressed as fold per basal. Statistical significance was determined by 
one-way ANOVA, followed by least significant difference post-hoc analysis 
##,P<0.01 versus basal and **, P<0.01 agonist versus antagonist. 
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5.3.5 Thrombin mediated transactivation of the EGFR leading to 
the phosphorylation of the Smad2 linker region is 
sustained for 4 hours. 
 
We have shown that in VSMCs thrombin mediated transactivation of the 
TGFBR1 leading to Smad2 linker region phosphorylation is time dependent. We 
know that in VSMCs thrombin mediated transactivation of the EGFR leading to 
linker region phosphorylation occurs rapidly at 30 mins however we wanted to 
investigate whether this response was sustained for 240 mins. To address this 
question VSMCs were treated with thrombin in a time dependent manner in the 
presence and absence of EGFR antagonist AG1478. EGF stimulation at 15 mins 
in the presence of AG1478 was used as a positive control. 
 Thrombin stimulated VSMCs at 60 mins showed a 6-fold (P<0.01) 
increase in phospho-Smad2(Thr220), this was inhibited by 75% to 2-fold 
(P<0.01) in the presence of AG1478 (Figure 5.5A). Thrombin treated VSMCs 
at 120 mins lead to a 4.5-fold (P<0.01) increase in the phospho-Smad2(Thr220) 
and at 240 mins a 4-fold (P<0.01) increase (Figure 5.5A). When VSMCs where 
treated with thrombin in the presence of AG1478 the phosphorylation of both 
these time points was inhibited by 50% to 2- (P<0.01) and 1.8-fold (P<0.01) 
respectively. EGF treated VSMCs caused a large increase in 
phospho-Smad2(Thr220) and this response was abolished in the presence of 
AG1478 (P<0.01). Thus showing that the phosphorylation of the Thr220 
residue occurs via thrombin transactivation of the EGFR and is sustained for the 
4 hours of this study. 
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Thrombin stimulation of VSMCs at 60 mins had a 2.5-fold (P<0.01) 
increase in phospho-Smad2(Ser245). In the presence of AG1478 at 60 mins 
there was no change in the phosphorylation of this residue. Thrombin treated 
VSMCs at 120 mins leads to a 2-fold (P<0.01) increase in 
phospho-Smad2(Ser245) and this was partially inhibited to 1.8-fold (P<0.01) in 
the presence of EGFR antagonist AG1478 (Figure 5.5B). At 240 mins post 
thrombin stimulation VSMCs had a 2-fold (P<0.01) increase in 
phospho-Smad2(Ser245), this response was partially inhibited to 1.5-fold 
(P<0.05) in the presence of AG1478. EGF treatment caused a 2-fold (P<0.01) 
increase in phospho-Smad2(Ser245), which was abolished (P<0.01) in the 
presence of AG1478 (Figure 5.5B). 
 Thrombin stimulated VSMCs at 60 mins leads to a 2.2-fold (P<0.01) 
increase in phospho-Smad2(Ser250) (Figure 5.5C) which is completely inhibited 
(P<0.01) in the presence of AG1478. The pattern was the same for this residue 
at the 120 and 240 min time points, with a 2- and 2.5-fold (P<0.01) increase in 
phospho-Smad2(Ser250) that was inhibited to 1- and 1.5-fold (P<0.01), 
respectively, in the presence of AG1478. EGF treatment caused a 2.2-fold 
(P<0.01) increase in phospho-Smad2(Ser250) and in the presence of AG1478 
the response was abolished (P<0.01)(Figure 5.5C). The Smad2 linker region 
residue Ser255 followed the same signalling pathway as described with the 
previous residues (Figure 5.5D). Thrombin treated VSMCs caused a 2-fold 
increase in phospho-Smad2(Ser255) at 60, 120 and 240 min (P<0.01). In the 
presence of AG1478, the response was inhibited by approximately 90-95% 
(P<0.01) for the 3 time points (Figure 5.5D). 
 These results demonstrate that thrombin transactivation of the EGFR 
phosphorylates Thr220, Ser245, Ser250 and Ser255 residues of the Smad2 
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linker region. The EGFR transactivation pathway leading to the phosphorylation 
of the Smad2 linker region residues is activated from 30 to 240 mins in the 
residues investigated, with the exception of the Ser245 residue. The 
phosphorylation of Smad2 linker region residue Thr220, Ser250 and Ser255 is 
inhibited by 80-90% in the presence of AG1478 at the three time points studied, 
thus showing that almost all the phosphorylation of these three residues is 
occurring through the transactivation of the EGFR. However when looking at 
the Ser245 residue we see that there is no inhibition with AG1478 at 60 min and 
only a 20-30% inhibition at 120 and 240 mins, thus showing that not all the 
thrombin mediated signalling is through EGFR transactivation for this residue. 
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Figure 5.5: Thrombin mediated Smad2 linker region phosphorylation via 
the EGFR is sustained for four hours. 
VSMCs were treated with thrombin (10 Units/ml) over 240 min time course or 
EGF (100nM) for 15 mins in the presence and absence AG1478 (5µM). Cell 
lysates were collected and proteins were resolved on 10% SDS-PAGE and 
transferred to a PVDF membrane. The membranes were incubated overnight 
A. anti-phospho-Smad2/3(Thr220/179) B. anti-phospho-Smad2(Ser245) 
C. anti-phospho-Smad2(Ser250) and D. anti-phospho-Smad2(Ser255) (1:1000). 
Followed by peroxidase-labelled rabbit IgG secondary antibody. The 
membranes were reprobed with GAPDH HRP conjugated antibody. Blots are 
representative of three-independent experiments. Histogram represents band 
density expressed as fold per basal. Statistical significance was determined by 
one-way ANOVA, followed by least significant difference post-hoc analysis 
##,P<0.01 versus basal and **, P<0.01 agonist versus antagonist.  
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5.3.6 The involvement of serine/threonine kinases in thrombin 
mediated phosphorylation of Smad2 linker region residues 
via the transactivation of the EGFR in VSMCs. 
 
 Smad2 linker region phosphorylation also termed ‘non Smad signalling’ 
(Zhang, 2009) or ‘Smad independent signalling’(Derynck and Zhang, 2003) is 
activated by intracellular serine/threonine kinases (Burch et al., 2010 , Kamato 
et al., 2014a, Kamato et al., 2013c, Rezaei et al., 2012). The results presented 
above show that thrombin mediated phosphorylation of the Smad2 linker region 
is via the transactivation of both the EGFR and the TGFBR1 however the 
specific intermediate kinases which lead to the phosphorylation of the individual 
linker region residue is yet to be determined.  
GAG chain hyperelongation on biglycan involves the phosphorylation of 
Smad2 linker region by serine/threonine kinases (Burch et al., 2010 ). We have 
shown that at 30 mins thrombin mediated phosphorylation of the Smad2 linker 
region is solely through the transactivation of the EGFR. This section will focus 
on the kinases which mediate thrombin transactivation of the EGFR leading to 
the phosphorylation of the individual residues on the Smad2 linker region. The 
following serine/threonine kinase were examined using these inhibitors; MEK 
1/2 inhibitor, UO126, to inhibit its downstream kinase Erk, SB202190 as a p38 
inhibitor, Jnk inhibitor SP600125, PI3K inhibitor, LY294002 and flavopirodol 
as the CDK inhibitor. Concentrations of the inhibitors were based on a previous 
study from our laboratory which examined the phosphorylation of the individual 
residues on the Smad2 linker region in bovine aortic endothelial cells (Kamato 
et al., 2014a). 
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 Smad2 linker region residue - Thr220  
VSMCs treated with thrombin for 30 mins showed a 2.7-fold (P<0.01) 
increase in phospho-Smad2(Thr220) (Figure 5.6A). The presence of the Erk and 
CDK inhibitor, UO126 and flavopiridol respectively they had no effect on the 
thrombin mediated phospho-Smad2(Thr220). The presence of p38 and Jnk 
inhibitors, SB202190 and SP600124 partially inhibited thrombin mediated 
phospho-Smad2(Thr220) to 1.8-fold (P<0.01) (Figure 5.6A). PI3K inhibitor, 
LY294002, completely inhibited the thrombin mediated 
phospho-Smad2(Thr220). These results demonstrate that the phosphorylation of 
the Thr220 residue of the Smad2 linker region via thrombin tranactivation of the 
EGFR involves p38, Jnk and PI3K pathways but not Erk and CDK. 
Smad2 linker region residue – Ser245  
Consistent with earlier results (Figure 5.1), thrombin treatment of 
VSMCs caused an increase in phospho-Smad2(Ser245) to 2-fold (P<0.01) at 
30 mins (Figure 5.6B). The presence of inhibitors to Erk, p38 and Jnk had no 
effect on the thrombin mediated phospho-Smad2(Ser245). PI3K inhibitor, 
LY294002, partially inhibited (P<0.01) thrombin mediated phospho-
Smad2(Ser245). The presence of CDK inhibitor, flavopiridol, completely 
inhibited thrombin mediated phospho-Smad2(Ser245). Thus, thrombin mediated 
transactivation of the EGFR stimulated Ser245 phosphorylation through the                                                                                                                                                                         
activation of PI3K and CDK pathways. 
Smad2 linker region residue – Ser 250 
Cells treated with thrombin, increased the phospho-Smad2(Ser250) to 
3-fold (P<0.01) (Figures 5.6C). The presence of Erk inhibitor, UO126, partialy 
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inhibits phospho-Smad2(Ser250) to 2-fold (P<0.05). In the presence of 
inhibitors to p38, Jnk, PI3K and CDK the thrombin mediated 
phospho-Smad2(Ser250) is unnaffected (Figure 5.6C). Thus showing that Erk is 
the only kinase involved in thrombin mediated transactivation of the EGFR 
leading to the phosphorylation of Smad2 linker region residue Ser250. 
Smad2 linker region residue – Ser 255  
Conistent with the results in Figure 5.1D VSMCs treated with thrombin 
showed a 3-fold (P<0.01) increase in the phospho-Smad2(Ser255) (Figure 5.6 
D). In the presence of UO126 the thrombin mediated response is completely 
inhibited (P<0.01). Treatment with p38 inhibitor, SB202190, caused a partial 
inhibition to 2-fold (P<0.01) of thrombin mediated phospho-Smad2(Ser255). 
Jnk inhibitor had no effect on this response. PI3K and CDK antagonists inhibit 
phospho-Smad2(Ser255) to 1.5- and 1.2-fold (P<0.01), respectively (Figure 5.6 
D). Thus showing that thrombin mediated transactivation of the EGFR leading 
to the phospho-Smad2(Ser255) occurs via the activation of the Erk, p38, PI3K 
and CDK pathways. Taken together the results of these experiments show that 
the individual Smad2 linker region residues are phosphorylated by different 
serine/threonine kinases, with the PI3K being a common kinase for Thr220, 
Ser245 and Ser255 (see Figure 5.9A). 
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Figure 5.6: Effects of inhibitors to MAPK (Erk, P38 and Jnk), CDK and 
PI3K on thrombin mediated Smad2 linker phosphorylation via the 
transactivation of the EGFR. 
VSMCs were treated with thrombin (10Units/mL) in the presence and absence 
of each of the following serine/threonine kinase inhibitors: UO126, SB202190, 
SP600125, LY294002 and flavopiridol for 15 mins. Cell lysates were collected 
and protein (30µg) were resolved on 10% SDS-PAGE and transferred to a 
PVDF membrane. The membrane was incubated overnight 
A. anti-phospho-Smad2/3(Thr220/179) B. anti-phospho-Smad2(Ser245) 
C. anti-phospho-Smad2(Ser250) and D. anti-phospho-Smad2(Ser255) (1:1000). 
Followed by peroxidase-labelled rabbit IgG secondary antibody. The 
membranes were reprobed with GAPDH HRP conjugated antibody. Blots are 
representative of three-independent experiments. Histogram represents band 
density expressed as fold per basal. Statistical significance was determined by 
one-way ANOVA, followed by least significant difference post-hoc analysis 
##,P<0.01 versus basal and **, P<0.01 agonist versus antagonist.  
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5.3.7 The involvement of serine/threonine kinases in thrombin 
mediated phosphorylation of Smad 2 linker region 
residues via the transactivation of the TGFBR1. 
 
The data presented so far shows that thrombin mediated phosphorylation 
of the Smad2 linker region at 4 hours is via the transactivation of both the EGFR 
and TGFBR1. This section will focus on the serine/threonine kinases involved 
in thrombin mediated phosphorylation of the Smad2 linker region residues via 
the transactivation of the TGFBR1. To address this aim the serine/threonine 
kinases inhibitors were utilised in the presence of the EGFR antagonist AG1478, 
to eliminate the contribution of the EGFR and to show that the kinases involved 
in the TGFBR1 transactivation signalling pathway only. 
Smad2 linker region residue - Thr220 
Thrombin treated VSMCs showed a 2.4-fold (P<0.01) increase 
phospho-Smad2(Thr220) at 4 hours compared to the non-treated cells (Figure 
5.7A). The presence of EGFR antagonist, AG1478, blocked the thrombin 
mediated phospho-Smad2(Thr220) to 1.2-fold (P<0.01). In the presence of both 
AG1478 and the MAPK inhibitors, there is a further reduction in 
phospho-Smad2(Thr220) when compared to thrombin treatment in the presence 
of AG1478. UO126 and SB202190 inhibited thrombin mediated 
phospho-Smad2(Thr220) via transactivation of TGFBR1 to 0.6-fold (P<0.05) 
(Figure 5.7A). SP600125 had a slight inhibitory effect on thrombin mediated 
phospho-Smad2(Thr220) via transactivation of TGFBR1 however this effect did 
not reach statistical significance. LY294002 and flavopiridol in the presence of 
AG1478 inhibited phospho-Smad2(Thr220) to 0.4- (P<0.01) and 0.8-fold when 
compared to VSMCs treated with thrombin in the presence of AG1478. These 
results demonstrated that thrombin mediated phospho-Smad2(Thr220) is mostly 
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via the transactivation of the EGFR through p38, Jnk and CDK. The thrombin 
mediated transactivation of the TGFBR1 leading to phospho-Smad2(Thr220) 
appears to be predominantly through the activation of Erk, p38 and PI3K. 
Smad2 linker region residue – Ser245 
Thrombin treatment of VSMCs caused an increase in 
phospho-Smad2(Ser245) to 2-fold (P<0.01)(Figure 5.7B). In the presence of 
AG1478, there is a partial inhibition in the thrombin mediated 
phospho-Smad2(Ser245) to 1.6-fold (P<0.05). MAPKs inhibitor UO126 
(P<0.01) and SP600125 had a slight inhibition on phospho-Smad2(Ser245) via 
thrombin transactivation of TGFBR1. However the SB202190, LY294002 and 
flavopiridol had no effect (Figure 5.7B). These results show that thrombin 
mediated phospho-Smad2(Ser245) is via the transactivation of the TGFBR1 and 
it requires the activation of Erk. 
Smad2 linker region residue – Ser250 
Cells treated with thrombin at 4 hours stimulated 
phospho-Smad2(Ser250) to 2.1-fold (P<0.01)(Figure 5.7C). AG1478 blocked 
the thrombin mediated phospho-Smad2(Ser250) to 1.4-fold (P<0.01)(Figure 
5.7C). AG1478 in the presence UO126, had a slight inhibition of the 
phospho-Smad2(Ser250) to 0.9-fold (P<0.05) when compared to thrombin in 
the presence of AG1478. When AG1478 was in the presence of SB202190, 
SP600125, LY294002 and flavopiridol there was no change to 
phospho-Smad2(Ser250) (Figure 5.7C). These results demonstrate that Erk but 
not p38, Jnk, PI3K and CDK are mediators of thrombin transactivation of 
TGFBR1 stimulated phosphorylation of Ser250 (see Figure 5.9B). 
Smad2 linker region residue – Ser255 
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Phosphorylation of Ser255 was stimulated to 1.5-fold (P<0.01)(Figure 
5.7D) when VSMCs were treated with thrombin for 4 hours. AG1478 slightly 
inhibited thrombin mediated phospho-Smad2(Ser255) to 1.25-fold (P<0.05). 
UO126 and SP600125 in the presence of AG1478 had no effect on thrombin 
mediated phospho-Smad2(Ser255) via the TGFBR1. In the presence of AG1478 
with either SB202190, LY294002 or flavopiridol the thrombin mediated 
phosphorylation of Ser255 was inhibited (P<0.01) when compared to thrombin 
mediated phospho-Smad2(Ser255) in the presence of AG1478. These results 
indicated that p38, PI3K and CDK are involved in the thrombin mediated 
phospho-Smad2(Ser255) via the transactivation of TGFBR1. Taken together 
with our earlier findings, this implies that thrombin mediated phosphorylation of 
the Smad2 linker region occurs via the transactivation of both the EGFR and the 
TGFBR1 to induce the mRNA expression of CHST11 and CHSY1 in human 
VSMCs. The signalling intermediates involved in thrombin mediated 
phosphorylation of the Smad2 linker region via the transactivation of the EGFR 
differ to those involved in the transactivation of the TGFBR1. A summary of the 
findings of the kinases involved in the two transactivation pathways is presented 
in Table 5.1. 
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Figure 5.7: Effects of inhibitors to MAPK (Erk, P38 and Jnk), CDK and 
PI3K on thrombin mediated Smad2 linker phosphorylation via the 
transactivation of the TGFBR1 in VSMCs. 
VSMCs were treated with thrombin (10Units/mL) in the presence and absence 
of each of the following serine/threonine kinase inhibitors: UO126, SB202190, 
SP600125, LY294002 and flavopiridol for 4 hours. Cell lysates were collected 
and protein were resolved on 10% SDS-PAGE and transferred to a PVDF 
membrane. The membranes were incubated overnight with 
A. anti-phospho-Smad2/3(Thr220/179) B. anti-phospho-Smad2(Ser245) 
C. anti-phospho-Smad2(Ser250) and D. anti-phospho-Smad2(Ser255) (1:1000). 
Followed by peroxidase-labelled rabbit IgG secondary antibody. The 
membranes were reprobed with GAPDH-HRP conjugated antibody. Blots are 
representative of three-independent experiments. Histogram represents band 
density expressed as fold per basal. Statistical significance was determined by 
one-way ANOVA, followed by least significant difference post-hoc analysis 
##,P<0.01 versus basal, **, P<0.01 agonist versus AG1478 and ^^,P<0.01 
AG1478 versus serine/threonine kinase inhibitors. 
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5.3.8 Serine/threonine kinases differentially regulate thrombin 
mediated mRNA expression of GAG synthesizing genes 
CHST11 and CHSY1. 
  
Chapter 3 shows that thrombin mediated mRNA expression of GAG 
synthesizing enzymes CHST11 and CHSY1 correlate to our published data on 
proteoglycan synthesis and GAG elongation (Burch et al., 2013). The data 
shows that thrombin mediated GAG gene mRNA expression and GAG 
elongation signal via the transactivation of both the EGFR and TGFBR1 
(Chapter 3 Section 3.3.5). Proteoglycan synthesis and GAG chain elongation 
have previously been shown to correlate with the phosphorylation of the Smad2 
linker region (Burch et al., 2010 ). Smad2 linker region phosphorylation occurs 
indirectly via serine/threonine kinases (Matsuzaki, 2011). Hence, the 
serine/threonine kinases which are involved in thrombin mediated 
phosphorylation of the Smad2 linker region residues (Sections 5.3.6 and 5.3.7) 
will differentially regulate thrombin mediated mRNA expression of CHST11 
and CHSY1.   
 In VSMCs, TGF-β mediated GAG chain hyperelongation requires Erk 
and p38 activity (Burch et al., 2010 ). To study the role of these serine/threonine 
kinases on the mRNA expression of CHST11 and CHSY1, VSMCs were treated 
with thrombin for 6 hours in the presence and absence of inhibitors towards each 
of the following kinases; MEK 1/2 (UO126), p38 (SB202190), Jnk (SP600125), 
PI3K (LY294002) and CDK (flavopiridol). The concentration of the inhibitors 
used was identical to the previous experiments in this Chapter. 
 VSMCs treated with thrombin showed a 2.9-fold (P<0.01)(Figure 5.8 A) 
increase in the mRNA expression of CHST11 compared to non-treated cells 
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(Figure 5.8A). In the presence of inhibitors to Erk and p38; UO126 and 
SB202190 thrombin stimulated mRNA expression of CHST11 was almost 
completely inhibited to 1.2- and 1.1-fold (P<0.01), respectively. The presence 
of Jnk inhibitor SP600125 showed no inhibition of CHST11 mRNA expression 
stimulated by thrombin. Inhibitors to PI3K and CDK, LY294002 and 
flavopiridol, completely inhibited thrombin mediated mRNA expression of 
CHST11. Thus data correlates to that observed with TGF-β signalling of GAG 
hyperelongation in which Erk and p38 are involved but not Jnk. This data shows 
that Erk, p38, PI3K and CDK pathways are involved in thrombin stimulation of 
CHST11 mRNA expression. 
 The kinases involved in thrombin mediated mRNA expression of GAG 
synthesizing gene, CHSY1, also examined. Thrombin treatment of VSMCs 
showed a 2-fold increase (P<0.01) of CHSY1 mRNA expression (Figures 5.8B) 
compared to untreated cells. VSMCs treated with thrombin in the presence of 
UO126 showed an inhibition of CHSY1 mRNA expression to 1.5-fold (P<0.05) 
when compared to thrombin treatment alone (Figure 5.8 B). The presence of 
SB202190 resulted in a total inhibition (P<0.01) of thrombin mediated mRNA 
expression of CHSY1. The CHSY1 mRNA expression was not blocked by 
SP600125. However cells treated with thrombin in the presence of LY294002 
and flavopiridol showed an inhibition of CHSY1 mRNA expression to 1.2- and 
0.8-fold (P<0.01), respectively. These data demonstrated that thrombin 
signalling to CHSY1 mRNA expression involved MAPK Erk and p38 but not 
Jnk, as well as PI3K and CDK. The serine/threonine kinases involved in 
thrombin mediated mRNA expression of GAG enzymes CHST11 and CHSY 
are the same for both genes (see Figure 5.9). 
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Figure 5.8: Serine/threonine kinases differentially regulate thrombin 
mediated mRNA expression of GAG synthesizing enzymes CHST11 and 
CHSY1. 
VSMCs were pre-incubated with UO126 (3μM), SB202190 (3μM), SP600125 
(1μM), LY294002 (20μM) or flavopiridol (500nM) for 30 mins prior to 
thrombin (10 Units/ml) exposure for 6 hours to determine the effects on the 
mRNA expression of A. CHST11 and B. CHSY1. Total RNA was harvested and 
the mRNA expression of CHST11 and CHSY1 were analysed using RT-PCR. 
18S was used as a house keeping gene. Data are expressed as the mean ± 
standard error from three experiments. Statistical significance was determined 
by one-way ANOVA, followed by least significant difference post-hoc analysis. 
##,P<0.01 basal versus thrombin and *,P<0.01 and **,P<0.01 thrombin versus 
antagonist was used for statistical analysis. 
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Figure 5.9: Schematic diagram illustrating the proposed thrombin 
mediated transactivation leading to Smad2 linker region phosphorylation. 
Transactivation of A. EGFR or B. TGFBR1 involving serine/threonine kinases 
and individual Smad2 linker region residues to stimulate CHST11 and CHSY1 
mRNA expression.  
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5.4 Summary of results 
 The results presented in this chapter demonstrate that thrombin through 
PAR-1 mediates transactivation of the EGFR and TGFBR1 to phosphorylate the 
individual residues of the Smad2 linker region by serine/threonine kinase 
intermediates as well as the signalling to GAG synthesizing enzyme mRNA 
expression in VSMCs in vitro. The specific findings from these experiments are: 
 Thrombin mediated phosphorylation of the Smad2 linker region residues 
had a rapid increase response at 15 min, the phosphorylation of the 
residues gradually declined however was sustained for the 4 hours. 
 Thrombin mediated phosphorylation of the Smad2 linker region occurs 
via the transactivation of the EGFR within 15 mins and is sustained for 
up to 4 hours. 
 Thrombin mediated phosphorylation of the Smad2 linker region also 
occurs via transactivation of the TGFBR1, this signalling pathway is 
delayed with an activation period from 2-4 hours. 
 Thrombin mediated transactivation of the EGFR leads to the 
phosphorylation of the Smad2 linker Thr220 residue through the 
activation of p38, Jnk and PI3K and not through Erk and CDK. 
Phosphorylation of Ser245 is mediated by PI3K and CDK. Ser250 
phosphorylation occurs through Erk whereas Ser255 phosphorylation 
involved Erk, p38 and CDK (see Table 5.1). 
 Thrombin mediated transactivation of the TGFBR1 leads to the 
phosphorylation of the Thr220 residue through the activation of Erk, p38 
and PI3K. Phosphorylation of Ser245 occurs through Erk activation. The 
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Ser250 phosphorylation is mediated through Erk whereas p38, PI3K and 
CDK lead to the phosphorylation of Ser255 (see Table 5.1). 
 Thrombin mediated mRNA expression of CHST11 and CHSY1 involves 
Erk, p38, PI3K and CDK but not Jnk (see Table 5.1). 
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Table 5.1: A summary of thrombin signalling via the transactivation of the 
EGFR and TGFBR1 pathways. 
Transactivation dependent signalling pathways involving serine/threonine 
kinases, individual Smad2 linker region residues and the mRNA expression of 
CHST11 and CHSY1.    
 
 
Serine/threonine kinases 
Erk p38 Jnk PI3K CDK 
EGFR Thr220      
Ser245      
Ser250      
Ser255      
TGFBR1 Thr220      
Ser245      
Ser250      
Ser255      
GAG genes CHST11     
CHSY1     
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5.5 Discussion 
 The studies in this chapter show that in VSMCs, thrombin mediated 
Smad2 linker region phosphorylation occurs via the EGFR and TGFBR1. The 
phosphorylation of the individual Smad2 linker region residues is mediated by a 
number of serine/threonine kinases. Data outlined in Chapter 3 demonstrates 
that thrombin mediated proteoglycan modification correlates with mRNA 
expression of GAG synthesizing genes. These results show that thrombin signals 
through the transactivation of both the EGFR and TGFBR1, which leads to an 
increase in biglycan size and an increase in the expression of CHST11 and 
CHSY1 mRNA expression. Earlier studies from our lab had shown that Erk and 
p38 are associated with the increase in size of GAG chain on biglycan through 
Smad2 linker region phosphorylation. Here we aimed to characterise whether or 
not Smad2 linker region phosphorylation occurs via thrombin transactivation of 
the EGFR and TGFBR1. Phosphorylation of Smad2 at the carboxy terminal 
occurs directly through the activation of the TGFBR1. Smad2 linker region 
phosphorylation occurs indirectly through the activation of serine/threonine 
kinases which in turn phosphorylate the Smad2 linker region residues 
(Matsuzaki, 2011). Here we aimed to identify the serine/threonine kinases 
involved in thrombin transactivation of the EGFR compared to the kinases 
involved in thrombin transactivation of the TGFBR1 and whether these kinases 
are involved in regulating the mRNA expression of GAG synthesizing genes 
responsible for GAG elongation.  
 There are at least four important phosphorylation sites in the Smad2 
linker region. In humans, the Smad2 linker region residues are Thr220, Ser245, 
Ser250 and Ser255. This study has focused on the Smad2 transcription factor as 
in VSMCs it has been shown to play an important role in proteoglycan 
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synthesis. The TGF-β stimulated CHSY1 protein was inhibited in nucleus 
pulposus cells of intervertebral discs with Smad2 siRNA but not Smad3 siRNA, 
indicating that Smad2, but not Smad3 was involved in the regulation of CHSY1 
expression (Hu et al., 2015). Thrombin treatment of VSMCs has a rapid increase 
in the phosphorylation of the individual Smad2 linker region residues with a 
peak phosphorylation at 15 min. The Smad2 linker region phosphorylation 
varies between the individual residues. Thrombin had a substantial increase in 
the phosphorylation of Thr220, Ser250 and Ser255 compared to the 
phosphorylation of Ser245. TGF-β mediated phosphorylation of the Ser245 
residue in bovine aortic endothelial cells (Kamato et al., 2014a) and VSMCs 
(Rostam et al., 2016) was less then two fold in both studies whereas the other 
residues were phosphorylated to a much higher fold change. In mouse embryo 
fibroblasts infected with Smad2 mutant, TGF-β mediated phosphp-
Smad2(Ser245) was considerably less than the phosphorylation of the three 
other residues of the linker region (Matsuzaki et al., 2009). These results 
indicate that the Ser245 residue of the Smad2 linker region may not be as 
heavily implicated in signalling via the TGFBR1 as compared to the other 
residues.  
The rapid increase in the phosphorylation of the Smad2 linker region 
residues is due to thrombin transactivation of the EGFR. GPCR agonists such as 
LPA (Brusevold et al., 2014, Jeong et al., 2013, Daub et al., 1997), thryrotropin 
releasing hormone (Ohmichi et al., 1994), ET-1 (Cazaubon et al., 1994, Daub et 
al., 1996) and thrombin (Burch et al., 2013, Huang et al., 2012, Smiljanic et al., 
2014) rapidly induce the transactivation of PTKR, EGFR. GPCR mediated 
transactivation of the EGFR occurs via the activation of a membrane bound 
MMPs resulting in the cleavage and release of the EGF ligand which 
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subsequently activated its cognate receptor in an autocrine manner (Prenzel et 
al., 1999, Fischer et al., 2003, Gschwind et al., 2002). The results presented in 
this chapter reveal that thrombin transactivation of the TGFBR1 leading to the 
phosphorylation of the Smad2 linker region is time dependent and is delayed 
when compared to EGFR transactivation. GPCR mediated transactivation of the 
TGFBR1 is time dependent in various conditions. In mouse embryonic 
fibroblast transfected with β6 integrin, LPA mediated transactivation of the 
TGFBR1 studied by the phosphorylation of the downstream intermediate Smad2 
was evident at 2-4 hours post treatment (Xu et al., 2009). In human airway 
smooth muscle cells, LPA and methacholine induced cells resulted in a delayed 
increase in the phosphorylation of the Smad2 protein signifying a delay in 
GPCR mediated transactivation of the TGFBR1 (Tatler et al., 2011). In VSMCs, 
the protracted time course in thrombin mediated transactivation of the TGFBR1 
is not due to new protein synthesis. Inhibitor of translation and transcription 
cycloheximide had no effect on thrombin mediated phosphorylation of the 
Smad2 (Burch et al., 2013). GPCR transactivation of the TGFBR1 occurs via 
cytoskeletal rearrangement which activates ROCK signalling, preceding to the 
activation of cell surface integrins which bind to the latent TGF-β complex. This 
results in the exposure of the TGF-β ligand to the receptor (Munger et al., 1999). 
The cell surface integrin activation which are involved in the transactivation of 
the TGFBR1 are predicted to be the reason this transactivation cascade is 
delayed. Integrins signal via inside out signalling, which allow for the talin and 
kindlin to bind to the cytoplasmic end of the β subunit (Munger et al., 1999). 
Signalling via transactivation of TGFBR1 leading to Smad2 linker region 
phosphorylation as compared to GPCR transactivation of EGFR is delayed due 
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to the cell surface mechanisms which are involved in transactivation dependent 
signalling.  
Interestingly, thrombin mediated phosphorylation of Smad2 linker 
region via the EGFR was sustained for the 4 hour duration of the study, 
coinciding with the TGFBR1 mediated transactivation pathway. The cross over 
in the transactivation pathways makes it difficult to distinguish whether there is 
a difference in the kinases which lead to the phosphorylation of the Smad2 
linker region residues. To study the kinases involved in thrombin mediated 
phosphorylation of the Smad2 linker region residues via the transactivation of 
the TGFBR1, EGFR antagonist was utilised to block out EGFR signalling. The 
use of the EGFR inhibitor blocks most of the thrombin mediated 
phosphorylation of Thr220, Ser250 and Ser255 therefore not allowing for a true 
representation of thrombin transactivation of the TGFBR1. To distinguish the 
signalling occurring via the TGFBR1 leading to the phosphorylation of Smad2 
linker region, EGFR signalling will need to be neutralised. An experimental 
approach that could address this issue is by using siRNA specific to the EGFR 
can be used to knock down EGFR signalling in VSMCs. Once the knockdown 
has been validated the transfected cells will need to be treated in the presence of 
thrombin and the serine/threonine kinases outlined above to determine 
specifically which kinases are involved in thrombin transactivation of TGFBR1 
leading to phosphorylation of individual residues of Smad2 linker region. A 
genetically modified cell line containing a frame shift mutation in a coding exon 
of EGFR may be another way to studying signalling pathways of thrombin 
transactivation of the TGFBR1. This cell line may be purchased or can be 
customised using clustered regularly interspaced short palindromic repeat 
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(CRISPR) technology. The cell line can be used as a model to signify how the 
signalling may occur in human VSMCs. 
 Phosphorylation of Thr220 via thrombin transactivation of the EGFR is 
through the activation of MAPKs, p38 and Jnk and through the activation of 
PI3K but not through Erk and CDK. Transactivation of the TGFBR1 leading to 
the phosphorylation of the Thr220 did not require Jnk activity, however was 
through the stimulation of Erk, p38 and PI3K. Studies published by our lab 
show that in VSMCs, TGF-β mediated Smad2 linker region phosphorylation of 
the serine residues occurs through the activation of Erk and p38 but not Jnk, thus 
showing that the transactivation pathway going through the TGFBR1 signal via 
the same kinases to phosphorylate the Thr220 residue. Interestingly, Thr220 
phosphorylation via the transactivation of the EGFR required the activation of 
Jnk. There has been a number of studies showing that PTKR agonists have 
activated the Jnk pathway leading to the phosphorylation of the Smad2/3 linker 
region. Hepatocyte growth factor treated RGM-1 cells activated the Jnk 
pathway, inducing phosphorylation of Smad2 carboxy terminal and Smad2 
linker region (Mori et al., 2004). PDGF treated rat hepatic stellate cells caused a 
rapid increase in the phosphorylation of the Smad2/3 threonine residue that was 
dose dependently inhibited in the presence of Jnk inhibitor (Yoshida et al., 
2005). Interestingly, Jnk, was not involved in the phosphorylation of any of the 
other Smad2 linker region residues in thrombin mediated transactivation of both 
EGFR and TGFBR in VSMCs. However in a rat model of liver injury activation 
of Jnk was accompanied by phosphorylation of Smad2 Ser249 and 254 (Yoshida 
2005). Thus showing that Jnk activation of the threonine residue of the Smad2 
linker region may be specific for PTKR signalling in VSMCs.  
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 Erk was shown to regulate thrombin mediated transactivation of the 
EGFR leading to the phosphorylation of Ser250 and Ser255 (Figure 5.9A). In 
thrombin transactivation of the TGFBR1 Erk was shown to activate the Thr220, 
Ser245 and Ser250 residues of the Smad2 linker region (Figure 5.9B). In 
VSMCs, TGF-β signalling of Smad2 linker region leading to proteoglycan 
synthesis and GAG hyperelongation occurred via Erk activation (Burch et al., 
2010). However due to the use of the pan linker antibody, the individual 
residues involved were not identified. In this study antibodies targeting the 
individual residues of the Smad2 linker region where utilised. The data 
presented in this chapter demonstrates that Smad2 linker region phosphorylation 
varies between the individual residues. Another recent study by our lab showed 
that in bovine aortic endothelial cells, TGF-β activation of Erk leads to the 
phosphorylation of Ser245, Ser250 and Ser255 (Kamato et al., 2014a). In TGF-β 
mediated phosphorylation of the Smad2 linker region in human VSMCs, Erk 
was involved in the phosphorylation of Ser245, Ser250 and Ser255 residues but 
not the phosphorylation of the Thr220 (Rostam et al., 2016). Interestingly the 
Thr220 residue was not phosphorylated by TGF-β mediated Erk 
phosphorylation in both bovine aortic endothelial cells and VSMCs. Hence we 
could postulate that signalling of TGFBR1 via transactivation could activate 
different signalling intermediates when compared to direct stimulation of the 
TGFBR1. To address this, a knock out model of the EGFR as outlined above 
could be used to study the signalling specifically via the transactivation of the 
TGFBR1. The cell surface mechanisms involved in the transactivation 
dependent signalling may also justify why there is a difference between direct 
TGFBR1 signalling and transactivation dependent signalling on the Smad2 
linker region. To address this the role of the cell surface proteins involved in the 
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transactivation dependent signalling will need to be investigated on thrombin 
mediated phosphorylation of the individual serine/threonine kinases involved. 
Thus allowing to interpret whether the difference between the direct TGFBR1 
signalling and transactivation dependent signalling is due to the cell surface 
mechanisms.  
CDK activation is involved in thrombin transactivation of the EGFR and 
the TGFBR1 leading to the phosphorylation of Smad2 linker region serine 
residues. Thrombin mediated transactivation of the EGFR via CDK 
phosphorylates the Ser245 and Ser255 residues, however transactivation via the 
TGFBR1, CDK only phosphorylates the Ser255 residue (Figure 5.9). In both 
signalling pathways the activation of CDK does not phosphorylate the Thr220 
and the Ser250 residue. In bovine aortic endothelial cells, TGF-β activation of 
CDK lead to the phosphorylation of Ser245 and Ser255 but not Ser250 (Kamato 
et al., 2014a). Thus showing that in these two cell models CDK does not activate 
the Ser250 residue of the Smad2 linker region leading to PAI-1 expression in 
endothelial cells (Kamato et al., 2014a) or the expression of CHST11 and 
CHSY1 in VSMCs. Consistent with the results presented in this chapter 
flavopiridol is not involved in the phosphorylation of the Smad2 linker region 
residue Thr220 in a melanoma model (Cohen-Solal et al., 2011). Direct 
TGFBR1 signalling in VSMCs reveals that CDK is only involved in the 
phosphorylation of the Thr220 residue of the Smad2 linker region (Rostam et 
al., 2016). Interestingly, unlike what we see in our model the literature shows 
that TGF-β stimulated CDK family phosphorylation has a greater preference 
over the Thr220 than the serine residues (Yumoto et al., 2013, Matsuura et al., 
2004, Matsuzaki et al., 2009). The use of specific Smad3 linker phosphorylated 
antibodies shows that the four sites (Thr179, Ser204, Ser208 and Ser213) were 
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phosphorylated by CDK4 and CDK2 (Matsuura et al., 2004). CDK 8 and CDK9 
were able to phosphorylate the linker region of Smad3 at Thr179, Ser208 and 
Ser213 (Alarcon et al., 2009). The CDK mediated phosphorylation events create 
variable Smad2/3 phospho-isoforms that can differentially interact with Smad4 
and either translocate or be blocked from entering the nucleus to initiate 
transcription of target genes. Based on these studies, we found that there may be 
a number of CDK isoforms that may be responsible for the phosphorylation of 
the Smad2 linker region. This study used the CDK inhibitor flavopiridol, which 
targets at least six CDK isoforms and limits the conclusions about specific CDK 
isoforms. Future investigations should endeavour to identify which of the many 
CDK isoforms are activated by thrombin in VSMCs. In the event that more than 
one is activated, the use of specific CDK inhibitors or isoforms knockdown can 
be used to identify which CDK isoforms are responsible for the phosphorylation 
of the individual Smad2 linker residues. In Mv1Lu mink lung epithelial cells, 
the Smad3 linker region is phosphorylated by CDK 2 and 4 acting as mediators 
in the anti-proliferative effects of TGF-β (Matsuura et al., 2004). CDK activity 
is involved in cell cycle progression (Malumbres and Barbacid, 2009), hence is 
increased in the proliferative diseases such as cancer (Massague, 2004). The 
progression of atherosclerosis involves cellular proliferation and migration of 
VSMCs and there is evidence to suggest it is regulated by CDK driven cell cycle 
(Wessely, 2010, Ross et al., 2001). In aortas of cholesterol-fed rabbits, elevated 
expression and activity of CDK1, CDK2 and CDK4 was reported after 8 weeks 
of modest plaque development (Zettler et al., 2010). The results presented here 
support the involvement of CDK in the development of atherosclerosis 
highlighting a novel role of CDK which causes an increased GAG chain 
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elongation represented by the change in expression levels of GAG genes, 
CHST11 and CHSY1. 
PDGF and thrombin are known to activate PI3K via Akt (Osman et al., 
2011). In VSMCs, PI3K participates in PDGF stimulated synthesis of 
proteoglycan core protein (Getachew et al., 2010a, Osman et al., 2014). 
Unpublished data from our lab shows that PI3K is partially involved in thrombin 
mediated proteoglycan synthesis. The role of Akt in thrombin mediated Smad2 
linker region was studied at the 1-hour time point (Osman et al., 2011). VSMCs 
treated with thrombin increased the phosphorylation of the serine residues of 
Smad2 linker region, this was unaffected by Akt inhibitor SN30978 (Osman et 
al., 2011). PAR-1 stimulation has been shown to promote intracellular signalling 
though the activation of Erk, PKC and PI3K cascades which are involved in the 
regulation of the cell cycle regulator cyclin D (Parrales et al., 2011). PI3K in this 
study was involved in thrombin mediated phosphorylation of Smad2 linker 
region through the transactivation of both the EGFR and TGFBR1. PI3K was 
also shown to participate in thrombin mediated mRNA expression of CHST11 
and CHSY1. Studies have shown that PI3K could act as upstream mediators for 
CDK activation (Major et al., 2004). PI3K/PDK1 (phosphoinistide dependent 
kinase-1) signalling is reported to activate the CDK-cyclin complexes required 
for ForkheadBoxM1B dependent transcriptional activity (Major et al., 2004). In 
the data presented in this chapter, thrombin mediated transactivation of the 
EGFR leads to the phosphorylation of the Smad2 linker region residues Ser245 
and Ser255 is via PI3K and CDK. Similarly both CDK and PI3K are involved in 
thrombin mediated transactivation of TGFBR1 leading to the phosphorylation of 
Smad2 linker region residue Ser255. These results demonstrate that in VSMCs 
thrombin regulation of the Smad2 linker serine residues does not involve the 
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PI3K/Akt signalling but instead the PI3K/CDK pathway. Thus correlating with 
the literature that thrombin mediated linker region phosphorylation does not 
involve Akt (Osman et al., 2011). 
In fibroblasts, TGF-β induced replication can be regulated through PI3K 
activated Erk signalling pathway and lead to the phosphorylation of Smad linker 
region phosphorylation and gene expression (Hough et al., 2012). PI3K acts 
upstream of Erk in TGF-β mediated phosphorylation of Smad2 linker residues 
Ser245, Ser250 and Ser255 in bovine aortic endothelial cells (Kamato et al., 
2014a). In this study the PI3K/Erk pathway is involved in thrombin mediated 
phosphorylation of Ser255 residue via transactivation of the EGFR and 
thrombin mediated phosphorylation of Thr220 via transactivation of TGFBR1. 
Thus showing that PI3K signalling cascade can be cell or receptor dependent. 
TGF-β mediated phosphorylation of Thr220 in bovine aortic endothelial cells 
occurs via the PI3K/CDK signalling cascade. In this present study, we 
demonstrate that thrombin mediated transactivation of the EGFR leads to the 
phosphorylation of Thr220 through PI3K activity however CDK was not 
involved. The PI3K/Erk pathway was also ruled out as Erk inhibitor had no 
effect on thrombin mediated phosphorylation of Thr220 via transactivation of 
the EGFR. We postulate that phosphorylation of the Thr220 in this model occurs 
via the PI3K/Akt pathway as published data in VSMCs shows that the three 
serine residues are unaffected by PI3K.  
Thrombin mediated mRNA expression of CHST11 and CHSY1 is via 
the transactivation of the TGFBR1 and the EGFR (see Chapter 3). The mRNA 
expression of the GAG synthesizing genes correlates with proteoglycan 
synthesis and GAG elongation (Burch et al., 2011). TGF-β mediated GAG chain 
elongation has been shown to correlate with the phosphorylation of the Smad2 
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linker region. Our results show that thrombin can activate Erk, p38, PI3K and 
CDK to stimulate an increase in the mRNA expression of CHST11 and CHSY1. 
Among the MAPK involved in TGF-β signalling in VSMCs, Erk and p38 but 
not Jnk have been identified to modify GAG chains. In nucleus pulposus cells of 
invertebral discs, Erk is shown to participate in TGF-β regulation of CHSY1 
expression (Hu et al., 2015). The data presented in this chapter is consistent with 
these two models. Interestingly the TGF-β mediated GAG elongation does not 
require Jnk activation, similarly thrombin signalling to GAG gene mRNA 
expression does not require Jnk. This study shows that Jnk activity is not 
required in the phosphorylation of the serine residues in thrombin 
transactivation of the EGFR or TGFBR1 however thrombin mediated 
transactivation of the EGFR leading to the phosphorylation of Thr220 required 
Jnk activity. From this we can postulate that the Thr220 residue may not be 
involved in the GAG elongation process but may be involved in other processes 
such as the initiation of the linkage region. To study whether thrombin mediated 
transactivation of EGFR leading to the phosphorylation of Thr220 via Jnk is 
involved in the initiation of the linkage region of the GAG chains, VSMCs 
should be treated with thrombin in the presence and absence of Jnk inhibitor and 
the mRNA expression of XXYLT-1 should be measure. The XXYLT-1 enzyme 
is responsible for the transfer of a xylose to the proteoglycan core protein to 
initiate the biosynthesis of the CS GAG chain.  
 The use of phospho-specific antibodies highlights the unique role of each 
responsible kinase that phosphorylates different individual serine/threonine 
residues despite mediating similar outcomes of increased GAG synthesizing 
enzyme CHSY1 and CHST11 mRNA expression. The exact mechanism(s) by 
which the specificity of individual Smad2 linker region phosphorylation regulate 
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Smad2 signalling remains to be clearly elucidated. Linker region 
phosphorylation may allosterically regulate intramolecular interactions between 
the MH1 and MH2 domains, and intermolecular interactions between Smads 
and other molecules (e.g. cytoplasmic anchors or cofactors) (Ross and Hill, 
2008). Differential localization of protein kinases that can phosphorylate 
Smad2/3 whether in the cytoplasm or nucleus also affects multiple signalling 
responses that determine the functional cell outcome (Matsuzaki, 2013). Apart 
from investigations on the upstream signalling events at the protein kinase level, 
it is also essential to elucidate the involvement of co-activators or co-repressors 
that modulate the promoter sequences of each individual GAG enzyme genes 
that ultimately affects the transcriptional gene regulation (Matsuzaki, 2013). 
Smad2/3-Smad4 complex must interact with other DNA-binding cofactors to 
achieve high affinity and selectivity for specific subsets of target genes 
(Massague et al., 2005). The activator protein-1 knockout cells was shown to 
prevent the TGF-β-mediated CHSY1 promoter activity indicating that this 
protein is required for CHSY1 promoter activity to occur (Hu et al., 2015). It 
remains to be shown whether CHST11 promoter is activated by similar 
combinations of co-activators as to CHSY1, which could provide explanation 
behind the same serine/threonine kinase mediators involved in CHSY1 and 
CHST11 regulation.  
In summary thrombin transactivates both the EGFR and TGFBR1 which 
leads to the phosphorylation of the Smad2 linker region residues. The two 
transactivation pathways activate different serine/threonine kinases which leads 
to the phosphorylation of Smad2 linker region residues. Thrombin mediated 
transactivation of the EGFR activates Jnk which phosphorylates the Thr220. Of 
the serine/threonine kinases studied Jnk was the only kinase which was not 
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involved in thrombin mediated mRNA expression of GAG synthesizing 
enzymes CHST11 and CHSY1. Therefore we postulate that phosphorylation of 
the serine residues are most likely to induce GAG synthesizing genes that are 
closely associated with GAG chain elongation whereas the Thr220 
phosphorylation may be associated with enzymes which determine the level of 
GAG chain synthesis. These findings highlights the complex nature but also the 
specificity of signalling pathways contributing to GAG chain hyperelongation. 
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6.1 Introduction 
We wished to address the question as to the overall contribution of 
transactivation dependent signalling to total GPCR (PAR-1) signalling to try to 
put transactivation signalling into context. To determine the extent of 
transactivation dependent GPCR signalling a combined genome-wide gene 
expression and differential pharmacology study can help identify genes and 
biological processes regulated by PAR-1 transactivation of the TGFBR1 or 
EGFR. Whole genome RNA sequencing allows for the comprehensive study of 
the mRNAs in the individual treatment groups relating to each of the 
transactivation signalling pathways which can be isolated by the use of our well-
characterised pharmacological tools (described below). This new platform has 
produced high throughput sequencing in the study of various diseases such as 
bone dysplasia, schizophrenia, rheumatic disease and cancers such as lymphoid 
cancer and melanoma (Giannopoulou et al., 2015, Xu et al., 2012, Ceol et al., 
2011, Steidl et al., 2011, Briggs et al., 2011). RNA-Seq sequencing has been a 
superior tool in profiling complex diseases (Costa et al., 2013, Byron et al., 
2016, Robert and Watson, 2015), but has not been implicated in studies of 
specific signalling pathways. Champlovier (Champelovier et al., 2010) adapted 
a pharmacological approach to study the role of Jnk in gene modulation. Jnk 
inhibitor, SP600125, was used to determine differentially expressed genes and 
signalling pathways as a potential therapeutic in treatment of leukaemia cells. 
 Hannan (George et al., 2013) using a functional siRNA screen of the 
human genome to identify the underlying biology in transactivation of the 
EGFR. The role of 720 kinases was investigated in Angiotensin II mediated 
transactivation of the EGFR (George et al., 2013). In the present study, RNA 
sequencing analysis was employed to examine the changes induced by PAR-1 
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transactivation dependent signalling in global and selective pathway gene 
expression in human VSMCs. 
6.2 Materials and Methods 
6.2.1 Materials 
RNAse-Free DNase set and miRNeasy kit were purchased from Qiagen. 
Dynabeads® mRNA DIRECT™ Micro kit, Ion PI™ Template OT2 Supplies 
200 kit v2, Ion PI™ Template OT2 Reagents 200 Kit v2, Ion PI™ Template 
OT2 Solutions 200 kit v2, Ion PI™ Sequencing Supplies 200, Ion PI™ 
Sequencing reagents 200, Ion PI™ Sequencing solutions 200 v2, Ion PI™ Chip 
preparation solution and Ion Proton™ Chip Adapter where purchased from Life 
Technologies. 
6.2.2 Cell culture  
Cells were grown in DMEM (5mM glucose, 10% FBS and 1% 
antibiotics at 37⁰C in 5% CO2) CASMCs were seeded in 60mm dishes 
(described in more detail Chapter 2 Section 2.2.1). Cells were grown to 
confluence then rendered quiescent by serum deprivation for 48 hours. 
Inhibitors were pre-incubated for 30 mins prior to treatment with thrombin for 6 
hours. The RNA extraction and library preparation are described in detail in 
Chapter 2 Section 2.2.9. 
6.2.3 Quality control and read alignment 
Venkata Vijayanand Bhaskarala from the Department of Biotechnology 
and Environmental Biology at RMIT University conducted the RNA-sequencing 
analysis. QUADtrim was used to remove the adapter from the RNA-sequencing 
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reads and to check the quality of the raw reads. The reads were mapped to the 
human reference genome (hg19) using TopHat v2.1.1. Parameters of TopHat 
were set to allow only unique alignment to the reference genome. HTSeq was 
used to generate the counts.  
6.2.4 Differential gene expression and functional analysis 
The genes differentially expressed between the different treatments were 
identified using the Bioconducter edgeR software (v3.0.7) (Robinson et al., 
2010). This method uses a Poisson distribution to model genic read counts 
following normalization based on size factors and variance, therefore this 
software allows normalization of RNA-sequence data based on sequencing 
depth GC content and gene length for analysis of differentially expressed genes. 
Differentially expressed genes were defined with log2FC of >0.7 or <-0.7 
significant at p value <0.01. STRING (v10.0) (http://string-db.org), a publically 
available online database of functional interaction (Szklarczyk et al., 2015) was 
used to identify gene ontology analysis and networks, the differentially 
expressed genes were analysed. The Venn diagrams were depicted using JVenn 
an interactive tool to view Venn diagrams and respective lists (Bardou et al., 
2014).  
6.3 Results and Discussion 
6.3.1 Gene expression profiles of treatments involved in PAR-1 
mediated transactivation of the EGFR and the TGFBR1 
 
 A genome wide RNA-Seq sequencing study was conducted to determine 
the portion of GPCR signalling which is occurring via transactivation dependent 
signalling in human CASMCs (Figure 6.1). The individual treatment groups 
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(Basal, Thrombin, Thrombin+AG1478, Thrombin+SB431542 or 
Thrombin+AG1478+SB431542) contained 2-4 individual samples pooled 
together for each of the groups to identify the differentially expressed genes. A 
total of 3 pooled samples from RNA isolated from untreated CASMCs (Basal, 
Figure 6.1A), averaged 8 million reads and 82.7% of the total reads were 
mapped to the human reference genome (hg19). The RNA was harvested from 
human CASMCs treated with thrombin for 6 hours (Figure 6.1B Thrombin), 
consisted of 4 pooled samples with an average of 12 million reads. Among the 
total number of reads 83.3% of the reads were mapped to the human reference 
genome (hg19). To study the differentially expressed genes occurring via the 
transactivation of the EGFR VSMCs were treated with thrombin in the presence 
of EGFR antagonist, AG1478. For this treatment, there was a total of 2 pooled 
samples (Figure 6.1C) with an average of 13.5 million reads, 82.3% of these 
reads were mapped to the human reference genome (hg19). To determine the 
number of differentially expressed genes occurring via the transactivation of the 
TGFBR1, VSMCs were treated with thrombin in the presence of TGFBR1 
antagonist, SB431542. For this treatment group there was a total of 4 samples 
pooled together with an average read of 13.1 million reads (Figure 6.1D). 
Among the total number of reads 81.2% of the reads were mapped to the human 
reference genome (hg19). The treatment showing the genes regulated via dual 
transactivation dependent signalling pathways were treated with thrombin in the 
presence of EGFR and TGFBR1 antagonists AG1478 and SB431542, 
respectively (Figure 6.1E). A total of 3 individual samples were pooled to give 
an average of 10.9 million reads. Among the total reads 82.2% of the reads were 
aligned to the human genome (hg19).  
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 The small sample size in our RNA-Seq study is consistent with other 
RNA-Seq sequencing studies published which are based on sample sizes of 
equal to or less than 3 (Xu et al., 2012). In human samples greater than 80% of 
the read pairs can be expected to be mapped to the reference genome (Djebali et 
al., 2012). Consistent with the literature (Wang et al., 2009b) the output from 
our RNA-Seq study shows that over 80% of the reads are mapped to the human 
genome. Thus validating that the RNA used to identify the differentially 
expressed genes is of high quality.    
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Figure 6.1: Summary of RNA sequencing data. 
 Average mapping statistics for each of individual treatments using aligned 
using TopHatv2.1.1. RNA was extracted from human VSMCs which were A. 
untreated, B. treated with thrombin (10 unit/ml), pre-incubated for 30 mins with 
C. EGFR antagonist, AG1478 (5µM), D. TGFBR1 antagonist, SB431542 
(3µM), or E. both receptor antagonists, followed by thrombin treatment for 6 
hours. The results show that over 80% of the reads are aligned to the human 
genome in the 5 treatment conditions.  
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6.3.2 Number of genes regulated by thrombin transactivation 
dependent and independent signalling in coronary artery 
smooth muscle cells. 
 
To study the role of transactivation dependent pathways in GPCR 
signalling, RNA sequencing was conducted to assess the number of genes 
regulated by each of the transactivation dependent signalling pathways. To study 
the role of PTKR, the EGFR antagonist, AG1478, was used and to study S/TKR 
transactivation the TGFBR1 antagonist, SB431542, was utilized. In the present 
study the differential expression analysis was carried out using edgeR which 
required multiple comparison analysis. Each of the treated samples were initially 
compared to the basal sample. The samples treated with thrombin in the 
presence of the receptor antagonists were further compared to the CASMCs 
treated with thrombin alone. The results from this multiple comparison are 
presented in Figure 6.2. 
 VSMCs treated with thrombin (6hours) resulted in 293 differentially 
expressed genes increasing in expression as compared to basal. A total of 209 
genes are differentially regulated when CASMCs were treated with thrombin in 
the presence of AG1478. The presence of the EGFR antagonist, AG1478, 
resulted in an increase in the expression of 80 genes when compared to thrombin 
treatment alone. The expression of 129 genes was down regulated in the 
presence of AG1478 as compared to thrombin alone (Figure 6.2). A total of 177 
genes are differentially expressed when CASMCs are treated with thrombin in 
the presence of SB431542. The expression of 26 genes increase in the presence 
of SB431542 as compared to thrombin treatment alone and 151 genes down 
regulated in the presence of the antagonist (Figure 6.2). When the two 
antagonists are combined a total of 212 genes are differentially expressed, 166 
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genes were down regulated as compared to thrombin and the expression of 46 
genes were increased as compared to thrombin treatment alone (Figure 6.2). 
Thus these results show that transactivation dependent signalling plays an 
important role in GPCR signalling with 209 genes regulated via the 
transactivation of the EGFR, 177 genes regulated via thrombin transactivation of 
the TGFBR1 and 212 genes regulated via dual transactivation of the EGFR and 
TGFBR1. 
Over the past two decades there have been studies expanding on GPCR 
mediated transactivation signalling of PTKR specifically the EGFR (Smiljanic 
et al., 2014, George et al., 2013, Wang, 2016). GPCR mediated transactivation 
dependent signalling also spans out to include activation of the TGFBR1. 
Although this pathway was first identified a decade ago (Jenkins et al., 2006) 
there has been a limited amount of studies investigating this transactivation 
pathway as compared to the EGFR transactivation dependent pathway. 
Interestingly the results of this RNA sequencing data show that transactivation 
dependent signalling via the TGFBR1 is equally as important as transactivation 
of the EGFR as there is a large number of genes regulated when CASMCs are 
treated with the respective receptor antagonists in the presence of thrombin.  
Of the total number of genes differentially regulated by the individual 
treatments a Venn diagram was composed to show commonly regulated genes 
between the individual transactivation dependent pathways (Figure 6.3). Of the 
209 genes differentially expressed in thrombin transactivation of the EGFR, 
there are 14 genes common to transactivation of TGFBR1 and 19 genes were 
found to be common in thrombin transactivation of the EGFR and in 
transactivation of both EGFR and TGFBR1. The genes differentially expressed 
by thrombin transactivation of the EGFR have 50 genes, which are not common 
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with either of the other two treatments (Figure 6.3). 177 genes that are 
differentially expressed via thrombin transactivation of the TGFBR1, 20 of these 
genes are in common with thrombin transactivation of both the EGFR and 
TGFBR1, and 17 genes are specific to transactivation of the TGFBR1. The three 
individual lists of differentially expressed genes from each of the transactivation 
pathways share 126 genes which are common. This shows that over 60% of the 
differentially expressed genes are common between the transactivation 
dependent signalling pathways. These results indicate that although these two 
transactivation dependent pathways are independent of each other and their 
activation are mechanistically distinct, they regulate over 60% of the same genes 
which may indicate that they may be involved in regulating common biological 
processes. 
There are a number of common downstream signalling intermediates 
which are common to both EGFR and TGFBR1 signalling. MAPKs such as Erk, 
p38 and Jnk are amongst the common signalling intermediates between the two 
pathways. MAPKs play a role in transmitting extracellular signals from cell 
surface receptors to intracellular target and are activated by both TGF-β (Yu et 
al., 2002, Gui et al., 2012, Yamaguchi et al., 1995, Zhang, 2009) and 
EGF.(Roberts and Der, 2007, Scaltriti and Baselga, 2006, Hong et al., 2014). 
Similarly other serine/threonine kinases such as PI3K and glycogen synthase 
kinase 3 are common downstream intermediates to both these signalling 
pathways (Scaltriti and Baselga, 2006, Moustakas and Heldin, 2005, Yi et al., 
2005, Osman et al., 2011, Guo et al., 2008, Mills et al., 2011). Thus common 
downstream signalling intermediates may allow for convergence; allowing for 
over 60% of differentially expressed genes to be common between the two 
pathways.  
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Chapter 5 of this thesis showed that phosphorylation of the linker region 
of transcription factor Smad2 was common to both transactivation signalling 
pathways (Figures 5.4 and 5.5). The phosphorylation of the Smad2 linker region 
has been shown to be activated by multiple serine/threonine kinases (Figure 5.9) 
(Rostam et al., 2016, Kamato et al., 2014a, Burch et al., 2010 , Alarcon et al., 
2009, Matsuura et al., 2004). The work from our lab (Burch et al., 2010 , 
Rostam et al., 2016) shows that the phosphorylation of the Smad2 linker region 
correlates with stimulation of proteoglycan synthesis and GAG chain 
elongation. Smad2 linker region phosphorylation has been associated with a 
diverse range of pathophysiological conditions. The Smad2 linker region has 
been associated with cancer (Kretzschmar et al., 1999, Matsuzaki et al., 2009, 
Suzuki et al., 2015), renal fibrosis (Sun et al., 2014), endothelial dysfunction 
(Kamato et al., 2014a), esophagitis mucosae (Takahashi et al., 2016) and 
inflammatory related diseases (Yoon et al., 2015). Thus showing that the Smad2 
linker region can also play as a common downstream convergence point for 
regulating various differentially expressed genes mediated via transactivation 
dependent signalling.     
The differential expression data was divided into the up and down 
regulated genes of each of the transactivation pathways. The Venn diagram in 
Figure 6.4 illustrates that from the 80 genes up regulated in thrombin 
transactivation of EGFR, 19 genes are also commonly up regulated in thrombin 
transactivation of the TGFBR1. There are 129 genes that are down regulated via 
thrombin transactivation of the EGFR and of this gene list 108 are commonly 
down regulated in thrombin mediated transactivation of the TGFBR1. 
Interestingly there are 13 genes which are up regulated in thrombin 
transactivation of the EGFR and down regulated in transactivation of the 
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TGFBR1 (Figure 6.4). These results show that over 80% of the genes down 
regulated by either pathway are common with only 33% of EGFR mediated 
transactivation dependent signalling to be specific to EGFR and 20% specific to 
only TGFBR1 transactivation. 
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Figure 6.2: Number of genes regulated by thrombin transactivation of the 
EGFR and TGFBR1 or both. 
Thrombin compared to basal treatment has a total of 293 genes up regulated. 
Thrombin transactivation of the EGFR denoted by thrombin in the presence of 
EGFR antagonist AG1478 has a total of 209 genes differentially regulated (80 
up regulated and 129 down regulated). Thrombin transactivation of TGFBR1 
denoted by thrombin in the presence of TGFBR1 antagonist SB431542 has a 
total of 177 genes differentially regulated (26 up regulated and 151 down 
regulated). Thrombin transactivation of both EGFR and TGFBR1 results in 212 
genes differentially regulated (46 up regulated and 166 down regulated).  
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Figure 6.3: Venn diagram showing the differentially expressed genes of 
each of the treatments. 
Thrombin transactivation of the EGFR (209 genes), thrombin transactivation of 
the TGFBR1 (177 genes) and thrombin transactivation of both EGFR and 
TGFBR1 (212 genes).  
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Figure 6.4: Venn diagram showing the genes up and down regulated by 
each of the transactivation dependent signalling pathways. 
209 genes are differentially expressed via thrombin transactivation of the EGFR 
(80 upregulated and 129 down regulated) and 177 genes are differentially 
expressed via thrombin transactivation of the TGFBR1 (26 upregulated and 141 
down regulated). 
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6.3.3 Genes most up and down regulated by the individual 
transactivation dependent pathways. 
 
Overall, there were 209 genes differentially regulated by thrombin 
transactivation of the EGFR (Figure 6.2). The top 10 up regulated genes are 
involved in molecular functions such as cytokine activity which controls cell 
growth, survival and differentiation as well as genes which are involved in 
transcription factor activity (Table 6.1). The top most down regulated genes via 
EGFR transactivation are involved in receptor protein activity and protein 
kinase binding (Table 6.1).  
There were a total of 177 genes regulated by thrombin transactivation of 
the TGFBR1 (Table 6.2). The top 10 most upregulated genes include genes 
which were associated with GTP-binding including TUBB2A, TUBB4B and 
TUBA1C (Table 6.2). Also included in the top most up regulated genes by 
thrombin transactivation of the TGFBR1 were genes associated with 
phospholipid binding and phosphatase activity. The majority of the genes down 
regulated by this transactivation dependent pathway include genes which were 
associated with transcription factor activity (Table 6.2). 
Treatment with the two receptor antagonists to account for all the 
transactivation dependent signalling resulted in 212 genes differentially 
expressed. The top 10 most upregulated genes of this transactivation pathway 
were associated with transcription factor activity, cytokine activity and receptor 
binding activity (Table 6.3). From the list of differentially expressed genes 
occurring via the transactivation of both receptors the most down regulated 
genes are associated with receptor protein and cytokine activity.  
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Interestingly many of the top 10 up and down regulated genes are 
common between the three treatments. NR4A1, CCL20 and IL6 are amongst the 
top 10 most up regulated genes in thrombin transactivation of the EGFR (Table 
6.1) and the genes regulated via dual transactivation dependent pathways (Table 
6.3). These genes are involved in regulating transcription factor, cytokine and 
growth factor activity. The SERPINB2 and the EGR1 are common in the top up 
regulated genes in thrombin transactivation of EGFR (Table 6.1) and TGFBR1 
(Table 6.2). Interestingly although these two genes are in the top upregulated 
genes of each of the transactivation dependent pathways when the two receptor 
antagonists were used together these genes did not appear to be in the top 10 
most upregulated genes. 
In the top most down regulated genes of each of the treatments there 
were more than 70% commonly expressed genes. FGL2, PGCC, IL11, MALL, 
LRRc38 and EDN1 are common in the top 10 most down regulated genes 
dependent on transactivation of the EGFR, TGFBR1 or both (Tables 6.1, 6.2 
and 6.3). These genes are commonly associated with cytokine activity and 
receptor binding. The NR4A2 and NR4A3 genes are common in the top 10 most 
down regulated genes in thrombin transactivation of TGFBR1 (Table 6.2) and 
transactivation of the EGFR (Table 6.1), interestingly when the two receptor 
antagonists were applied together (Table 6.3) these two genes are amongst the 
top most up regulated genes. The NR4A1 gene found in the most up regulated 
genes in thrombin transactivation of the EGFR (Table 6.1) and dual 
transactivation (Table 6.3) is amongst the top most down regulated gene via 
thrombin transactivation of the TGFBR1 (Table 6.1). Similarly, the PDGFB and 
the AREG genes associated with protein hetrodimerization and EGFR binding 
respectively were found in the top 10 most down regulated genes in the dual 
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transactivation dependent signalling (Table 6.3) and in the top 10 most up 
regulated genes in thrombin transactivation of the EGFR alone (Table 6.1). 
These results show that while genes may be up/down regulated when the dual 
transactivation pathways are activated, the genes may act opposing in the 
presence of a single receptor antagonist thus showing the complex nature of 
transactivation dependent signalling.  
In ovarian cancer cells the ET-1 receptor transactivates the EGFR 
(Vacca et al., 2000, Rosano et al., 2007) and the vascular endothelial growth 
factor receptor (Spinella et al., 2013) leading to the expression of EDN1. The 
expression of EDN1 has also been shown to be involved in colon and prostate 
cancer cell lines (Kim et al., 2005, Sun et al., 2006). EDN1 is one of the most 
down regulated genes in thrombin mediated transactivation of the TGFBR1 
(Table 6.2) and is highly down regulated in the presence of receptor antagonists 
to both transactivation receptor pathways (Table 6.3). The role of EDN1 in 
GPCR mediated transactivation of S/TKR is unknown however EDN1 has a 
binding site for TGF-β activated Smad transcription factor (Stow et al., 2011). In 
palate development TGF-β treatment increased the expression of EDN1 (Zhu et 
al., 2012), thus consistent with our results which show that thrombin can 
transactivate the TGFBR1 which is involved in the regulation of EDN1. Thus 
showing that thrombin transactivation of the TGFBR1 and EGFR has the 
potential to be involved in growth related diseases such as cancer and palate 
development.  
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Table 6.1: Genes most up regulated and down regulated by thrombin 
transactivation of the EGFR. 
Most Up regulated 
Gene ID Gene  Gene Title Thr Thr+AG 
ENSG00000123358 NR4A1 Nuclear receptor subfamily 4 
group A member 1 
14.02 19.63 
ENSG00000100311 PDGFB Platelet-Derived Growth Factor 
Beta Polypeptide 
6.74 7.05 
ENSG00000109321 AREG Amphiregulin 6.87 6.92 
ENSG00000115009 CCL20 Chemokine (C-C Motif) Ligand 
20 
4.67 6.42 
ENSG00000197632 SERPINB
2 
Serpin Peptidase Inhibitor, Clade 
B (Ovalbumin), Member 2 
1.34 5.01 
ENSG00000136244 IL6 Interleukin 6 3.82 4.63 
ENSG00000154319 FAM167A Family With Sequence 
Similarity 167, Member A 
3.08 4.38 
ENSG00000120738 EGR1 Early Growth Response 1 1.39 4.30 
ENSG00000117525 F3 Coagulation Factor III 
(Thromboplastin, Tissue Factor) 
2.27 3.83 
ENSG00000168389 MFSD2A  Major Facilitator Superfamily 
Domain Containing 2A 
1.41 3.59 
Most down regulated 
Gene ID Gene  Gene Title Thr Thr+AG 
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.22 3.12 
ENSG00000153234 NR4A2 Nuclear receptor subfamily 4 
group A member 2 
9.09 8.15 
ENSG00000102760 RGCC Regulator Of Cell Cycle 8.99 4.09 
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4 
group A member 3 
8.11 4.92 
ENSG00000095752 IL11 Interleukin 11 6.14 3.03 
ENSG00000144063 MALL Mal, T-Cell Differentiation 
Protein-Like 
5.81 1.16 
ENSG00000162494 LRRC38 Leucine Rich Repeat Containing 
38 
5.48 3.87 
ENSG00000078401 EDN1 Endothelin 1 5.17 1.02 
ENSG00000111859 NEDD9 Neural Precursor Cell 
Expressed, Developmentally 
Down-Regulated 9 
4.92 2.06 
ENSG00000106278 PTPRZ1 Protein Tyrosine Phosphatase, 
Receptor-Type, Z Polypeptide 1 
4.57 1.03 
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Table 6.2: Genes most up regulated and down regulated by thrombin 
transactivation of the TGFBR1. 
Most Up regulated 
Gene ID Gene  Gene Title Thr Thr+SB 
ENSG00000171246 NPTX1 Neuronal Pentraxin I 1.62 6.26 
ENSG00000197632 SERPINB
2 
Serpin Peptidase Inhibitor, Clade B 
(Ovalbumin), Member 2 
1.34 4.68 
ENSG00000120738 EGR1 Early Growth Response 1 1.39 4.55 
ENSG00000168389 MFSD2A Major Facilitator Superfamily 
Domain Containing 2A 
1.41 3.28 
ENSG00000137267 TUBB2A Tubulin, Beta 2A Class Iia 2.38 3.16 
ENSG00000138166 DUSP5 Dual Specificity Phosphatase 5 1.46 3.12 
ENSG00000188229 TUBB4B Tubulin, Beta 4B Class Ivb 1.67 2.90 
ENSG00000167553 TUBA1C Tubulin, Alpha 1c 1.99 2.85 
ENSG00000173641 HSPB7 Heat Shock 27kDa Protein Family, 
Member 7 (Cardiovascular) 
1.45 2.66 
ENSG00000128228 SDF2L1 Stromal Cell-Derived Factor 2-
Like 1 
1.41 2.61 
Most down regulated 
Gene ID Gene  Gene Title Thr Thr+SB 
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.26 4.43 
ENSG00000123358 NR4A1 Nuclear receptor subfamily 4 group 
A member 1 
14.07 10.21 
ENSG00000153234 NR4A2 Nuclear receptor subfamily 4 group 
A member 2 
9.11 3.93 
ENSG00000102760 RGCC Regulator Of Cell Cycle 9.00 2.59 
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4 group 
A member 3 
8.12 3.24 
ENSG00000100311 PDGFB Platelet-Derived Growth Factor 
Beta Polypeptide 
6.76 1.31 
ENSG00000095752 IL11 Interleukin 11 6.16 0.84 
ENSG00000144063 MALL Mal, T-Cell Differentiation 
Protein-Like 
5.81 1.84 
ENSG00000162494 LRRC38 Leucine Rich Repeat Containing 
38 
5.50 2.46 
ENSG00000078401 EDN1 Endothelin 1 5.18 0.46 
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Table 6.3: Genes most up regulated and down regulated by thrombin 
transactivation of the TGFBR1 and EGFR in vascular smooth muscle cells. 
Most Up regulated 
Gene ID Gene Gene Title Thr Thr+AG+SB 
ENSG00000123358 NR4A1 
Nuclear receptor subfamily 4 
group A member 1 
14.05 16.91 
ENSG00000153234 NR4A2 
Nuclear receptor subfamily 4 
group A member 2 
9.10 20.95 
ENSG00000119508 NR4A3 
Nuclear receptor subfamily 4 
group A member 3 
8.12 7.14 
ENSG00000115009 CCL20 
Chemokine (C-C Motif) 
Ligand 20 
4.69 6.88 
ENSG00000136244 IL6 Interleukin 6 3.83 4.50 
ENSG00000073756 PTGS2 
Prostaglandin-Endoperoxide 
Synthase 2  
3.33 3.81 
ENSG00000146374 RSPO3 R-Spondin 3 2.50 2.74 
ENSG00000115008 IL1A Interleukin 1, Alpha 2.45 2.73 
ENSG00000143878 RHOB 
Ras Homolog Family 
Member B 
2.42 2.70 
ENSG00000088826 SMOX Spermine Oxidase 2.14 2.21 
Most down regulated 
Gene ID Gene Gene Title Thr Thr+AG+SB 
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.26 4.14 
ENSG00000102760 RGCC Regulator Of Cell Cycle 9.00 3.48 
ENSG00000109321 AREG Amphiregulin 6.89 3.93 
ENSG00000100311 PDGFB 
Platelet-Derived Growth 
Factor Beta Polypeptide 
6.75 2.82 
ENSG00000095752 IL11 Interleukin 11 6.16 1.51 
ENSG00000144063 MALL 
Mal, T-Cell Differentiation 
Protein-Like 
5.81 1.65 
ENSG00000162494 LRRC38 
Leucine Rich Repeat 
Containing 38 
5.51 1.56 
ENSG00000078401 EDN1 Endothelin 1 5.19 0.55 
ENSG00000111859 NEDD9 
Neural Precursor Cell 
Expressed, Developmentally 
Down-Regulated 9 
4.93 1.61 
ENSG00000106278 PTPRZ1 
Protein Tyrosine 
Phosphatase, Receptor-Type, 
Z Polypeptide 1 
4.59 1.23 
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6.3.4 Biological processes regulated by the transactivation 
dependent pathways 
 
One of the objectives of this RNA-sequencing work was to determine the 
biological terms enriched by the transactivation dependent pathways. In order to 
examine the biological processes influenced by each of the transactivation 
pathways, genes differentially expressed by the different treatments were 
subjected to functional enrichment analysis based on their gene ontology (GO) 
annotations. From the 209 differentially expressed genes by thrombin 
transactivation of the EGFR there was 512 GO terms with a false discovery rate 
(FDR) value of less than 0.05. The top 50 biological terms occurring via 
thrombin transactivation of the EGFR are listed in Table 6.4. There was a total 
of 177 genes differentially regulated by thrombin transactivation of the 
TGFBR1, from this gene list 428 GO terms with an FDR value of less than 0.05. 
The top 50 biological terms from the 428 genes associated with thrombin 
transactivation of the TGFBR1 listed in Table 6.5. Treatment with two receptor 
antagonists to account for all the transactivation dependent signalling resulted in 
212 differentially expressed genes. From this list of genes 440 terms were 
enriched by dual transactivation dependent signalling. The top 50 GO terms 
respective to this signalling cascade are listed in Table 6.6.  
From the lists of the top 50 processes most significantly enriched by 
transactivation dependent signalling, 28 terms were found to be common 
between the three lists (Table 6.4, 6.5 and 6.6). Many of these GO terms are 
associated with regulation of cell activity as well as terms which are associated 
with vascular development. This includes development of the cardiovascular 
system, circulatory system, vasculature and blood vessel. From the list of 50 
terms associated with dual transactivation dependent signalling (Table 6.6) five 
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enriched terms were common to thrombin transactivation of the TGFBR1 (Table 
6.5). The common terms include biological processes which are involved in cell 
growth, cell death and tissue development. Similarly there are five GO terms 
which are common to dual transactivation dependent signalling (Table 6.6) and 
thrombin transactivation of the EGFR (Table 6.4). Terms common to these two 
lists include biological processes associated with the regulation of angiogenesis, 
vasculature development and blood vessel morphogenesis as well as terms 
involved in cellular activity. When comparing the terms regulated by 
transactivation of the TGFBR1 (Table 6.5) and the EGFR (Table 6.4) there are 5 
GO terms which are common to these two pathways which were not found in 
the top 50 list of terms via dual transactivation (Table 6.6). These 5 terms are 
associated with regulation of metabolic processes and signal transduction. 
Furthermore, network analysis was conducted using String DB, Figure 6.5, 6.6 
and 6.7 show the networks over represented in the gene list of the respective 
transactivation dependent pathways.  
The results above show that thrombin transactivation of the EGFR, 
TGFBR1 or both receptors are involved in regulating a large number of 
biological processes 512, 428 and 440 terms, respectively. With the two 
transactivation dependent pathways being mechanistically distinct (Burch et al., 
2013), the results of these experiments show that over 55% of the top 50 terms 
regulated are common between the three treatments. Over 60% of the 
differentially expressed genes described in section 6.3.2 were common to both 
thrombin mediated transactivation of the TGFBR1 and transactivation of the 
EGFR. The common differentially expressed genes resulted in over 55% 
biological terms, which are common between both transactivation pathways. 
The commonality between the two individual pathways is due the EGFR 
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pathway sharing common downstream signalling intermediates with the 
TGFBR1 downstream pathway. Serine/threonine kinases such as MAPKs (Yu et 
al., 2002, Gui et al., 2012, Yamaguchi et al., 1995, Zhang, 2009) are one of 
many common downstream intermediates to both the transactivation dependent 
pathways and may play a role in the convergence of the two signalling pathways 
to regulate the same biological processes.  
Our lab has focused on GAG elongation because of its associated with 
atherosclerosis but also because signalling pathways for GAG elongation are 
distinct from there signalling common responses such as protein signalling and 
cell proliferation (Little et al., 2010, Burch et al., 2010, Burch et al., 2013, 
Ghiselli and Maccarana, 2016). Never the less GAG elongation has also 
proceeded to be an excellent response to characterise transactivation dependent 
signalling and in that context our work has shown how transactivation 
dependent signalling makes a major contribution to PAR-1 signalling.  
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Table 6.4: Gene ontology terms in the analysis of genes expressed in 
thrombin transactivation of the EGFR 
GO ID GO Term Count FDR 
GO.0051272 positive regulation of cellular component movement 24 3.87E-10 
GO.0070887 cellular response to chemical stimulus 57 4.94E-10 
GO.0071310 cellular response to organic substance 51 4.94E-10 
GO.1901342 regulation of vasculature development 19 4.94E-10 
GO.2000147 positive regulation of cell motility 23 4.94E-10 
GO.0051094 positive regulation of developmental process 38 1.15E-09 
GO.0030335 positive regulation of cell migration 22 1.51E-09 
GO.0045765 regulation of angiogenesis 17 6.90E-09 
GO.2000145 regulation of cell motility 28 7.31E-09 
GO.0030334 regulation of cell migration 27 8.80E-09 
GO.1904018 positive regulation of vasculature development 14 8.80E-09 
GO.0009653 anatomical structure morphogenesis 51 1.09E-08 
GO.0051270 regulation of cellular component movement 29 1.32E-08 
GO.0051239 regulation of multicellular organismal process 54 1.85E-08 
GO.0042981 regulation of apoptotic process 40 1.89E-08 
GO.0043067 regulation of programmed cell death 40 2.16E-08 
GO.0001568 blood vessel development 23 2.38E-08 
GO.0050793 regulation of developmental process 50 2.41E-08 
GO.0022603 regulation of anatomical structure morphogenesis 31 2.59E-08 
GO.0042127 regulation of cell proliferation 41 2.59E-08 
GO.0001944 vasculature development 23 5.07E-08 
GO.0072358 cardiovascular system development 29 7.69E-08 
GO.0072359 circulatory system development 29 7.69E-08 
GO.0040012 regulation of locomotion 27 9.01E-08 
GO.0051240 positive regulation of multicellular organismal process 38 9.01E-08 
GO.0010033 response to organic substance 53 1.83E-07 
GO.0048514 blood vessel morphogenesis 20 1.88E-07 
GO.0051726 regulation of cell cycle 31 1.93E-07 
GO.0042221 response to chemical 68 2.21E-07 
GO.0048468 cell development 41 2.60E-07 
GO.0045766 positive regulation of angiogenesis 12 2.79E-07 
GO.0048583 regulation of response to stimulus 63 2.79E-07 
GO.0014070 response to organic cyclic compound 28 2.83E-07 
GO.0008284 positive regulation of cell proliferation 28 2.92E-07 
GO.0071407 cellular response to organic cyclic compound 19 3.23E-07 
GO.0071840 cellular component organization or biogenesis 79 5.43E-07 
GO.0010941 regulation of cell death 38 7.50E-07 
GO.0032879 regulation of localization 49 7.79E-07 
GO.0001525 angiogenesis 17 1.04E-06 
GO.0051128 regulation of cellular component organization 47 1.04E-06 
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GO.0009966 regulation of signal transduction 50 1.23E-06 
GO.0006928 movement of cell or subcellular component 35 1.73E-06 
GO.2000026 regulation of multicellular organismal development 38 1.86E-06 
GO.0043065 positive regulation of apoptotic process 22 2.16E-06 
GO.0065009 regulation of molecular function 53 2.16E-06 
GO.0071495 cellular response to endogenous stimulus 30 2.37E-06 
GO.0019220 regulation of phosphate metabolic process 37 3.60E-06 
GO.0009605 response to external stimulus 42 3.92E-06 
GO.0048519 negative regulation of biological process 70 4.03E-06 
GO.1902531 regulation of intracellular signal transduction 35 4.43E-06 
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Figure 6.5: Network represents the protein-protein interactions involved in 
thrombin transactivation of the EGFR.  
The functions of this network include biological processes, molecular functions 
and cellular component. The colour of the nodes indicates the query protein and 
its first shell of interactions. Protein nodes which are enlarged indicate the 
availability of 3D protein structure information. The coloured lines between the 
nodes indicate the query protein-protein interactions. The known interactions us 
a light blue (from curated database) or pink (experimentally determined) lines 
between the proteins. The predicted interactions use green (gene 
neighbourhood), red (gene fusions) and dark blue (gene co-occurrence). The 
yellow represents text mining, the black represents co-expression and the light 
purple lines represent protein homology.      
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Table 6.5: The top 50 Gene ontology terms in the analysis of genes 
expressed in thrombin transactivation of the TGFBR1.  
GO ID GO Term Count FDR 
GO.0051094 positive regulation of developmental process 34 1.63E-08 
GO.0009653 anatomical structure morphogenesis 46 1.66E-08 
GO.0030334 regulation of cell migration 25 1.66E-08 
GO.0070887 cellular response to chemical stimulus 48 1.66E-08 
GO.0071310 cellular response to organic substance 43 1.66E-08 
GO.0072358 cardiovascular system development 28 1.66E-08 
GO.0072359 circulatory system development 28 1.66E-08 
GO.0019220 regulation of phosphate metabolic process 37 8.63E-08 
GO.0031399 regulation of protein modification process 38 8.63E-08 
GO.0051239 regulation of multicellular organismal process 47 9.10E-08 
GO.0048468 cell development 38 1.03E-07 
GO.1902531 regulation of intracellular signal transduction 35 1.04E-07 
GO.0030335 positive regulation of cell migration 18 1.35E-07 
GO.0051270 regulation of cellular component movement 25 1.42E-07 
GO.0048519 negative regulation of biological process 65 2.26E-07 
GO.0042981 regulation of apoptotic process 34 2.67E-07 
GO.0040012 regulation of locomotion 24 2.81E-07 
GO.0043067 regulation of programmed cell death 34 2.81E-07 
GO.0009888 tissue development 36 3.06E-07 
GO.0030154 cell differentiation 53 4.72E-07 
GO.0051240 positive regulation of multicellular organismal process 33 4.72E-07 
GO.0050793 regulation of developmental process 42 4.79E-07 
GO.1901342 regulation of vasculature development 14 5.83E-07 
GO.0007507 heart development 19 7.20E-07 
GO.0045597 positive regulation of cell differentiation 25 7.20E-07 
GO.0009966 regulation of signal transduction 45 7.39E-07 
GO.0009892 negative regulation of metabolic process 46 8.03E-07 
GO.0065009 regulation of molecular function 48 8.03E-07 
GO.0042221 response to chemical 58 1.34E-06 
GO.0042325 regulation of phosphorylation 31 1.34E-06 
GO.0048583 regulation of response to stimulus 54 1.34E-06 
GO.0010033 response to organic substance 45 1.48E-06 
GO.0044057 regulation of system process 18 1.60E-06 
GO.0051128 regulation of cellular component organization 41 2.63E-06 
GO.0051726 regulation of cell cycle 26 3.13E-06 
GO.0016477 cell migration 23 3.49E-06 
GO.0001932 regulation of protein phosphorylation 29 3.61E-06 
GO.0045937 positive regulation of phosphate metabolic process 26 3.67E-06 
GO.0001568 blood vessel development 18 3.71E-06 
GO.0048869 cellular developmental process 52 4.09E-06 
GO.0050790 regulation of catalytic activity 41 4.57E-06 
GO.0071407 cellular response to organic cyclic compound 16 4.58E-06 
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GO.2000026 regulation of multicellular organismal development 33 5.80E-06 
GO.0048523 negative regulation of cellular process 58 5.83E-06 
GO.0051246 regulation of protein metabolic process 43 6.58E-06 
GO.0001944 vasculature development 18 6.70E-06 
GO.0042127 regulation of cell proliferation 32 7.24E-06 
GO.0010941 regulation of cell death 32 7.49E-06 
GO.0014070 response to organic cyclic compound 23 7.63E-06 
GO.0006928 movement of cell or subcellular component 30 8.32E-06 
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Figure 6.6: Network represents protein-protein interactions involved in 
thrombin transactivation of the TGFBR1. 
The colour of the nodes indicates the query protein and its first shell of 
interactions. Protein nodes which are enlarged indicate the availability of 3D 
protein structure information. The coloured lines between the nodes indicate the 
query protein-protein interactions. The known interactions us a light blue (from 
curated database) or pink (experimentally determined) lines between the 
proteins. The predicted interactions use green (gene neighbourhood), red (gene 
fusions) and dark blue (gene co-occurrence). The yellow represents text mining, 
the black represents co-expression and the light purple lines represent protein 
homology. 
  
 Chapter-6. Transactivation dependent RNA Sequencing Page 274 
Table 6.6: Top 50 Gene ontology terms in the analysis of genes expressed in 
thrombin transactivation of both the EGFR and TGFBR1. 
GO ID GO Term Count FDR 
GO.0070887 cellular response to chemical stimulus 63 1.11E-12 
GO.0071310 cellular response to organic substance 56 1.11E-12 
GO.0051094 positive regulation of developmental process 39 9.25E-10 
GO.0010033 response to organic substance 58 4.30E-09 
GO.0030334 regulation of cell migration 28 4.30E-09 
GO.0042221 response to chemical 74 4.30E-09 
GO.0048468 cell development 45 1.04E-08 
GO.0072358 cardiovascular system development 31 1.08E-08 
GO.0072359 circulatory system development 31 1.08E-08 
GO.0051240 positive regulation of multicellular organismal process 40 2.15E-08 
GO.0042981 regulation of apoptotic process 40 4.01E-08 
GO.0051239 regulation of multicellular organismal process 54 4.01E-08 
GO.0043067 regulation of programmed cell death 40 4.27E-08 
GO.0050793 regulation of developmental process 50 5.47E-08 
GO.0030335 positive regulation of cell migration 20 6.37E-08 
GO.0051270 regulation of cellular component movement 28 8.18E-08 
GO.0071407 cellular response to organic cyclic compound 20 1.08E-07 
GO.0071495 cellular response to endogenous stimulus 33 1.14E-07 
GO.1901342 regulation of vasculature development 16 1.21E-07 
GO.0009653 anatomical structure morphogenesis 49 1.22E-07 
GO.0014070 response to organic cyclic compound 29 1.22E-07 
GO.0040012 regulation of locomotion 27 1.27E-07 
GO.0001568 blood vessel development 22 1.37E-07 
GO.0051726 regulation of cell cycle 31 2.93E-07 
GO.0048519 negative regulation of biological process 74 3.54E-07 
GO.0010941 regulation of cell death 39 4.20E-07 
GO.0045597 positive regulation of cell differentiation 28 5.27E-07 
GO.0048522 positive regulation of cellular process 74 1.00E-06 
GO.0048518 positive regulation of biological process 81 1.01E-06 
GO.0042127 regulation of cell proliferation 38 1.22E-06 
GO.0051716 cellular response to stimulus 90 1.38E-06 
GO.0001944 vasculature development 21 1.41E-06 
GO.0060548 negative regulation of cell death 29 1.41E-06 
GO.0051241 negative regulation of multicellular organismal process 30 1.45E-06 
GO.1901698 response to nitrogen compound 28 1.95E-06 
GO.0045765 regulation of angiogenesis 14 1.97E-06 
GO.0009892 negative regulation of metabolic process 51 2.92E-06 
GO.0048583 regulation of response to stimulus 61 3.06E-06 
GO.0032879 regulation of localization 48 3.55E-06 
GO.0009888 tissue development 38 3.89E-06 
GO.0009890 negative regulation of biosynthetic process 36 4.25E-06 
GO.0033993 response to lipid 26 4.25E-06 
 Chapter-6. Transactivation dependent RNA Sequencing Page 275 
GO.0043069 negative regulation of programmed cell death 27 4.39E-06 
GO.0051128 regulation of cellular component organization 46 4.39E-06 
GO.0010629 negative regulation of gene expression 36 4.58E-06 
GO.0044057 regulation of system process 19 4.88E-06 
GO.0048514 blood vessel morphogenesis 18 5.31E-06 
GO.0022603 regulation of anatomical structure morphogenesis 27 5.70E-06 
GO.1904018 positive regulation of vasculature development 11 5.71E-06 
GO.0010632 regulation of epithelial cell migration 12 5.80E-06 
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Figure 6.7: Network represents protein-protein interactions involved in 
thrombin transactivation of both the EGFR and TGFBR1. 
The colour of the nodes indicates the query protein and its first shell of 
interactions. Protein nodes which are enlarged indicate the availability of 3D 
protein structure information. The coloured lines between the nodes indicate the 
query protein-protein interactions. The known interactions us a light blue (from 
curated database) or pink (experimentally determined) lines between the 
proteins. The predicted interactions use green (gene neighbourhood), red (gene 
fusions) and dark blue (gene co-occurrence). The yellow represents text mining, 
the black represents co-expression and the light purple lines represent protein 
homology. 
6.3.5 Transactivation dependent signalling is associated with 
genes regulating vasculature development. 
 
In order to more clearly assess the processes influenced by 
transactivation dependent signalling, the differentially expressed genes were 
subjected to functional enrichment analysis based on their GO annotations as 
described in Section 6.3.4. The processes most commonly enriched by the three 
treatments were linked with vascular development. There were 29 genes 
associated with cardiovascular system development in thrombin transactivation 
of the EGFR (Table 6.4); 28 genes in thrombin transactivation of the TGFBR1 
(Table 6.5) and 31 genes in thrombin transactivation of both the TGFBR1 and 
EGFR (Table 6.6). Table 6.7 shows gene expression data for significantly 
regulated genes categorized as cardiovascular system development 
(GO.0072358). All the genes were up regulated by thrombin when compared to 
basal and down regulated in the presence of AG1478 with the exception of 
EGR1, HES1, NR4A1, PDGFB, RHOB, SPHK1 and TIPARP (Table 6.7). In 
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the presence of thrombin and TGFBR1 antagonist, SB431542, most of the genes 
associated with cardiovascular system development were down regulated with 
the exception of EGR1 and TIPARP (Table 6.7). When looking at dual 
transactivation dependent signalling associated with cardiovascular system 
development all genes apart from EGR1, HES1 ID1, KLFS, NR4A1, PTGS2 
and RHOB were down regulated as compared to thrombin stimulation alone 
(Table 6.7). 
The EGR1 (early growth response 1) gene associated with 
cardiovascular system development was regulated by the three treatments when 
compared to thrombin (Table 6.7). EGR1 is involved in the development of 
atherosclerotic lesions and has been shown to play a role in regulating 
neointimal thickening in response to vascular injury (Blaschke et al., 2004, 
Harja et al., 2004, Khachigian et al., 1996, McCaffrey et al., 2000). The 
transactivation dependent signalling discussed in Chapter 4 in which treatment 
with antagonists to the EGFR and TGFBR1 inhibit thrombin mediated GAG 
elongation evaluated by the mRNA expression of CHST11 and CHSY1. 
However the RNA-Sequencing results show that with treatment of the receptor 
antagonists in the presence of the thrombin there is an increase in the expression 
of the EGR1 gene, this may be due to work in earlier chapters looking at the pre-
inflammatory phase of atherosclerosis. The EGR1 gene is commonly involved 
in the neointimal thickening which is in the inflammatory phase of 
atherogenesis.  
The ANKRD1 (Ankyrin Repeat Domain 1) gene belongs to the 
conserved muscle Ankyrin repeat family and is induced in response to 
inflammation, injury and response to cell stress (Miller et al., 2003, Jeyaseelan 
et al., 1997). The ANKRD1 gene is amongst the differentially expressed genes 
 Chapter-6. Transactivation dependent RNA Sequencing Page 279 
associated with vascular development. The ANKRD1 gene was involved in the 
transactivation of the EGFR and the TGFBR1 (Table 6.7). ANKRD1 is directly 
mediated via TGF-β mediated signalling as the ANKRD1 promotor region 
contains a Smad binding motif (Kanai et al., 2001, Labbe et al., 2007). The 
ANKRD1 gene is associated with the actin cytoskeleton signalling network 
(Ponsuksili et al., 2009), in Chapter 4 (Sections 4.3.3 and 4.3.4) of this thesis 
thrombin mediated transactivation of the TGFBR1 activates Rho/ROCK 
signalling via cytoskeletal rearrangement leading to the activation of cell surface 
integrins. Thus demonstrating a potential signalling pathway for the activation 
of the ANKRD1 gene via thrombin transactivation of the TGFBR1. The role of 
ANKRD1 downstream of the EGFR in unknown however ANKRD1 is induced 
by stress activated kinases (Zhong et al., 2015, Liang and Sheikh, 2016, Song et 
al., 2012) hence we speculate that thrombin mediated transactivation of the 
EGFR induces the expression of ANKRD1 via the activation of downstream 
stress activated MAPKs (Erk, p38 and Jnk). In Chapter 5 (refer to Figure 5.9) 
we show that thrombin mediated phosphorylation of the Smad2 linker region 
occurs via the transactivation of the EGFR and the TGFBR1 which activate 
downstream serine/threonine kinases including Erk, p38 and Jnk. Thus 
providing a potential signalling pathway in GPCR mediated activation of 
ANKRD1. 
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Table 6.7 List of genes and respective fold change of expression associated 
with gene ontology term cardiovascular development. 
The differentially expressed genes with no fold change presented in the table did 
not reach the statistical significance cut off (P<0.01 and Log2FC>0.7)  
Gene ID Gene Name Thr Thr+AG Thr+SB Thr+SB+AG 
ENSG00000148677 ANKRD1 3.514 0.612 0.962 0.352 
ENSG00000183337 BCOR 1.646   0.533 0.543 
ENSG00000118523 CTGF 2.662 1.251 0.901 0.933 
ENSG00000142871 CYR61 2.631 2.133 2.298 2.024 
ENSG00000164741 DLC1 1.755   0.731 0.901 
ENSG00000078401 EDN1 5.188 1.013 0.458 0.547 
ENSG00000120738 EGR1 1.394 4.249 4.505 3.684 
ENSG00000196159 FAT4 1.292   0.601   
ENSG00000176692 FOXC2 1.671     0.694 
ENSG00000170961 HAS2 2.047 0.544   0.293 
ENSG00000114315 HES1 3.058 3.152 1.154 3.115 
ENSG00000100644 HIF1A 1.471 0.639 0.627   
ENSG00000125968 ID1 4.482 0.626 0.775 0.194 
ENSG00000115738 ID2 1.302 0.544   0.337 
ENSG00000117318 ID3 3.315 1.153 0.814 0.549 
ENSG00000121361 KCNJ8 2.129 0.706 0.894 0.637 
ENSG00000102554 KLF5 2.679 1.933 2.141 2.690 
ENSG00000085276 MECOM 1.673 0.437 0.488 0.486 
ENSG00000164134 NAA15 1.639 0.793 0.804   
ENSG00000162614 NEXN 1.815 0.821 0.876 0.886 
ENSG00000086991 NOX4 2.015 0.566 0.347 0.423 
ENSG00000123358 NR4A1 14.061 19.477 10.102 16.838 
ENSG00000180914 OXTR 2.303 0.854 0.616 0.746 
ENSG00000138650 PCDH10 1.322 0.667 0.613 0.581 
ENSG00000100311 PDGFB 6.773 6.991 1.294 2.835 
ENSG00000073756 PTGS2 3.350 3.195 2.066 3.791 
ENSG00000127329 PTPRB 1.731     0.829 
ENSG00000143878 RHOB 2.416 2.434 1.028 2.691 
ENSG00000124216 SNAI1 1.783   0.650 1.174 
ENSG00000176170 SPHK1 2.078 2.630 1.731 1.424 
ENSG00000120156 TEK 1.936 0.543 0.549 0.576 
ENSG00000163659 TIPARP 1.416 2.162 2.084   
ENSG00000006327 TNFRSF12A 1.578   1.309   
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6.4 Conclusions 
 GPCRs are one of the most successful class of drugtargets on the human 
genome for the treatment of a variety of diseases (Fang et al., 2015, Stockert and 
Devi, 2015). Hence the role of GPCR signalling is of great interest to medical 
research. GPCRs signal in three main mechanisms, which includes signalling 
via G proteins to secondary messenger intermediates and via utilization of the 
signalling pathway and via the utilization of a β-arrestin molecule both which 
have been extensively reviewed (Tuteja, 2009, Ferguson et al., 1996). The third 
GPCR signalling pathway is via transactivation of PTKR and via transactivation 
of S/TKR. We subsequently described S/TKR transactivation but again the 
contribution to overall GPCR signalling was unknown. Hence in this present 
study, the aim was to determine the contribution of dual transactivation of 
GPCR mediated signalling by utilizing RNA sequencing to facilitate the 
identification of the genes regulated by these two transactivation pathways. 
Using this approach, we have uncovered that thrombin mediated signalling 
results in 293 differentially expressed genes of these genes approximately 50% 
of the signalling is occurring via transactivation dependent signalling. Using this 
approach we have also uncovered that transactivation of the TGFBR1 is as 
equally important as the transactivation of the EGFR noting that the TGFBR1 
transactivation pathway has not yet been as extensively researched. 
Hannan et al. (George et al., 2013) using a siRNA approach studied 720 
kinase genes associated with Angiotensin II transactivation of the EGFR. 
Knockdown of 3 genes, TRIO, BMX and CHKA revealed that their activity is 
required for Angiotensin II mediated transactivation of the EGFR in human 
mammary epithelial cells (George et al., 2013). This RNA-Seq sequencing study 
we explored all the genes that were involved in GPCR mediated transactivation 
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of the EGFR and TGFBR1 in human VSMCs. Although the two transactivation 
signalling pathways have been reported as to be mechanistically distinct (Burch 
et al., 2010, Burch et al., 2013) this study shows that these two pathways share 
in over 65% of the differentially expressed genes. The transactivation dependent 
signalling pathways shared in over 55% of its top 50 enriched terms, with a 
majority of these GO terms associated with cardiovascular system development.  
The two transactivation dependent signalling pathway share in over 65% 
of common differentially expressed genes. The top most regulated genes of 
these transactivation mediated pathways are involved in molecular functions 
such as cytokine activity which controls cell growth survival and differentiation. 
Cytokine activity is involved in different aspects of cancer, development, 
treatment and prognosis (Bower et al., 2002, Chen et al., 2013, Esquivel-
Velazquez et al., 2015). The EGFR (Normanno et al., 2006a, Normanno et al., 
2006b, Seshacharyulu et al., 2012) and the TGFBR1 (Pasche et al., 2014, 
Principe et al., 2014, Moore-Smith and Pasche, 2011) signalling pathways alone 
play a role in cancer development. Both the EGFR and TGFBR1 signalling 
pathways share a common transcription factor, Smad2 linker region. The Smad2 
linker region plays a role in cancer development (Kretzschmar et al., 1999, 
Matsuzaki et al., 2009, Suzuki et al., 2015). The Smad2 linker region is also 
associated with other pathophysiological conditions which include but are not 
limited to proteoglycan synthesis and GAG chain elongation associated with 
atherosclerosis development (Chapter 5) (Rostam et al., 2016, Burch et al., 2010 
). Thus showing that the linker region of the Smad2 may be a transcription 
factor of interest for to study different biological process occurring via thrombin 
mediated transactivation of both the EGFR and TGFBR1. 
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In summary by providing high throughput RNA-Seq data, we have 
identified that GPCR signalling via transactivation of either of the EGFR or 
TGFBR1 account for 50% of GPCR signalling. We have identified that these 
two pathways share in regulation of over 65% of genes of which a majority are 
involved in the development of the vasculature. This work provides the platform 
for investigating the molecular basis for transactivation dependent signalling and 
provides proof that genome wide studies can offer powerful insights into this 
process. 
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The current paradigm of GPCR signalling includes transactivation 
independent signalling, β-arrestin signalling and transactivation dependent 
signalling. The work in this thesis has focused on thrombin receptor, PAR-1, 
mediated transactivation of the TGFBR1 and EGFR in human VSMCs. 
Transactivation has been defined as “the agonist occupancy of its cognate GPCR 
complex which leads in a relatively short time and in the absences of ‘de novo’ 
protein synthesis to the activation of and cytosolic generation of the immediate 
downstream products of a second cell surface protein kinase receptor” (Little et 
al., 2011). Our group has shown that PAR-1 is involved in the transactivation of 
EGFR and the TGFBR1 leading to proteoglycan synthesis and GAG elongation 
(Burch et al., 2010). Proteoglycan synthesis and GAG elongation, are implicated 
in the initiation of atherosclerosis as modified proteoglycans show a higher 
binding affinity to LDL (Ivey and Little, 2008). Variation in the structure of 
proteoglycans either by an increase in chain length or a greater degree of 
sulphation is the main contributor that influences the binding towards lipids 
(Chait and Wight, 2000, Little et al., 2002). Therefore, preventing the alteration 
in proteoglycan synthesis and structure is proposed to be a potential therapeutic 
target for the prevention of atherosclerosis (Ballinger et al., 2004). Findings 
from this current study revealed that increased GAG synthesizing enzyme 
expression led to GAG chain hyperelongation on biglycan. Therefore, it is 
postulated that elevated GAG synthesizing enzyme expression is associated with 
an increased capacity of lipid binding by biglycan ultimately contributing to the 
development of atherosclerosis. For that reason, identifying the specific target 
and rate limiting enzymes and the signalling pathways that control this process 
is of utmost importance for the future treatment of atherosclerosis.  
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The first aim of this study was to identify whether PAR-1 mediated 
transactivation of the EGFR and TGFBR1 is involved in the regulating the 
expression of GAG synthesizing genes relevant to GAG chain hyperelongation 
and is addressed in Chapter 3. In human VSMCs, thrombin an agonist of the 
GPCR PAR-1, stimulates GAG chain hyperelongation via transactivation of the 
EGFR and TGFBR1 (Burch et al., 2013). Findings from this study showed that 
in VSMCs, thrombin stimulates the mRNA expression of CHST11, CHSY1 and 
CHST3 (Figure 3.2) via the transactivation of EGFR and TGFBR1 (Figure 3.5). 
In vivo studies show that in a CHSY1 knockout mouse model, the CS GAG 
chain synthesis was reduced (Wilson et al., 2012). In a CHST11 deficient mouse 
model there was a 90% decrease in GalNAc structure and CS amount 
(Izumikawa et al., 2011). Thus in the human VSMCs model thrombin mediated 
GAG hyperelongation requires CHSY1 regulation and the CHST11 is most 
likely the enzyme regulating the sulphation on the GAG chains. Hence thrombin 
mediated GAG chain hyperelongation associated with an increase in LDL 
binding would most likely require direct involvement of both genes. On the 
assumption that these agents are important in GAG synthesis and 
hyperelongation, and noting that Emoto and colleagues (Anggraeni et al., 2011) 
have reported an increase in the expression of CHST11 in the vessels of murine 
model of atherosclerosis, then we can speculate that the inhibition of the 
expression of these genes can prevent GAG hyperelongation, lipid deposition 
and atherosclerosis. It is important to note that we are focusing on preventing 
GAG chain hyperelongation by inhibiting the signalling pathways that cause the 
hyperelongation process rather than the fundamental processes of GAG 
elongation, a target which would most likely interfere with normal physiological 
processes. The two transactivation pathways signal via distinct mechanisms and 
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both pathways contribute to proteoglycan synthesis and GAG elongation hence 
lead to the second aim of this thesis to find a common signalling point to inhibit 
all transactivation dependent signalling. 
 Limited availability of antagonists to the GPCR Gαq proteins has 
restricted the study of their role in GPCR signalling. The Gαq family consists of 
four subunits, however the Gαq and the Gαq/11 are the most prominent and 
ubiquitously expressed in VSMCs and hence were the focus of this study. With 
an identical number of amino acids and an 88% homology at the protein level, 
Gαq and Gαq/11 would be expected to have similar if not identical functions. 
However in Chapter 4 we showed that PAR-1 mediated transactivation of EGFR 
and TGFBR1 leading to GAG elongation is regulated exclusively via Gαq. 
Although both isoforms were found to be present in human VSMCs at a similar 
expression level only knockdown of the Gαq, not the Gαq/11 inhibited 
transactivation dependent signalling. GPCR transactivation of both PTKR 
(Harada et al., 2014, Barauna et al., 2013, Jin et al., 2009, Taboubi et al., 2010) 
and S/TKR (Xu et al., 2009, Scotton et al., 2009, Deng et al., 2008) is dependent 
on Gαq signalling. The current knowledge in human VSMCs is that Gαq 
mediates all transactivation dependent signalling hence Gαq can play as a 
potential therapeutic target to prevent GAG hyperelongation which (Figure 7.1), 
under the “response to retention hypothesis” of atherosclerosis, is the initiating 
step in atherogenesis. Although of lesser importance than Gαq in PAR-1 
signalling it may be of interest to investigate the role of other G proteins such as 
the Gαi and Gαs in this model.  
Gαq signalling plays an important role in the vasculature (D'Angelo et 
al., 1997, Adams et al., 1998). The role of Gαq signalling has been shown to be 
important in platelet function (Uemura et al., 2006a), vascular contractions 
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(Uemura et al., 2006a, D'Angelo et al., 1997), arterial thrombosis (Kawasaki et 
al., 2005, Kawasaki et al., 2003), neointimal formation (Kawasaki et al., 2005) 
and cardiac hypertrophy (Dorn and Force, 2005, Keys et al., 2002, Adams et al., 
1998). The findings from this current study support the involvement of the Gαq 
protein in mediating the progression of atherosclerosis through the role of Gαq 
in GAG chain hyperelongation. This work outlines that Gαq is the central 
integrating point of transactivation dependent signalling and a potential 
therapeutic target during atherogenesis (Figure 7.1). Hence, there is a need for 
the development of a small chemical entity that targets GPCR mediated Gαq 
signalling.  
Our group has shown that PDGF inhibitor, imatinib, when administered 
to ApoE knockout mice fed high fat diet, reduced lesion size in the aortic arch of 
the mice (Ballinger et al., 2010). Imatinib treatment also inhibited GAG chain 
synthesis and reduced LDL binding to proteoglycans in vitro (Ballinger et al., 
2010). Hence a small chemical entity, which inhibits GPCR mediated Gαq 
signalling should be studied in vivo in a high fat fed atherosclerotic mouse 
model to establish the role of Gαq in early atherosclerotic development 
occurring via transactivation dependent signalling. Supporting this future study 
is the work by Soto (Soto et al., 2012) and colleagues, which showed that 
targeting proteoglycans is efficacious in preventing lesion progression in vivo. A 
chimeric mouse/human IgG1 monoclonal antibody that recognizes pro-
atherogenic CS GAG chains was shown to dose dependently interfere with LDL 
binding to CS GAGs in vitro (Soto et al., 2012). This is an alternative approach 
to ours demonstrating the validity of our overall approach. The antibody also 
affected lesion state in vivo.  
 Chapter-7. General discussion Page 289 
Proteoglycan synthesis and GAG chain elongation are dependent on 
Smad2 linker region phosphorylation in human VSMCs (Burch et al., 2010 ). 
Erk and p38 are involved in TGF-β mediated phosphorylation of the 3 serine 
residues of the Smad2 linker region. The Erk and p38 kinases are also shown to 
be involved in TGF-β mediated proteoglycan synthesis and GAG chain 
elongation (Burch et al., 2010 ). Thrombin is a well characterized agonist which 
drives the pathways that result in proteoglycan modification (Ivey and Little, 
2008, Burch et al., 2010) In human VSMCs thrombin mediated proteoglycan 
synthesis and GAG chain elongation is via the transactivation of the EGFR and 
the TGFBR1 (Chapter 3)(Burch et al., 2013). In human VSMCs, Smad2 linker 
region phosphorylation mediates proteoglycan synthesis and GAG chain 
elongation hence the Smad2 linker region can play as an important integrating 
point that can allow cross talk between various receptor-signalling pathways. 
The signalling pathway of thrombin mediated up regulation of CHSY1 and 
CHST11 mRNA expression involved Erk, p38, PI3K and CDK but not Jnk 
(Figure 5.3 Section 5.3.8). These kinases are important regulators of 
atherosclerosis (Rivard and Andres, 2000, Senokuchi et al., 2004, Elkhawad et 
al., 2012, Hu et al., 2000, Fougerat et al., 2009). Of these kinases Erk, p38, Jnk 
and PI3K have been shown to be downstream of Gαq signalling (Cramer et al., 
2001, Esposito et al., 2001, Taboubi et al., 2010, Yamauchi et al., 1997). There 
have been no studies to support whether CDKs are involved in Gαq signalling 
however in bone epithelial cells the PI3K signalling cascade can activate CDK 
(Major et al., 2004), hence there is a possibility that the PI3K downstream of 
Gαq (Taboubi et al., 2010) can direct its signalling to activate CDK.   
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Figure 7.1: Gαq as the central integrating point of PAR-1 mediated 
transactivation of the EGFR and TGFBR1 leading to GAG chain 
elongation. 
The GPCR, PAR-1 via its Gαq leads to the transactivation of the EGFR as 
studied by the phosphorylation of downstream intermediate Erk. PAR-1 via Gαq 
leads to the activation of ROCK signalling which activates cell surface integrins, 
in particular the αVβ5, which leads to the activation of the TGFBR1 as denoted 
by the phosphorylation of downstream intermediate Smad2 carboxy terminal. 
Both these transactivation pathways lead to the regulation of GAG genes and 
GAG chain hyperelongation in VSMCs.   
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Thrombin mediated signalling to four important phosphorylation sites of 
the Smad2 linker region were studied in Chapter 5. The transactivation of the 
EGFR (Figure 5.6) and the TGFBR1 (Figure 5.7) activate different 
serine/threonine kinases which lead to the phosphorylation of Smad2 linker 
region residues. The two transactivation dependent pathways at the 2-4 hour 
time points are both involved in the phosphorylation of the Smad2 linker region. 
The crossover in signalling times proposes difficulties in studying the signalling 
pathways involved specifically in Smad2 linker region phosphorylation 
occurring via the transactivation of the TGFBR1. In this study the EGFR 
antagonist was utilized to block EGFR dependent signalling allowing for the 
study of signalling pathways involved in Smad2 linker region phosphorylation 
occurring via the TGFBR1 transactivation. However as the signalling occurring 
via the EGFR transactivation was not completely blocked using a 
pharmacological approach a molecular approach should be considered. To 
address this siRNA specific to the EGFR can be used to knock down EGFR 
signalling in VSMCs. The findings from these future experiments should give 
insight into whether there is a common signalling cascade in thrombin mediated 
phosphorylation of Smad2 linker region residues occurring via transactivation of 
EGFR and TGFBR1.  
Among the MAPK involved in TGF-β signalling in VSMCs,  signalling 
is via Erk and p38 but not Jnk has been identified to modify GAG chains (Burch 
et al., 2010 ). In nucleus pulposus cells of invertebral discs, Erk participates in 
TGF-β regulation of CHSY1 expression (Hu et al., 2015). The data presented in 
this thesis (Chapter 5) is consistent with these two models. Thrombin 
transactivation of the TGFBR1 leading to GAG gene mRNA expression does 
not involve Jnk, however phosphorylation of the Thr220 via the transactivation 
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of the EGFR required Jnk. Interestingly Jnk was not involved in the 
phosphorylation of either of the three serine residues downstream of either of 
the two transactivation pathways supporting our earlier work (Burch et al., 2010 
). In human VSMCs, TGF-β mediated phosphorylation of the Thr220 occurred 
via CDKs and only the phosphorylation of Thr220 was associated with the 
regulation of XT-1 mRNA expression, a critical enzyme associated in chain 
initiation (Rostam et al., 2016). From this we can speculate that the serine 
residues of the Smad2 linker region are involved in thrombin mediated GAG 
elongation, however the Thr220 residue may be involved in other processes 
such as the initiation of the linkage region.  
Of the serine/threonine kinases investigated in this study, there was no 
common kinase that phosphorylated all three serine residues. ROCK is a 
member of intracellular serine/threonine kinases that is involved in the 
regulation of Smad activity via the linker region (Chen et al., 2006, Kamaraju 
and Roberts, 2005). The ROCK signalling pathways is downstream of the EGFR 
(Nakashima et al., 2011, Ramis et al., 2012) and our group amongst others has 
shown the ROCK pathways in involved in GPCR transactivation of TGFBR1 
(Burch et al., 2013, Jenkins et al., 2006, Scotton et al., 2009, Xu et al., 2009). 
Hence further experiments are warranted to study ROCK in thrombin mediated 
phosphorylation of the serine residues of the Smad2 linker region. Chapter 4 of 
this thesis outlines the role of ROCK in thrombin mediated mRNA expression 
of CHSY1 and CHST11 (Figure 4.4) hence the role of this kinase in GAG 
elongation is established we postulate that ROCK should play a role in the 
phosphorylation of Smad2 linker region.  
Thrombin mediated Smad2 linker region phosphorylation occurs via the 
transactivation of both TGFBR1 and EGFR (Figure 5.9). The results presented 
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in this thesis reveal that thrombin mediated transactivation of the TGFBR1 
leading to the phosphorylation of the Smad2 linker region is time dependent and 
delayed when compared to the transactivation of the EGFR (Figures 5.4 and 
5.5). This is consistent with what has previously been described about these two 
transactivation pathways. In human VSMCs and in mouse epithelial cells 
thrombin and LPA mediated transactivation of the TGFBR1 did not involve 
‘de novo’ protein synthesis (Jenkins et al., 2006, Xu et al., 2009, Burch et al., 
2013). As discussed in this thesis, TGFBR1 transactivation is mediated by a 
dynamic cytoskeletal, ROCK, integrin interplay whereas transactivation 
mediated via EGFR involves MMP mediated ligand-dependent mechanisms. In 
human VSMCs, thrombin and ET-1 mediated transactivation of the TGFBR1 
occurred 2 hours post treatment (Burch et al., 2010, Little et al., 2010). LPA 
induced MEF cells had a peak phosphorylation of Smad2 for 1-4 hours post 
treatment (Jenkins et al., 2006). Moreover, agonists of various GPCRs within 
minutes induced the phosphorylation of endogenous EGFR in keratinocytes, 
COS7 cells, VSMCs and proximal tubular epithelial cells (Daub et al., 1997, 
Burch et al., 2010, Chung et al., 2013). Taking into account these previous 
studies, we expected thrombin mediated Smad2 linker region phosphorylation 
via transactivation of EGFR to occur much earlier than transactivation of the 
TGFBR1. We postulate that the difference in the transactivation dependent 
signalling pathways is due to the cell surface mechanisms involved. Although 
there is a difference in the time it takes to transactivate the individual receptors, 
the aim of this work was to find a common point that will inhibit transactivation 
dependent GAG elongation.  
We then addressed the question as to how important transactivation 
signalling was to overall GPCR (PAR-1) signalling. High throughput RNA-Seq 
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data (Chapter 6) showed that thrombin mediated transactivation of the EGFR 
and TGFBR1 accounted for 50% of all thrombin mediated signalling assessed as 
gene expression at 6 hours The two transactivation dependent signalling 
pathways share in over 65% of common differentially expressed genes. PAR-1 
mediated transactivation of the EGFR and TGFBR1 common transcription 
factor, Smad2 in the linker region (Chapter 5). The work from our group shows 
that the phosphorylation of the Smad2 linker region is associated with 
proteoglycan synthesis and GAG elongation (Burch et al., 2010 , Rostam et al., 
2016). The Smad2 linker region has been associated with cancer (Kretzschmar 
et al., 1999, Matsuzaki et al., 2009, Suzuki et al., 2015), renal fibrosis (Sun et 
al., 2014), endothelial dysfunction (Kamato et al., 2014a), esophagitis mucosae 
(Takahashi et al., 2016) and inflammatory related diseases (Yoon et al., 
2015).Thus showing that the Smad2 linker region may be a transcription factor 
of interest not only for its role in transactivation dependent GAG chain 
elongation but it for its role in advancing the signalling pathways for the 
common differentially expressed genes from the two transactivation pathways. 
This work provides proof the genome wide studies can offer powerful insights 
into transactivation dependent signalling pathways.  
Earlier work had shown that GAG chains were elongated but in the 
current work it has been shown that the expression of several genes, which my 
implication are rate limited, are activated as a result of PAR-1 mediated 
transactivation signalling. In conclusion, the current study has identified that 
thrombin via PAR-1 mediated the transactivation of the EGFR and TGFBR1 
regulates the mRNA expression of GAG synthesizing genes CHST11, CHSY1 
and CHST13 in human VSMCs. Thrombin mediated transactivation of the 
TGFBR1 is mediated by PAR-1 and is dependent on ROCK mediated 
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cytoskeletal contraction leading to the activation of cell surface integrin αVβ5, 
which activate the latent TGF-β complex. In addition, thrombin utilizes 
transactivation of the TGFBR1, cooperatively with the well-characterized 
transactivation of the EGFR, to stimulate GAG hyperelongation in human 
VSMCs. The Gαq mediates all transactivation dependent signalling and plays as 
a central target for transactivation dependent GAG elongation. A complex and 
highly specific signalling pathway from PAR-1 to Smad2 linker region 
phosphorylation exists in these cells. Serine/threonine kinases Erk, p38 PI3K 
and CDK were found to be key mediators in this pathway. Individual Smad2 
linker region sites are selectively phosphorylated. CHSY1 and CHST11 mRNA 
expression, closely associated with GAG chain elongation are induced by the 
phosphorylation of the serine residues of the Smad2 linker region. However the 
phosphorylation of the Thr220 residue may be associated with expression of 
another GAG gene such as XXYLT-1. Thrombin mediated transactivation of the 
EGFR and TGFBR1 in human CASMCs accounts for 65% of thrombin 
mediated signalling thus showing the importance of transactivation dependent 
signalling to overall PAR-1 signalling. Together these findings demonstrate the 
complex nature of transactivation dependent signalling and the complexity of 
the signalling pathways that contribute to GAG hyperelongation but the 
identification of Gαq as a central mediator may facilitate the identification of a 
specific therapeutic target in early development of atherosclerosis. 
The most interesting finding from this work has been the identification 
of the very specific role of Gαq in both pathways (PTKR and S/TKR) of 
transactivation dependent signalling. As we have identified that transactivation 
dependent signalling makes a major contribution to PAR-1 mediated signalling 
then it is likely that all of the vasoactive peptides in a diseased vessel ET-1, 
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angiotensin II and thrombin might mediate transactivation dependent signalling 
and this Gαq might be a highly efficacious target to prevent the deleterious 
pathophysiological effects of multiple GPCR agonists. G proteins such as Gαq 
may have important physiological roles apart from the findings presented in this 
thesis but the extent to which therapeutically targeting Gαq proteins in multiple 
diseases and in particular in the role of proteoglycans in atherosclerosis, cannot 
be known for certain until the appropriate experiments in reputable models are 
undertaken. 
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